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8Chapter 1 | General Introduction
Biological Challenges in Nanomedicine
Nanomedicine involves the application of nanotechnology for prevention, 
diagnosis and treatment of disease, using engineered nanoscale materials such 
as nanoparticles, nanotubes and nanofilms.1 Often, these complex systems 
consist of multiple components including at least one active ingredient, such 
as a drug molecule. This could result in new medical effects, which pushes 
treatment boundaries that could not be established by conventional drugs 
such as small molecules (MW < 1000 Da). Approximately 50 nanotherapeutics 
made it to clinic,2 and the amount of research and development in this area is 
overwhelming, especially in chemical design and manufacturing techniques.3 
The field of nanomedicine faces challenges which include large-scale 
manufacturing, biocompatibility and safety, intellectual property, government 
regulations, overall cost-effectiveness in comparison to current therapies 
and biological challenges.4 Biological challenges could be summarized in 
major hindrance in the prediction of a reliable read-out in vivo based on 
current technical knowledge in vitro.5 Although it is important to characterize 
nanomaterials morphologically and physicochemically, the biological 
characterization on the manufactured materials and on the materials after 
contact with relevant media in vitro and in vivo is crucial.6 Better understanding 
of the relationship between technology and biology, with special attention 
paid to the influence of the disease pathophysiology on nanomedicine, could 
improve successful clinical translation.7
Targeted Drug Delivery in Nanomedicine
Many healthcare applications can be addressed by nanomedicine such as drug 
delivery, drugs and therapy, in vivo imaging, in vitro diagnostics, biomaterials 
and active implants.8 
The application of drug delivery dominates the field of nanomedicine, both in 
terms of research activity and commercial applications.8 Drug delivery systems 
could provide many advantages compared to current treatments, which makes 
drug delivery one of the most promising applications of nanomaterials.9–11 Drug 
delivery systems could improve unfavorable tissue distribution of conventional 
drugs, and increase the therapeutic efficacy of drug molecules by achieving 
higher accumulation in the target tissue. By minimizing drug exposure to non-
target tissue, adverse effects could be reduced.12 
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In addition, multiple therapeutic agents could be combined including an 
imaging modality to visualize real-time targeting and treatment efficacy in 
vivo.13 Drug delivery systems could be manipulated to reduce interactions with 
plasma proteins and blood cells to improve circulation kinetics.12
Many tissues can only be reached via systemic administration in the blood 
stream, which makes injection the common mode of administration of drug 
delivery systems.14 Conventional therapeutics are injected in the blood stream 
or absorbed from the gastro-intestinal tract, where drug molecules can reach 
cells via diffusion through vascular pores (< 5 nm).15 After passing the cell 
membrane, the molecules reach their destination to perform the required 
action.16 In contrast, drug delivery systems could be targeted to a highly specific 
region of tissue or cell type.
Passive targeting refers to the accumulation of drug delivery systems in specific 
tissues with pathological properties such as affected and leaky vasculature 
(< 200 nm), for example enhanced leakiness of tumors, inflammations and 
infarcted areas.17 To achieve this, prolonged blood circulation kinetics would 
be crucial.
On the other hand, targeting moieties could be physically or chemically 
conjugated to drug delivery systems to increase target specificity for 
pathological features in diseased tissue.12 Active targeting involves the use of 
ligands such as antibodies, peptides or sugar moieties to facilitate localization 
to target cells.4 
Crossing Biological Barriers
The ability to deliver drugs in a controlled fashion including therapeutic targeting 
to a specific cell type or tissue is challenging. These challenges are represented 
by crossing endothelial barriers such as the blood-brain barrier (Figure 1a), 
uptake by target cells and subsequent escape from the endolysosomal system 
(Figure 1b), and prematurely clearing by the mononuclear phagocytic system 
(MPS) which results in reduced half-life and the inability to reach the effective 
dose (figure 1c).18 A crucial requirement for proper functioning of drug delivery 
vehicles is the ability to prevent immediate uptake and clearance by non-target 
tissues such as the liver and kidneys. Apart from avoiding kidney filtration 
which typically occurs for molecules less than 50 kDa in size,19 obstacles in the 
form of aggregation with serum proteins, phagocytotic uptake, and enzymatic 
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degradation could hinder successful drug delivery.15 As next step, the targeted 
therapeutic should be able to escape the blood vessels to the target site, and 
recognize the target cells with high specificity. It should be internalized by 
the target cells and preferably escape the endolysosomal system to exert its 
therapeutic effect. Last but not least, it should be cleared from the body safely, 
which requires larger molecular mass nanomaterials to be biodegradable.15
Figure 1. Schematic illustration of challenges faced by targeted drug delivery systems. (a) 
Endothelial barriers such as the blood-brain barrier, (b) Cellular uptake and escape from 
the endolysosomal system to the cytosol and (c) Clearance of drug delivery systems by the 
mononuclear phagocytic system (MPS) with specialized macrophages such as Kupffer cells, 
after systemically administration. Figure taken from reference 18. 
The blood-brain barrier
In 1885, Paul Ehrlich observed that after injection of different dyes in animals 
all organs were stained, except for the brain and spinal cord.20 At that time, 
this observation was explained as lack of affinity of the dye for neuronal 
tissue. However, his student Edwin Goldmann injected Trypan blue directly 
into the cerebrospinal fluid and managed to stain the brain. A few years later, 
the concept of the “blood-brain barrier” (BBB) was first described in 1900 by 
neurologist Max Lewandowsky.21
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In the 60s, electron microscopy revealed ultrastructure features of the BBB and 
many studies created greater understanding of the fundaments underlying the 
barrier function.22 The BBB entails protein complexes consisting of tight and 
adherent junctions connecting nonfenestrated brain capillary endothelial cells 
with low pinocytotic activity to restrict flow towards brain tissue.23 Additional 
elements of the BBB are the basement membrane, astrocytes, pericytes, neurons, 
vascular smooth muscle cells and immune cells.24 
This system is not a static, impermeable barrier, but a highly regulated and 
specific cellular system to allow proper neuronal functioning as well as protect 
the brain from toxins, pathogens, inflammation, injury and disease.24 The BBB 
restricts entry to 98 % of small molecule drugs, unless molecules are lipid-soluble 
with a molecular weight of 400 – 600 Da or less, and ~100 % of large-molecule 
neurotherapeutics.25 Existence of the barrier creates a major opportunity and 
need for drug combinations which are able to interfere with diseased neurons. 
Small molecule drugs such as antidepressants, medications for schizophrenia 
and epilepsy are able to pass, however entry is denied to most of the other 
drugs.23 The barrier is controlled by intra-, inter-, and paracellular  signaling 
events between endothelial cells, astrocytes and neurons and other cells.26
Transport over the BBB is arranged via two main types of transporters, namely 
efflux transporters and nutrient transporters. Efflux transporters such as the 
ATP-binding cassette family (ABC) use ATP to transport substrates against the 
concentration gradient and prevent small lipophilic drugs from diffusing into the 
brain. Influx transporters facilitate flow of nutrients down their concentration 
gradient mostly via the solute carrier class (SLC) involving the transport of 
glucose, lactate and pyruvate, and amino acids. Moreover, endothelial cells 
express a variety of specific receptor-mediated transport systems including the 
transferrin receptor, insulin receptor and low density lipoprotein (LDL) receptors 
for transcytosis.27 The non-specific transport occurs through adsorptive-mediated 
transcytosis, involving mainly cationic proteins interacting with the negatively 
charged membrane surface of endothelial cells.28
Generally, a blood circulating ligand interacts with its specific receptor at 
the apical side of the plasma membrane of endothelial cells. After binding, 
endocytosis is initiated and intracellular vesicles transport the receptor-ligand 
complex, or dissociated ligands, to the basolateral side of the endothelial cell 
where release takes place.27
12
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To increase entry of drugs, many of the above described transport systems are 
used as “Trojan horses” to facilitate drug delivery to the brain. This strategy 
entails conjugating nanomaterials with ligands, antibodies or peptides for 
cell-, carrier-, receptor-, or adsorptive-mediated transcytosis (Figure 2).29 
Examples are monoclonal antibodies (MAb) to the human insulin receptor or 
transferrin receptor and peptide-based strategies such as LDL-receptor related 
protein 1 peptides or cationic import peptides.30 However, these type of 
strategies in attempt to cross the BBB are challenging in different aspects, such 
as specificity, affinity, toxicity by interfering with endogenous ligands such as 
insulin and transferrin, dose-dependent toxicity in establishing a therapeutic 
effect, and immunogenic reactions.31
Figure 2. Schematic representation of transport systems to cross the blood-brain barrier, 
which compromises components such as endothelium, astrocytes, pericytes, neurons, 
and perivascular macrophages (PVM). The major transport mechanisms make use of cell-
mediated, receptor-mediated, adsorptive-mediated, or carrier-mediated transcytosis. Figure 
adapted from reference 29. 
13
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Spheroids as three-dimensional model for tumor tissue
About two-thirds of investigational applications in drug delivery systems 
focus on treatment of cancer, as this is in the top three of society’s killers.3 
Side-effects of cytotoxic chemotherapeutics are disastrous, and specific tumor 
targeting could increase anti-tumor efficacy, while decreasing toxic systemic 
side-effects.32 However, few nanodrugs are available for clinical cancer care as 
clinical trials do not achieve expected results in patients so far.33 For targeted 
drug delivery into three-dimensional (3D) tissues such as tumors, particle 
binding and porosity of tissue are key parameters in effective treatment 
using nanomaterials.34,35 Drug delivery systems must overcome biological 
barriers such as the interstitial compartment and extracellular matrix (ECM) 
for increased penetration depth.36 To study transport of the carrier systems in 
tumor tissue, in vitro 3D cell cultures such as spheroids provide an excellent 
platform to mimic the avascular regions of tumor tissue.35 Spheroids are non-
scaffold based cultures which are formed by cellular aggregates derived from 
fragments of tumors, cancer stem cell cultures, or single cancer cell cultures.36,37 
Spheroids could be technically generated in different ways, such as the hanging 
drop method, liquid overlay, or via spinner flasks.38 These techniques have in 
common that cells are deprived from contacts to a growth-promoting surface 
to establish contacts between cells.39 
The natural morphology of cells in 3D rather than 2D includes cell-cell 
interaction, cell-matrix interactions and the tissue-specific architecture which 
induce mechanical and chemical cues essential for cellular functions such as cell 
proliferation, differentiation, migration and intracellular signal transduction.40,41 
In addition, heterogeneity is increased due to a decrease of extracellular pH 
and oxygen partial pressure present with depth in spheroids (Figure 3).42 As a 
consequence of oxygen and nutrient gradients, spheroids contain hypoxic and 
necrotic areas.43 The latter are usually observed in spheroids with a diameter of 
approximately 500 µm.41 At the level of gene expression profiles, studies have 
demonstrated that 3D cell culture models represent in vivo gene expression 
more faithfully than 2D cell culture.44–47
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Figure 3. Schematic representation of tumor cells cultured in 3D microenvironment. The 
tissue-specific architecture induces different chemical and mechanical cues leading to altered 
cellular function compared to cells growing in 2D. Figure taken from reference 47. 
Since these physiological features are close to those of avascular cancer 
metastases, these models are widely used to study the ability of nanotherapeutics 
to penetrate and distribute inside tumor tissue. The effect of physicochemical 
properties such as size, shape and charge of surface of nanocarriers has been 
extensively evaluated, as well as the impact of a targeting moiety such as 
peptide iRGD to address specific tumor tissue.36
Cellular uptake
To interfere with complex events within living cells, drug delivery systems 
must be capable to reach their intracellular pharmacological target.48,49 Low-
molecular weight, hydrophobic molecules are able to simply diffuse through 
the lipid membrane bilayer of cells. However, nanoparticulate structures require 
active uptake mechanisms.50 The internalization pathway of the nanoparticles 
determines the intracellular fate and thus efficacy of the delivered drug. In 
mammalian cells, five main different mechanisms of endocytosis can be involved 
in the internalization of nanoparticles, depending on the physicochemical 
properties of the nanomaterial and the nature of the target cell.49,51 
15
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These five pathways include phagocytosis (“cell eating”), and the four 
pathways which could be shared under pinocytosis (“cell drinking”) 
namely macropinocytosis, clathrin-mediated endocytosis, caveolin-
mediated endocytosis and clathrin/caveolae-independent endocytosis. In 
general, endocytosis is the engulfment of nanoparticles via cell membrane 
invaginations, followed by the formation of endocytotic vesicles which are 
trafficked to intracellular sorting compartments. Phagocytosis is a key feature 
of phagocytotic cells such as macrophages, monocytes, neutrophils and 
dendritic cells, responsible for host defense and uptake of dead cells and 
debris.52 In the blood circulation, nanomaterials could be tagged by opsonins 
such as immunoglobulins or other blood serum proteins and subsequently 
internalized via specific ligand-receptor interactions at the macrophage 
surface.49 Alternatively, nanoparticles could be taken up via one of the non-
phagocytotic pathways, which is not necessarily restricted to specialized 
cells. Macropinocytosis is a form of non-specific bulk-uptake, regardless of 
the presence of specific receptors (Figure 4a). Clathrin-mediated endocytosis 
takes often place via receptor-ligand interactions using ligands such as iron, 
low-density lipoproteins, transferrin and epidermal growth factors (Figure 4b). 
However, non-specific receptor-independent uptake using clathrin-coated 
vesicles is also possible. Caveolae-mediated endocytosis is characterized by flask-
shaped membrane invaginations lined by dimeric protein caveolin (Figure 4c), 
often present in endothelial cells, smooth muscle cells and fibroblasts. The main 
goal of this process is to induce endocytosis or transcytosis of proteins and 
viruses. Endocytotic pathways independent of clathrin and caveolae formation 
are involved in lipid raft formation or the internalization of folic acid, however 
at molecular level these pathways are not yet fully understood. 
Endocytosis of nanoparticles leads to the formation of endosomes which 
eventually fuse with the highly acidic (pH = 4) and degradative environment of 
lysosomes.53 Unless lysosomal delivery is desired or needed for drug activation, 
strategies for cytosolic drug delivery via endosomal escape are widely 
explored.49 
Physical methods have been developed to allow nanoparticles to be delivered 
in the cytosol. Examples of these strategies are the micro-injection of 
nanoparticles directly in the cytosol using a microcapillary under a fluorescent 
microscopy, or electroporation where hydrophilic pores are generated in the 
plasma membrane. 
16
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A major drawback of this method is the high cell mortality and it is not possible 
to use this strategy in vivo.54
Figure 4. Intracellular pathways after nanoparticle uptake. (a) Macropinocytosis is involved 
in non-specific bulk uptake. (b) Clathrin-mediated endocytosis is mainly characterized by 
receptor-mediated uptake after which clathrin-coated pits are formed. (c) Caveolae-mediated 
endocytosis leads to the formation of vesicles which are surrounded by caveolae. Figure taken 
from reference 49. 
Nanoparticles in Targeted Drug Delivery
Different approaches to cross endothelial and cellular barriers could be used, 
using different materials with unique physicochemical properties and targeting 
ligands.48 Amongst drug delivery systems, nanoparticles represent the most 
widely studied drug delivery systems.14 
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Nanoparticles are nano-sized materials (diameter 1-200 nm) and often involve 
the use of biodegradable materials.55 Nanomaterials could be formulated into 
structures such as micelles, liposomes, dendrimers, polymer particles, carbon 
tubes, metallic or organic nanoparticles, quantum dots, and peptide-based 
nanoparticles (Figure 5).56 Generally three generations of nanoparticle systems 
are considered, namely first generation vectors consisting of nanospheres 
and nanocapsules, second generation vectors are nanoparticles coated with 
hydrophilic polymers such as polyethylene glycol (PEG), and lastly the third 
generation vectors which consisting of a biodegradable core and a polymer 
envelop (PEG) including a membrane recognition ligand.57 
 
 
 
 
 
 
Figure 5. Nanoparticles comprise different compositions, surface chemistry, targeting ligands 
and physical properties. Figure taken from reference 48. 
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Polymersomes
Liposomes are lipid vesicles surrounded by a lipid bilayer which separates an 
internal volume from an external solution. In the seventies, the pioneering 
work of  Gregoriadis et al. explored the potential of liposomes to use liposomes 
as carriers for drug.58,59 The first nano-drug approved by the US Food and Drug 
Administration (FDA) was Doxil® (1995), of which the formulation consists of 
PEGylated liposomes encapsulating anti-cancer compound doxorubicin.60 In 
clinical applications, drug delivery using liposomes has been proven most useful 
by passive targeting.61 However, liposomes do have certain disadvantages 
related to the thickness of the lipid bilayer, such as a high permeability of 
the membrane resulting in limited drug encapsulation effiency.62 Moreover, 
liposomes are expensive to manufacture and have limited stability because of 
the intrinsic softness of the phospholipid membrane. In addition, the retention 
of encapsulated molecules is difficult to control.63 
Polymersomes are synthetic replicas of liposomes and have tunable 
properties which could overcome limitations faced by liposomes. The shape 
of polymersomes is characterized by hollow spheres surrounded by a semi-
permeable bilayer membrane consisting of amphiphilic block copolymers, 
which create via self-assembly a bilayer with a hydrophobic part in the middle 
(Figure 6a, orange) and a hydrophilic corona both on the inside and outside 
(Figure 6a, blue). The aqueous core is suitable for the encapsulation of 
therapeutic molecules such as drugs and enzymes.64 The size of polymersomes 
could be tuned by changing the composition regarding amphiphilicity of the 
block copolymers as well as the method of formulation used for self-assembly. 
The thickness, fluidity and pore size of the membrane is dependent on the 
character of the block copolymer in terms of molecular weight and the block 
number.65 This characteristic polymer membrane leads to a higher stability of 
polymersomes compared to liposomes, which makes them useful for targeted 
delivery of biomacromolecules. In addition, polymersomes make an excellent 
candidate to be used as nanoreactor. The encapsulated molecule of interest such 
as an enzyme could react in the presence of substrate or could be activated by an 
external stimulus, as long as the membrane is semi-permeable.65 Nanoreactors 
based on polymersomal technology have been shown to undergo cellular 
integration, and confined enzyme activity was demonstrated with a number of 
cell lines in vitro.66–71 
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Moreover, pioneering studies using nanoreactors in vivo have yielded interesting 
results, with superoxide dismutase-loaded polymersomes functioning as 
antioxidants to reduce neuropathic pain (rat model) and β-galactosidase-
loaded polyion complex vesicles (PICsomes) showing specific function within 
tumor tissue (mouse model).72,73
Figure 6. Schematic representation of polymersomes and elastin-like polypeptide (ELP) 
nanoparticles. (a) Polymersomes are hollow spheres surrounded by a semi-permeable bilayer 
membrane consisting of amphiphilic block copolymers, which create via self-assembly a 
bilayer with a hydrophobic part in the middle (orange) and a hydrophilic corona both on the 
inside and outside (blue). Figure adapted from reference 74.74 (b) ELP nanoparticles with a 
hydrophilic ELP sequence (green) and a hydrophobic ELP sequence (purple). Upon raising the 
temperature above the lower critical solution temperature (LCST), micellar nanoparticles are 
formed. Figure adapted from reference 75. 
Elastin-like polypeptide nanoparticles
Protein-based nanoparticles have great potential as an alternative strategy 
for controlled drug delivery.75–77 In the same way as polymersomal block 
copolymers, polyamides could also be degraded into non-toxic natural building 
blocks. However, in comparison to synthetic polymers, for the formation of 
nanoparticles, different boundary conditions apply. For synthetic polymers, 
nanoparticle formation typically occurs by hydrophobic collapse, once a solution 
of organic solvent, containing the polymer, is diluted into an aqueous phase. For 
recombinant proteins whose intact tertiary structure defines functionality, this 
approach is not possible. They often have to be water soluble in their monomeric 
form in order to achieve high expression yields and purification. 
20
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Elastin-like polypeptides (ELPs) are derived from human tropoelastin, a 
precursor of elastin, a component of the extracellular matrix.76,78 ELPs consist 
of pentameric repeats of valine (V) – proline (P) – glycine (G) – X – glycine (G) 
pentapeptides, in which X may be any proteinogenic amino acid.79,80 ELPs with 
unnatural amino acids as guest residue have been reported as well.81 These 
peptides show a reversible, temperature-dependent self-organization into 
coacervates. Upon raising the temperature above the lower critical solution 
temperature (LCST), they undergo a shape transition from a disordered, soluble 
state into a spiral-like state consisting of type-II β-turns, type-I β-turns and 
β-strands, exposing the (hydrophobic) side chains.82 
This aggregation is thermodynamically driven and occurs over a short time 
scale. By changing the guest residue or length of the polymer it is possible 
to tune the LCST of ELPs.83,84 This aggregation could be directed towards the 
formation of well-defined nanoparticles which exist as micellar structures. It 
is possible to design diblock ELPs with a hydrophilic ELP sequence (high LCST) 
and with a hydrophobic ELP sequence (low LCST) with different guest residues 
(Figure 6b). Studies have demonstrated that ELP nanoparticles induce minimal 
inflammatory and immune effects in animal models.85–87 Even administration to 
human subjects was tolerated well without introducing immune effects.88 Drugs 
can be encapsulated either into the hydrophilic lumen or into the hydrophobic 
coacervate core, or via covalent coupling. In addition, ELPs could be extended 
by functional peptides to achieve cell-specific targeting or enhance cellular 
uptake.75 These characteristics make the use of ELP nanoparticles for drug 
delivery very attractive.89–94 Examples of therapeutic applications are local tumor 
therapy,95–101 joint degeneration,102 and  neuroinflammation with encouraging 
results both in vitro and in vivo.103
Disease model of interest: Complex I deficiency
The enormous potential of nanoparticles could be particularly beneficial for 
a variety of pathologies related to mitochondrial defects. Mitochondria are 
double-membrane organelles and an important source for the generation of 
energy in the form of adenosine 5’-tri-phospate (ATP). In addition to this crucial 
function for cell survival, mitochondria play a key role in other cellular processes 
such as adaptive thermogenesis, ion homeostasis, innate immune responses, 
programmed cell death and the production of reactive oxygen species (ROS).104 
21
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ATP is generated via the oxidative phosphorylation (OXPHOS) system 
embedded in the lipid bilayer of the mitochondrial inner membrane 
(Figure 7).105 This system consists of five enzyme complexes (Complex I, II, 
III, IV, V) and the two electron carriers coenzyme Q and cytochrome-c (cyt 
c). During glycolysis, β oxidation and the Kreb’s cycle, nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) are generated. 
At complex I, NADH is oxidized and the electrons released are transferred 
through a series of iron-sulphur (Fe-S) clusters to the ubiquinone reduction site 
(Q) and via reduced ubiquinone to the ubiquinone oxidation site on complex 
III. Complex II feeds electrons from oxidizing FADH2 to ubiquinone thus 
contributing to the reduced ubiquinone pool. This leads to a flux of electrons 
which flows from complex III via cytochrome-c to complex IV, where the final 
redox reaction takes place involving the transfer of electrons to oxygen, 
generating H2O. The flux of electrons from OXPHOS substrates to molecular 
oxygen results in the translocation of protons (H+) at complex I, III and IV.106 
This electrochemical gradient drives the generation of ATP from adenosine 
diphosphate (ADP) and inorganic phosphate (Pi) by complex V. 
Especially complex I is a main site of cellular superoxide production, although 
complex II and III can contribute to ROS production as well.107 Defects in this 
system lead to decreased energy production, increase in ROS formation such 
as superoxide (O2
• −) and its derivatives hydrogen peroxide (H2O2) and hydroxyl 
radicals (•OH), and release of death-promoting factors.108 These defects primarily 
affect tissues with high energy demands, such as heart, brain and muscle. 
22
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Figure 7. The oxidative phosphorylation system located in the mitochondrial inner membrane 
consists of five protein complexes (I, II, III, IV, V), and two electron carriers ubiquinone (Q) and 
cytochrome- c (cyt c). The flux of electrons (e-) leads to translocation of protons (H+) at complex 
I, III and IV. This high mitochondrial membrane potential (ΔµH
+) leads to the generation of ATP 
at complex V. Figure taken from reference 105. 
Mitochondrial disorders are most frequent among the inborn errors of energy 
metabolism. In this group, the most common pediatric manifestation is Leigh 
syndrome.109 The latter is a progressive neurodegenerative disorder first 
described by Leigh in 1951, with characteristic neuropathology behaviour 
symptoms including developmental retardation, hypotonia, ataxia, spasticity, 
dystonia, weakness, optic atrophy, retinopathy, hearing impairment, breathing 
abnormalities, dysarthria, swallowing difficulties, failure to thrive, and 
gastrointestinal problems.110 In many Mendelian cases of Leigh syndrome, 
deficiency of OXPHOS complex I is the primary cause of the disease.111 
Unfortunately, effective treatment strategies for Leigh syndrome are not 
available yet, as for most diseases resulting from mitochondrial dysfunction.112–115 
Recently, hypoxia (continuously breathing at 11 % O2) was demonstrated to 
have a beneficial effect within complex I-deficient Ndufs4-/- mice.116 
23
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Moreover, Liu et al. demonstrated that the onset of neurodegeneration and 
ensuing motor defects could be delayed by intraperitoneal injection of the 
blood-brain barrier penetrating antioxidant N-acetyl cysteine amide (AD4) 
in Ndufs4-/- mice.117 An overview of the potential pharmacological strategies 
towards treatment of mitochondrial disease with emphasis on complex I 
deficiency was recently presented by Koopman et al.114 
A potential treatment which is currently under clinical development is 
the small molecule KH176. It is a redox-modulating compound and its 
beneficial effects have been described and tested in vitro, in vivo and clinical 
studies.118–122 This compound, being a derivative of the antioxidant Trolox, 
was evaluated in cell lines from patients suffering from complex I deficiency, 
and demonstrated favorable properties at cellular level. One of these variants 
(Trolox ornithylamide hydrochloride) reduced effectively cellular ROS levels 
measured via dihydroethidium (HEt) oxidation and increased the maximal 
activity of complex I, complex IV and citrate synthase.118 This compound was 
further developed in a lead-optimization program to improve therapeutic 
potency and drug-like properties via classical medicinal chemistry. Compound 
KH176 was selected from these studies and demonstrated retained brain 
microstructural coherence, normalized lipid peroxidation and improved rotarod 
and gait performance in the complex I deficient Ndufs4-/- mouse model.119 As 
a next step was KH176 shown to be toxicologically safe and well tolerated 
in healthy male volunteers,120 and the compound completed Clinical Study 
Phase 2 (www.clinicaltrials.gov; NCT02909400).122 Quintana et al. developed 
a murine model with complex I deficiency, namely mice with an inactivated 
NDUFS4 gene encoding for this complex I subunit in all cells (whole-body KO 
mice). Subsequently, they created a mouse model lacking NDUFS4 in only 
neurons and astroglial cells (NesKO mice), to evaluate the role of the central 
nervous system in this syndrome. Interestingly, NesKO mice displayed a nearly 
identical phenotype as whole-body KO mice, providing strong evidence for the 
neurological origin of complex I deficiency.110 
Efforts have been made to deliver antioxidants specifically to the brain in order 
to scavenge high amounts of ROS, being the key player in neurodegenerative 
disease.123 For neurodegenerative disorders, specifically in which mitochondrial 
dysfunction is involved, an example of successful drug targeting is provided 
by ceria nanoparticles which are targeted to mitochondria and subsequently 
suppress neuronal death in an Alzheimer’s disease mouse model.124
24
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Apart from delivery at the preferential site, orally delivered antioxidants are 
vulnerable to acids and enzymes in the human body and nano-encapsulation 
could provide protection and stability to these compounds.125 Moreover, 
hydrophobic and high molecular weight antioxidants such as coenzyme Q result 
in poor availability and poor delivery significance. Antioxidants encapsulated 
in nanoparticles could be useful not only for brain targeting, but also for ocular 
delivery to reduce intraocular pressure or for airway epithelial cells to treat 
chronic respiratory diseases, which are distinguished by high oxidative stress 
levels.126,127 For delivery of coenzyme Q, a variety of drug delivery systems has 
been developed with different therapeutic applications such as cardiovascular 
disease, different cancers and reproductive disorders.128 
For the development of nanocarriers for successful delivery of mitochondrial 
medicine to the brain, nanoparticles with high efficacy and ability to repair 
neurons suffering from oxidative stress with minimal side effects both in vitro 
and in vivo hold great promise for future mitochondrial therapy.
25
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Aim and outline of this thesis
The aim of this thesis is to evaluate the potential of two types of nanoparticles, 
polymersomal nanoreactors and elastin-like polypeptide (ELP)-based 
nanoparticles, in terms of BBB passage, spheroid penetration, cellular uptake, 
intracellular localization and providing patient-derived cells with the required 
biological activity.
In chapter 2, the development, characterization and cellular uptake of 
biodegradable, semi-permeable polymersomes are evaluated in HEK293T cells. 
To induce efficient cellular uptake, these nanoreactors are functionalized with 
either the linear or cyclic variant of the cell penetrating peptide TAT, derived 
from human immunodeficiency virus (HIV).
Chapter 3 describes the functional assessment of TAT-mediated catalase-
loaded polymersomes in primary human skin fibroblasts from a patient with 
complex I deficiency.
In chapter 4, ELP nanoparticles are explored as drug delivery system. Special 
attention is paid to the density and configuration of the cell penetrating 
peptide octa-arginine (R8) incorporated in ELP nanoparticles. The impact of R8 
is evaluated in 2D monolayer skin fibroblasts in terms of efficient uptake and 
toxicity. In addition, the presence of the binding-site barrier and penetration 
depth of ELP nanoparticles is evaluated in 3D human glioblastoma spheroids.
Chapter 5 explores the therapeutic potential of ROS-redox modulator KH176 
conjugated to ELP nanoparticles in primary human skin fibroblasts from a 
patient with complex I deficiency.
Chapter 6 evaluates the targeting peptide G23 in ELP nanoparticles to induce 
transcytosis in an in vitro model of the blood-brain barrier.
In chapter 7, the obtained results are discussed along with conclusions 
regarding the biological challenges for nanomedicine.
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Chapter 2 | Synthesis, characterization and cellular integration of biodegradable, polymersomal 
nanoreactors
Abstract
Biodegradable, semi-permeable nanoreactors that are capable of undergoing 
cellular integration and, subsequently, function as synthetic organelles, 
represent an exciting therapeutic technology. Polymersomal nanoreactors 
have been investigated as a suitable candidate for the engineering of such a 
system, with the chemical versatility and structural robustness required for such 
a demanding application. Essential criteria of the polymersomes to function as 
therapy are biodegradability, intrinsic semi-permeability and cellular uptake. 
Herein, we describe cargo-loaded, biodegradable poly(ethylene glycol)-
block-poly(caprolactone-gradient-trimethylene carbonate) (PEG-PCLgTMC) 
polymersomal nanoreactors, readily fabricated using the biocompatible direct 
hydration methodology. Physical characterization of PEG-PCLgTMC polymersomes 
highlights their semi-permeable membrane and ability to shield enzymatic 
cargo. Surface modification with cell-penetrating peptides (CPPs) directs cellular 
integration of cargo-loaded PEG-PCLgTMC nanoreactors in a controlled fashion 
towards acidic compartments within HEK293T cells. The optimization of non-
toxic formulation conditions, subsequent characterization and cellular trafficking 
is an important first step in the development of autonomous nanoreactors 
encapsulating enzymes to be used as promising therapy.
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Introduction
Membrane-bound organelles (such as mitochondria, endosomes or the 
nucleus) are compartmentalized microenvironments where diverse enzymatic 
processes take place under highly regulated conditions.1,2 A striking feature of 
such sub-cellular compartments is that they permit selective trans-membrane 
molecular transport, a property vital for their function. The physicochemical 
elegance of organelles has inspired scientists to engineer synthetic counterparts, 
capable of performing complex functions within the cell.2–5 Indeed, substantial 
progress has been made in this area through the utilization of both micro and 
nanocompartments.6,7 Notable developments towards the in vitro application of 
microreactors (based on polymer capsules or liposomes) have been presented, 
with uptake into macrophages facilitated by macropinocytosis or via a 
microinjection method for other cell types.8–10 Although there are undoubtable 
advantages in using larger, more structurally complex microreactors, their large 
size makes them less versatile as compared to their nanoscopic counterparts. In 
particular, copolymer vesicles (polymersomes), synthetic replicas of liposomes, 
which are capable of encapsulating and stabilizing sensitive internal cargo such as 
enzymes,7,11 have great potential for cellular therapy.12,13 Especially, their utility as 
organelle-like nanosystems, capable of endogenously affecting cellular chemistry 
and performing tasks that would otherwise be malfunctioning (or absent), is an 
exciting prospect. Nanoreactors, based on polymersomal (and polymer capsule) 
technology have been shown to undergo cellular integration, and confined 
enzyme activity was demonstrated with a number of cell lines in vitro.14–19 
Evaluation of recent studies highlights essential properties that are of critical 
importance for the effective functioning of synthetic organelles: semi-permeability, 
biodegradability and biocompatibility. Regarding the former, progress has 
been made with both membrane post-modification (channel proteins, DNA 
pores or chemically),11,20–28 and complex morphological engineering,29,30 to 
generate functioning nanoreactors. Engineering polymersomal nanoreactors 
with an intrinsically semi-permeable membrane remains a challenge, however, 
with few examples that are sufficiently permeable to facilitate native chemical 
processing of external substrates utilizing compartmentalized enzyme(s).31–37 
Even more challenging is to realize such a system that is both biodegradable and 
biocompatible, vital features of a synthetic organelle to ensure cellular integration 
without toxic side effects that would undermine biomedical application. 
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To this end, we have undertaken to engineer, via the remarkably facile direct 
hydration approach, a biodegradable, semi-permeable polymersomal platform 
that can function as autonomous nanoreactors through enzyme encapsulation. 
Recently, the direct hydration method for preparation of poly(ethylene glycol)-
poly(caprolactone) (PEG-PCL) polymersomes was presented, using oligo(ethylene 
glycol) (OEG) as a non-toxic dispersant.38 This methodology can facilitate 
biomolecular encapsulation,39 however, it has not yet been presented as a route 
towards nanoreactor fabrication. 
Although the design and fabrication of biodegradable (autonomous) 
nanoreactors is already a substantial challenge, to obtain a relevant therapeutic 
effect, cellular uptake is crucial. An effective strategy for inducing the cell 
uptake of polymersomal nanoreactors is through surface decoration with cell-
penetrating peptides (CPPs).40,41 TAT, a CPP derived from the transactivator of 
transcription (TAT) of the human immunodeficiency virus (HIV),42 is known 
to translocate the cell plasma membrane,43 and direct endocytotic uptake of 
colloidal or proteinaceous cargo.44 Having previously reported the successful 
cellular integration of TAT-polymersomes,15 we wanted to evaluate whether more 
advanced properties of CPPs could be realized in this platform; such as endosomal 
escape.45 Recently, the cyclic variant of TAT (cTAT) was reported to direct cytosolic 
delivery of proteins in HeLa cells, thereby bypassing the endolysosomal system.46 
Therefore, we decided to compare the efficacy of the linear and cyclic TAT 
variants in facilitating polymersomal uptake in HEK293T cells (Figure 1). Because 
the diverse morphological features of nanoparticles (e.g. size, shape, stiffness 
and surface topology) can significantly impact cellular uptake it is important to 
evaluate this key behavior in such a new system.47,48
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Materials and Methods
Materials - Poly(ethylene glycol)-b-poly(ε-caprolactone)-g-poly(trimethylene 
carbonate) (PEG-PClgTMC) block copolymers were synthesized by David S. Williams, 
Loai K.E.A. Abdelmohsen and Pascal L.W. Welzen. Details on synthesis fall outside 
the scope of this thesis and are described in detail in van Oppen et al.49 DBCO-
amine was purchased from Click Chemistry Tools, reagents for peptide synthesis 
from Anaspec and all other chemicals, unless otherwise stated, were supplied 
by Sigma-Aldrich. Ultra-pure MilliQ water obtained from a Labconco Water Pro 
PS purification system (18.2 MΩ) was used for the preparation of polymersomes. 
Dialysis membranes from Spectrum Labs (1000 kD MWCO) and Superose 6 
(GE Healthcare) SEC columns were used for purification. Glucose oxidase from 
aspergillus niger (E.C. 232-601-0, G7141) and horseradish peroxidase (E.C. 232-668-
6, P6782) were supplied by Sigma-Aldrich.
General procedure for polymersome formation and encapsulation of cargo via 
direct hydration method  -  In a 5 mL vial, 20 μL of a 10 wt% PEG-PClgTMC block 
copolymer solution in oligo(ethylene glycol) (OEG, 350 Da) was added with stirring. 
Subsequently, 80 μL of aqueous solution was added, followed by continuous 
stirring for 5 min. 
 
 
 
 
 
 
 
 
Figure 1. Polymersomes that possess a semi-permeable double-layered membrane could function 
as autonomous nanoreactors. Cellular integration is directed by attaching a cell-penetrating 
peptide (CPP) to the polymersome surface. The cyclic and linear variant of CPP TAT will be evaluated 
in facilitating polymersomal uptake in HEK293T cells. Figure adapted from reference 49. 
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Polymersomes were subsequently diluted until the desired concentration was 
reached. In order to encapsulate cargo, polymersomes were prepared by addition 
of 80 mL of aqueous solution containing the desired concentration of cargo for 
encapsulation.
CPP synthesis - Azide-functionalized cell-penetrating peptides were synthesized 
via standard Fmoc solid phase peptide synthesis. Literature procedures were 
followed throughout and, after preparative HPLC purification, >99 % purity was 
achieved with appropriate mass and HPLC-UV traces.46
TAT: Ac-K(N3)-Ahx-rRrGrKkRr-NH2
  (Mw = 1591 Da)
cTAT: Ac-K(N3)-Ahx-K*-rRrGrKkRr-E*-OH (Mw = 1829 Da)
* denotes bridging residues
CPP labelling - DBCO copolymers were synthesized as described in van Oppen et 
al.,49 DBCO-modified polymersomes were formulated by blending in DBCO-PEG44-
PCL30gTMC30 with regular PEG22-50/13 prior to direct hydration. After polymersome 
formation (with or without cargo loading) 1 mg/mL solutions of either TAT or 
cTAT were added to give ca. 5-fold excess of CPP, followed by stirring at room 
temperature for 3 h. Purification of the modified polymersomes was performed 
afterwards using dialysis tubing with 12-14 kDa MWCO at 4 °C. The polymersome 
concentration was calculated by monitoring the absolute scattering intensity 
before and after processing.
CPP labelling efficiency - In order to confirm the successful modification of 
(active) DBCO moieties on the polymersome surface, we prepared 3-azido-7-
hydroxycoumarin according to a literature procedure.50 Using fluorescent read-out 
at 480 nm we calibrated the DBCO concentration using partially soluble DBCO-
acid (Click Chemistry Tools) at a range of concentrations (up to 40 µM) in order to 
estimate how much of the DBCO was modified by CPP.
Calcein release assay - Polymersomes encapsulating calcein were prepared using a 
calcein solution (100 mM) in 10 mM phosphate buffer (pH 7.4) in the encapsulation 
stage. Polymersomes encapsulating calcein were purified using a Sepharose (GE 
Healthcare) SEC column. Purified polymersomes were collected and divided into 2 
aliquots. The first aliquot was treated with 5 % of sodium dodecyl sulfate (SDS) in 
order to establish maximum release of calcein by disassembling the polymersomes 
and the second aliquot was studied for release behaviour. 
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Fluorescence increase resulting from calcein leakage, and concomitant de-
quenching, was recorded over 24 h and normalized against the SDS-treated 
sample. All experiments were performed in triplicate and with a delay inherent 
in the measurement of calcein release due to the time taken to transfer purified 
samples to the spectrophotometer.
Biodegradation of polymersomes - Biodegradation studies of polymersomes were 
performed by diluting polymersomes directly into 400 μL of human blood serum 
(HBS) after formation. Degradation was monitored by following the scattering 
intensity (turbidity) at 450 nm, and also using DLS.
FITC-BSA/Proteinase K assay - mPEG22-50/13 polymersomes encapsulating FITC-
labelled BSA were prepared using a 5 mg/mL FITC-BSA solution in the encapsulation 
stage of polymersome formation. Un-encapsulated protein was removed by SEC. 
Proteinase K was added to the polymersome solution at 1 mg/mL in order to probe 
protein cleavage by monitoring increase in the fluorescence at 520 nm. For the 
control experiment, SDS solution was added immediately to the polymersome 
solution and strong increase in the fluorescence was observed due to direct contact 
between released cargo and the protease. In the standard experiment, protease 
was added immediately and SDS was only added after 5 minutes in order to trigger 
disassembly and cargo release.
Ruthenium-labeling of enzymes and calculating enzyme encapsulation using 
inductively coupled plasma mass spectroscopy (ICPMS) - Ruthenium-labelled 
glucose oxidase (GOx) and horseradish peroxidase (HRP) were prepared using 
Ru-ITC as we have previously described.51  Briefly, enzymes were dissolved in 
0.1 M NaHCO3 buffer at pH 9 (2 mL at 5 mg/mL), to which a DMSO solution of 
Ru-ITC was added (100 µL at 3.5 mg/mL) in order to give ca. 2.5 equivalents 
of Ru-ITC per protein. The solution was gently mixed at 4 °C overnight before 
the enzyme was purified by spin filtration using Amicon Ultra centrifugal filters 
with a 10 kDa membrane, after which the enzymes were freeze-dried. Enzyme-
loaded polymersomes were prepared according to the described methodology 
and purified using a Superose 6 column. ICPMS samples were prepared by 
making a calibration series of the Ru-labelled enzyme and a dilution series of 
the enzyme-loaded polymersomes (including 10 vol% of 70 % HNO3 to destroy 
the samples). Taking into account the dilution factor of the polymersomes it 
was then possible to calculate the encapsulation efficiencies for the enzymes.
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Nanoreactor GOx/HRP assays - Polymersome batches with encapsulated 
enzymes were prepared (one encapsulating GOx and the other encapsulating 
HRP) by using solutions of GOx (8.2 mg/mL in PBS) or HRP (8 mg mL-1 in PBS) 
for the hydration of PEG22-50/13 copolymer. Another batch of polymersomes 
was prepared comprising both enzymes in a ratio of 1:1, using a combined 
solution of GOx and HRP for polymersome hydration (4.1 mg/mL and 4 mg/
mL, respectively). Samples were subsequently purified over a SEC column to 
remove non-encapsulated enzymes. GOx activity was evaluated at different 
glucose concentrations by mixing 2 mL ABTS solution (5 mM in PBS), 125mL 
of HRP solution (50 µg/mL) with 125 mL of polymersome solution (or a 15 µg/
mL GOx solution) and after 5 minutes, 250 mL of glucose solution was added 
and the formation of ABTSα+ was recorded at 420 nm. To measure HRP activity, 
different concentrations of H2O2 were used with the same amount of ABTS 
and peroxidation was monitored at 420 nm. ICPMS measurements confirmed 
that the encapsulation efficiency of enzymes in the single loaded and co-
encapsulated polymersomes was the same and, therefore, would scale for 
comparative activity measurements.
Dynamic light scattering measurements (DLS) - DLS measurements were 
conducted using a Malvern Instruments Zetasizer (ZEN 1600), and Zetasizer 
Software (Malvern Instruments) was used for processing and analyzing the 
data.
Cryogenic transmission electron microscopy (cryo-TEM) - Experiments were 
performed using a JEOL TEM 2100 microscope (JEOL, Japan). Analysis and 
processing of the data was performed using ImageJ, a program developed by the 
NIH and available as public domain software at http://rsbweb.nih.gov/ij/. Samples 
for CryoTEM measurements were prepared by first treating the grids (Quantifoil 
R2/2 Cu 200 mesh grids) in a 208HR sputter coater for 20 seconds. Afterwards, 3 µL 
of sample was brought on the grid and blotted in a FEI Vitrobot Mark IV, at 100 % 
humidity. Subsequently, the grid was blotted and directly frozen in liquid ethane.
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Asymmetric flow field-Flow fractionation, multi-angle light scattering and 
quasi elastic light scattering (AF4-MALS-QELS) - AF4-MALS-QELS experiments 
were performed on a Wyatt Eclipse AF4 instrument connected to a Shimadzu 
LC-20A Prominence system with Shimadzu CTO20A injector. The AF4 was further 
connected to the following detectors: a Shimadzu SPD20A UV detector; a Wyatt 
DAWN HELEOS II light scattering detector (MALS) installed at different angles 
(12.9 °, 20.6 °, 29.6 °, 37.4 °, 44.8 °, 53.0 °, 61.1 °, 70.1 °, 80.1 °, 90.0 °, 99.9 °, 109.9 °, 
120.1 °, 130.5 °, 149.1 °, and 157.8 °) using a laser operating at 664.5 nm; a QELS 
detector installed at an angle of 140.1° and a Wyatt Optilab Rex refractive 
index detector. Detectors were normalized using Bovine Serum Albumin. The 
processing and analysis of the LS data and radius of gyration (R G) calculations were 
performed on Astra 6.1.1 software (using the Berry model, which is recommended 
for particles of size > 50 nm). All AF4 fractionations were performed on an AF4 
short channel with regenerated cellulose (RC) 10 kDa membrane (Millipore) and 
spacer of 350 µm.
Polymersome purification via size exclusion chromatography (SEC) - SEC 
purification of the polymersomes was conducted using a Shimadzu system 
(equipped with an SPD-M20A photodiode array) with a Superose 6 column (GE 
Healthcare) using an eluent identical to that of the polymersome solution.
Inductively coupled plasma-mass spectrometry (ICP-MS) - ICP-MS measurements 
of Ru-labelled enzymes were performed on a Thermo Fischer Scientific X series I 
quadrupole machine.
Release assay measurements - Calcein release assays were performed in a 96- 
black well f-bottom microplate (Greiner-Bio-One) in a Berthold Tristar2 LB942 
Multidetection Microplate Reader equipped with a 550 nm excitation filter and a 
610 nm emission filter.
UV-VIS - Absorbance was recorded on a Varian Cary-50-UV-VIS spectrophotometer.
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Cell culture - HEK293T cells were grown as a monolayer in DMEM with GlutaMax, 
high glucose and pyruvate (#31966 GIBCO, Life Technologies Invitrogen, Breda, 
the Netherlands) supplemented with 10 % v/v fetal calf serum (FCS) (GIBCO, Life 
Technologies Invitrogen) and 100 IU/mL penicillin/streptomycin (#15140122 Life 
Technologies Invitrogen) in a humidified atmosphere of 95 % air – 5 % CO2 at 37 
°C. Assay medium for HEK293T cells was without glucose, glutamine, phenol red 
and sodium pyruvate (#A14430-01, GIBCO, Life Technologies), supplied with 10 % 
FCS, 100 IU/mL penicillin/streptomycin, 2 mM L-Glutamine (#25030-024, Gibco, 
Life Technologies), 5 mM D-glucose (#8769 GIBCO, Life Technologies) and 10 mM 
HEPES (#15630056, Gibco, Life Technologies).
Confocal microscopy for visualizing uptake in a cell monolayer - Two days prior 
to imaging, HEK293T cells were seeded in complete medium at 40,000 cells/well on 
an 8-well coverglass slide (#155411, Nunc Lab-Tek Chamber slide #1.0 Borosilicate 
coverglass, Nunc, Wiesbaden, Germany). One day before imaging, the medium 
was replaced by complete medium containing the appropriate concentration 
of polymersomes. After incubation, the medium including polymersomes was 
removed and the cells were washed three times with PBS and imaged in assay 
medium. Co-localization markers CellMask Green (C37608, Life Technologies 
Invitrogen) and CellMask Deep Red (C10046, Life Technologies Invitrogen) were 
used to stain the plasma membrane. Cells were incubated with the 1x working 
solution (provided solution is 1000x) for three minutes, washed three times with 
PBS and imaged within 10 minutes in assay medium. Imaging was performed with a 
TCS SP5 confocal microscope (Leica Microsystems, Mannheim, Germany) equipped 
with an HCX PL APO 63x N.A. 1.2 water immersion objective. Cells were maintained 
at 37 ºC on a temperature-controlled microscope stage. The polymersomes 
labeled with NBD and CellMask Green were excited by an argon laser at 488 nm 
and emission was collected between 500 and 550 nm. Polymersomes including 
AlexaFluor647-labelled bovine serum albumin (AF647BSA) and CellMask Deep Red 
were excited with a 633 nm HeNe laser and emission was collected between 655 
and 750 nm. Both green and red fluorescent labels were excited sequentially. 
Images were analyzed with Image Pro Plus 6.1 (Media Cybernetics, Rockville, MD, 
USA) and FIJI software (http://fiji.sc/). 
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Confocal microscopy for visualizing cellular trafficking in a cell monolayer 
Two days prior to imaging, HEK293T cells were seeded in complete medium 
at 40,000 cells/well on an 8-well coverglass slide (#155411, Nunc Lab-Tek 
Chamber slide #1.0 Borosilicate coverglass, Nunc, Wiesbaden, Germany). One 
day before imaging, the medium was replaced by complete medium containing 
the appropriate concentration of polymersomes. After incubation of one 
hour, the medium including polymersomes was removed and the cells were 
washed two times with PBS and for 24 h incubated with complete medium in 
a humidified atmosphere of 95 % air – 5 % CO2 at 37 °C. To stain the lysosomes, 
the cells were incubated with 75 nM LysoTracker Green DND-26 (Thermo Fisher 
Scientific) for one hour in a humidified atmosphere of 95 % air – 5 % CO2 at 37 
°C. After removal of staining, the cells were imaged in assay medium. Imaging 
was performed with a TCS SP8 microscope (Leica Microsystems, Mannheim, 
Germany) equipped with an HCX PL APO 63x N.A. 1.2. water immersion objective. 
Cells were maintained at 37 °C on a temperature-controlled microscope stage. 
LysoTracker Green was excited by an argon laser at 488 nm, and emission was 
collected between 500 and 550 nm. Simultaneously, AF647BSA was excited with 
a white light laser at 647 nm and emission was collected between 655 and 
750 nm. Both emission signals were simultaneously recorded with avalanche 
photodiode/photomultiplier tubes hybrid detectors (HyD, Leica). Images were 
analyzed with Image Pro Plus 6.1 (Media Cybernetics, Rockville, MD, USA) and 
FIJI software (http://fiji.sc/).
Flow cytometry for visualizing uptake of polymersomes in a cell monolayer 
HEK293T cells were seeded in 24-well plates (Sarstedt, Numbrecht, Germany) at 
80,000 cells/well two days prior to measurement. Cells were incubated with the 
indicated concentration of polymersomes in complete medium for 24 hours. After 
incubation, the cells were washed 3x with PBS and detached by trypsinisation 
for 2-3 minutes, spun down and resuspended in assay medium. The fluorescent 
signal of the polymersomes was measured using a FACSCalibur flow cytometer 
(BD BioSciences, Erembodegem, Belgium) and subsequently data was analyzed 
with FlowJo Software. The cells were gated on the live population by forward 
and side scatter and 10,000 cells were counted to determine cellular uptake by 
measure of mean cellular fluorescence in the FL-I channel.
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Statistical Analysis - The number of independent experiments is marked by 
n, each experiment performed in duplicate. Average values are represented 
as mean ± SD. Values were tested for significance using the two-way analysis 
of variance (ANOVA) at 95 % confidence level (p < 0.05), followed by Tukey’s 
multiple comparisons test (Graph Pad Prism software, version 6), unless 
stated otherwise. Significant differences are indicated by *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001.
Results
Engineering biodegradable PEG-PCLgTMC polymersomes via direct 
hydration
The essential requirements for polymersomal nanoreactors to be successfully 
implemented as synthetic organelles are biocompatibility and semi-
permeability. To accomplish this goal we set out to develop biodegradable 
block copolymers (BCPs) in order to generate self-assembled nanostructures 
with the desired properties. BCPs comprising poly(ethylene glycol) (PEG) with 
various hydrophobic, biodegradable polymers such as poly(caprolactone) (PCL), 
poly(lactide) (PLA) or poly(trimethylene carbonate) (PTMC) have been presented 
as biocompatible building blocks for the preparation of polymersomes.17,52–58 
Recently, the self-assembly of PEG-PCL via an unconventional direct hydration 
process was reported,39 replacing harmful solvents with non-toxic low 
molecular weight oligo(ethylene glycol) (OEG).38 Although PCL is a commonly 
used polyester in biomedical research,59 its high crystallization temperature 
(Tc) (ca. 55-60 °C) impedes control over self-assembly and causes undesirable 
membrane properties. Therefore, if we are to use BCPs related to PCL in the self-
assembly of polymersomal nanoreactors crystallinity should be reduced. To 
achieve this, it has been reported that copolymerization of caprolactone with 
a distinct monomer (capable of reducing overall crystallinity) imparts greater 
control over self-assembly.17
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Inspired by this work, a strategy was adopted for the preparation of (non-
crystalline) gradient copolymers comprising PCL and poly(trimethylene 
carbonate) (PCLgTMC) via organocatalyzed ring-opening polymerization.60,61 
For chemical optimization, PEG-PCLgTMC BCPs with varying PEG length (X), 
TMC content in the hydrophobic block (Y, wt%) and overall hydrophilic content 
(Z, wt%) were prepared; designated mPEGX -Y/Z. Cryo-TEM screening indicated 
that the optimal composition for polymersome formation was close to mPEG12 
or mPEG22-50/13. Physical optimization of direct hydration involved maximizing 
the [copolymer] in OEG (prior to hydration) and minimizing the amount of 
buffer necessary to induce subsequent polymersome formation, so as to make 
protein encapsulation more favourable (process outlined in Figure 2). 
Figure 2. (a) Synthesis of poly(ethylene glycol)-block-poly(caprolactone-gradient-
trimethylene carbonate) (PEG-PCLgTMC) copolymers via organocatalyzed ring-opening 
polymerisation. (b) Direct hydration protocol where a thin film of OEG/copolymer solution (1) 
is hydrated by a small volume of buffer containing functional cargo for encapsulation in the 
polymersomes (2) and diluted up to the desired [copolymer] (3). (c) Schematic illustrating the 
spontaneous hydration of polymersomes; encapsulating cargo as hydrophobic self-assembly 
occurs. Figure taken from reference 49.
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While [copolymer] (in OEG) > 10 wt% resulted in visible aggregation, formulation 
at 10 wt% resulted in uniform polymersomes and was, therefore, chosen for 
further tests. Using a combination of asymmetric flow field-flow fractionation 
(AF4) coupled with dynamic light scattering (AF4-DLS) we confirmed that 
adding 80 µL of phosphate-buffered saline (PBS) in the hydration of 20 µL 
of (stirred) OEG/copolymer solution (mPEG22-50/13) was optimal to obtain 
polymersomes of ca. 100 nm in size (Figure 3a). After stirring the cloudy 
solution for 5 minutes, subsequent dilution with 400 µL PBS yielded a visually 
homogenous polymersome suspension with [copolymer] = 4 mg/mL. Analysis 
of polymersomes comprising mPEG12 or mPEG22-50/13 (by AF4-DLS) yielded 
average sizes of 200 and 100 nm, respectively. Analysis of membrane thickness 
from cryo-TEM images yielded values of around 7 and 14 nm, respectively (data 
not shown). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Characterization of semi-permeable PEG-PCLgTMC polymersomes. (a) Cryo-TEM 
image of mPEG22-50/13 (50 wt% TMC in hydrophobic block / 13 wt% overall hydrophilic 
PEG content) polymersomes, fabricated by direct hydration from a 10 wt% OEG solution. (b) 
Calcein release curves for mPEG22-50/13 (red) and mPEG12-50/13 (blue) polymersomes. (c) 
Characterization of eGFP-loaded polymersomes using cryo-TEM (upper) and AF4-MALS/DLS 
(lower) - molecular weight of copolymer (red) and eGFP (green) in polymersomes (total mass 
in blue) was calculated from the corresponding dn/dc values and plotted against size (spheres) 
with the scattering fractogram inserted for reference (grey). (d) Macromolecular shielding of 
encapsulated FITC-BSA substrate from proteinase K degradation (blue line) as compared to 
the free substrate (red dashes). Polymersome disruption by surfactant addition (*) caused 
content leakage and rapid degradation of internal cargo. All scale bars = 200 nm
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Semi-permeability, protein encapsulation and shielding properties of 
polymersomes
With a platform for the facile preparation of well-defined, biodegradable 
polymersomes, a calcein release assay was performed to probe the permeability 
of the PCLgTMC membrane. Monitoring calcein release by the de-quenching 
of its fluorescence signal, it was evident that both mPEG12 and mPEG22-50/13 
polymersomes were semi-permeable (Figure 3b). mPEG12-50/13 polymersomes 
showed a faster release profile with ca. 90 % of encapsulated dye released after 
30 hours as compared to ca. 60 % in the case of the, thicker-walled, mPEG22-
50/13 counterpart.
To evaluate protein loading in this system we encapsulated eGFP (5 mg/mL). 
Measurement of the refractive index increment (dn/dc) of eGFP-loaded PEG-
PCLgTMC polymersomes revealed a value of 0.078. Using this value and the 
extinction coefficient of eGFP (ε480 = 55,000 M
-1cm-1) polymersome loading was 
quantified. By mass, the eGFP content averaged around 5 wt%, equivalent to 
approximately 200 proteins per polymersome with an approximate [eGFP]internal 
in the region of 20-60 mg/mL (Figure 3c).
A fundamental property of compartmentalized systems is that they are 
capable of shielding sensitive cargo from degradation. By encapsulating a self-
quenching FITC-BSA substrate we were able to demonstrate this property in 
the PEG-PCLgTMC polymersomes. Whilst the polymersome remained intact, 
proteinase K was not able to permeate the membrane, until concentrated 
surfactant was added into the system that resulted in rupture and rapid 
degradation of the sensitive cargo (Figure 3d).
Degradation studies, where polymersomes were diluted into human serum, 
revealed a striking difference between the stability of polymersomes comprising 
mPEG12 and mPEG22 copolymers. Although both scattering and DLS confirmed 
that mPEG22-50/13 polymersomes did not show any degradation within 24 
hours, mPEG12-50/13 degraded rapidly within 3 hours (Figure 4).
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Figure 4. (a) Monitoring the degradation of mPEG12-(red) and mPEG22-50/13 polymersomes 
(black) in human serum, as detected by the solution turbidity at 450 nm. (b-c) DLS correlation 
data for human serum (blue) compared to fresh polymersome dispersions (black) and after 
24 h of incubation (red). It is evident from the data that mPEG22-50/13 is stable after 24 h with 
no change in the correlogram (b), whereas the mPEG12-50/13 sample only shows the presence 
of serum after this time (c).
This observed behaviour was attributed to the thinner membrane of mPEG12-
50/13 polymersomes and contributed to the decision to use mPEG22-50/13 as 
the basis for our studies. The observed semi-permeability and biodegradability 
of soft PEG-PCLgTMC polymersomes make them an exciting candidate for 
development as autonomous (not requiring any additional modification) 
nanoreactors.
Enzyme-loaded polymersomes function as autonomous nanoreactors
Through encapsulation of functional enzymatic cargo, such as glucose oxidase 
(GOx) and horseradish peroxidase (HRP), we evaluated the performance 
of PEG-PCLgTMC polymersomes as autonomous nanoreactors. Inductively 
coupled plasma mass spectrometry (ICPMS) was used to calculate the loading 
efficiencies of ruthenium-labelled GOx and HRP, which were 4.2 (± 0.2) and 
1.2 (± 0.3) %, respectively. Although the loading with HRP was appreciably 
lower than with GOx this reflects known (but poorly understood) variations 
in encapsulation efficiencies between different enzymes.51,62 Encapsulation 
efficiency values vary to the former value presented for eGFP due to the nature 
of the measurement, i.e. the latter was a direct content measurement in purified 
polymersomes. Subsequent assays were designed to compare the kinetics 
of free and encapsulated enzymes. Because exact [enzyme] encapsulated 
could not be determined to the necessary degree of accuracy, only the 
Michaelis-Menten constant (KM) was evaluated.
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Firstly, the kinetics of either HRP or GOx-loaded nanoreactors was evaluated 
using ABTS peroxidation as a photometric readout (Figure 5a-b). Either H2O2 
or D-glucose were used as substrates for assays using HRP or GOx, respectively, 
with HRP used in excess for the latter and ABTS always used at a saturating 
concentration. Interestingly, increases in the observed KM values (KM(obs)) were 
measured for both encapsulated systems, with ca. 70 % increase for HRP and 
ca. 240 % increase for GOx. Although Vmax values were similar, the apparent 
increase in KM(obs) is striking and can be best understood by the diffusive barrier 
experienced by the encapsulated enzymes arising from the semi-permeable 
(PEG-PCLgTMC) membrane. In the case of HRP this arises due to the hampered 
diffusion of H2O2 into the nanoreactor (reducing the actual [substrate] at the 
enzyme) and for GOx this arises due to the hampered diffusion of glucose 
in and H2O2 out of the compartment. It is therefore consistent that KM(obs) 
values for GOx are almost 4-fold larger, as compared to HRP. To demonstrate 
the positive benefits of compartmentalization, experiments were performed 
to compare the consequences of co-encapsulation on the performance of the 
cascade reaction. In accordance with the previous data, a kinetic improvement 
in the cascade was observed in the co-encapsulated system as compared to 
the mixture of mono-encapsulated nanoreactors (Figure 5c). The observed 
percentage increase in the rate of ABTS peroxidation between mono- and co-
encapsulated nanoreactors decreased as [glucose] increased (from 70 to 20 
%). This observation was understood to arise from a more detrimental effect 
of substrate diffusion at lower [glucose], diminishing as saturating conditions 
are approached. Although our discussion has focussed upon KM and substrate 
diffusion, kinetic enhancements that arise due to compartmentalization cannot 
be discounted,63 however, a full examination of this is beyond the scope of the 
present experimental work.
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Figure 5. Nanoreactor characterization of enzyme-loaded polymersomes using Michaelis-
Menten kinetic plots to compare free and encapsulated (a) HRP and (b) GOx alongside (c)
a mono- (red) and co-encapsulated (blue) HRP/GOx cascade; the black curve shows the 
difference in rate between the co- and mono-encapsulated systems.
Figure 6. Uptake of NBD-labeled polymersomes in HEK293T cells after 24 h at different 
polymersome concentrations (0.05-0.1 mg/mL) and with different percentages of CPP (c)TAT 
(0-5 %), quantified by flow cytometry (mean fluorescence of live cells presented ± SD, n = 3). 
Significant differences are indicated by **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Cell uptake of CPP-functionalized polymersomes
To investigate whether and how cell penetrating peptides TAT and cTAT would 
induce efficient cellular uptake of polymersomes, trafficking behaviour was 
evaluated in HEK293T cells after covalently coupling azido-TAT or azido-cTAT 
to fluorescent nitrobenzoxadiazole (NBD)-doped polymersomes comprising 
either a 2.5 or 5 wt% doping of dibenzocyclooctyl (DBCO)-modified PEG-
PCLgTMC using biorthogonal click chemistry. HEK293T cells were treated with 
polymersomes for 24 h prior to analysis of cell uptake by flow cytometry and 
confocal laser scanning microscopy (CLSM). Flow cytometry revealed that cell 
uptake was virtually absent for unmodified polymersomes (0 % CPP), whereas 
TAT- and cTAT-polymersomes were readily taken up in a concentration-
dependent manner (Figure 6). At both concentrations, the effect of TAT was 
already maximal at 2.5 % surface loading, whereas for cTAT a further increase 
was observed at 5 %, suggesting the possibility of higher uptake with the latter 
TAT variant.
In agreement with the flow cytometry data, CLSM showed virtually no cell 
uptake for unmodified polymersomes (Figure 7a-b). In sharp contrast, (c)TAT-
polymersomes were abundantly present both at the cell membrane and within 
intracellular punctate structures (Figure 7c-f).
52
Chapter 2 | Synthesis, characterization and cellular integration of biodegradable, polymersomal 
nanoreactors
 
Figure 7. Subcellular distribution of NBD-labeled polymersomes in HEK293T cells. All cells were 
treated with 0.1 mg/mL polymersomes for 24 h. Cells were: (a) non-treated, or treated with (b) 
unmodified polymersomes, (c) 2.5 % TAT, (d) 2.5 % cTAT, (e) 5 % TAT or (f) 5 % cTAT modified 
polymersomes. Polymersomes (green), cell membranes (red) and scale bars represent 20 µm. 
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Calculation of the Pearson’s colocalization coefficient (PCC), which provides 
an estimate on the extent of overlap between green (polymersomes) and red 
(plasma membrane) pixels, showed no difference between TAT and cTAT for the 
two percentages tested (Figure 8). Similarly, the PCC did not differ between 
2.5  and 5 % TAT, whereas a significantly higher PCC value was observed at 5 % 
cTAT. Because the data obtained did not show any beneficial effect of the cyclic 
variant and, due to its reduced tendency to accumulate in the cell membrane, 
TAT was used at its optimal concentration of 2.5 % in further experiments. 
Figure 8. Quantification of Pearson’s correlation coefficient (PCC) calculated from the green 
fluorescent signal (polymersomes) over the red fluorescent signal (plasma membrane) as 
described in detail in Koopman et al, 2006.64 Figure 7 for relevant confocal images. Average 
values are represented as mean ± SD. The mean represents 3 field of views per condition, with 
each field of view representing 4 areas of interest, each containing 30-40 cells. ****P < 0.0001.
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The ability of 2.5 % TAT-polymersomes to deliver macromolecular cargo was 
demonstrated using AlexaFluor647-labelled bovine serum albumin (AF647BSA). 
Orthogonal projections of HEK293T cells treated with AF647BSA-loaded 
polymersomes for 24 h unequivocally demonstrated the presence of cargo (red) 
in punctate structures located within the cell (Figure 9a). Such structures are 
indicative of endolysosomal uptake, which was confirmed by pulse incubating 
cells with AF647BSA encapsulating 2.5 % TAT-polymersomes for 1 h followed by a 
chase incubation of 24 h and staining with LysoTracker Green showing a strong 
colocalization (PCC value of 0.6 ± 0.19; Figure 9b). Visual inspection of the Lyso 
Tracker Green-positive structures (Figure 9c) shows a marked enlargement upon 
treatment with AF647BSA encapsulating 2.5 % TAT-polymersomes (Figure 9c/
iii). The overlay shows that these structures are AF647BSA-positive, indicating the 
lysosomal accumulation of AF647BSA-polymersomes. 
Similarly enlarged Lyso Tracker Green-positive structures were observed upon 
treatment with free AF647BSA (Figure 9c/ii). Also in this case these structures 
appeared, though extremely faintly, AF647BSA-positive. The possibility of cross-
talk was excluded (Figure 10). Because equal amounts of AF647BSA were used, 
either free or encapsulated, this result clearly demonstrates the strong uptake-
facilitating properties of TAT-polymersomes. The 2.5 % TAT-polymersomes, loaded 
with catalase, were used to add functionality to the cells in subsequent studies 
(Chapter 3).
> Figure 9. (a) Confocal microscopy images (sequential scanning mode) depicting the sub-cellular 
distribution of 2.5 % TAT-polymersomes encapsulating AF647BSA (red) after 24 h incubation at a 
concentration of 0.4 mg/mL (plasma membrane stained with CellMask Green (b) Quantification of 
Pearson’s correlation coefficient (PCC) calculated from the red fluorescent signal (polymersomes) 
over the green fluorescent signal (LysoTracker Green) as described in detail in Koopman et al, 
2006.64 Calculations were performed on original (non-processed) confocal images (simultaneous 
scanning mode). Average values are represented as mean ± SD. The mean represents data of 
three independent experiments, with at least 5 images per condition per experiment. **P < 0.01, 
***P < 0.001, ****P < 0.0001. (c) Confocal microscopy images (simultaneous scanning mode) 
depicting the endolysosomal localization of 2.5 % TAT-polymersomes encapsulating AF647BSA 
after a 1 h pulse with 0.4 mg/mL polymersomes followed by a 24 h chase period in polymersome-
free medium. Acidic cellular compartments stained with LysoTracker Green. (i) LysoTracker Green, 
(ii) LysoTracker Green and free AF647BSA, (iii) LysoTracker Green and 2.5 % TAT-polymersomes 
encapsulating AF647BSA. For visualization purposes, brightfield images were contrast-optimized 
using a Linear Contrast Stretch (LCS) operation. Both green and red channels were depicted using 
grey scale (0-80). Scale bars = 10 µm. 
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Figure 10. Confocal microscopy images (simultaneous scanning mode) depicting the cellular 
uptake of 2.5 % TAT-polymersomes encapsulating AF647BSA after a 1 h pulse with 0.4 mg/mL 
polymersomes followed by a 24 h chase period in polymersome-free medium. (a) Non-treated, 
(b) free AF647BSA, (c) 2.5 % TAT-polymersomes encapsulating AF647BSA. For visualization 
purposes, brightfield images were contrast-optimized using a Linear Contrast Stretch (LCS) 
operation, other channels displayed  (L to R) are green (LysoTracker-absent in these studies 
but present in Figure 9), red (AF647BSA) and merge. Both green and red channels were depicted 
using grey scale (0-80). Scale bars represent 10 µm.
Discussion
The aim of this study was the evaluation of an enzyme-containing nanoreactor 
formed through self-assembly of PEG-PCLgTMC copolymers in terms of 
biocompatibility, -degradability and -stability, size and loading capacity, 
permeability and shielding effectivity, and cell uptake and subcellular 
localization. The data obtained show that most of these requirements are met 
by PEG22-b-(PCl50-g-TMC13) copolymers and that, therefore, polymersomes made 
from these copolymers are suitable for further development into synthetic 
organelles aimed at substituting for missing or lost activity in human disease.
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Biocompatibility, -degradability and -stability are crucial requirements for 
successful polymersome-based therapy in the human body.65,66 All three 
requirements were successfully met by self-assembled PEG22-b-(PCl50-g-TMC13) 
polymersomes, consisting of copolymers with a hydrophilic part, poly(ethylene 
glycol) (PEG), in combination with the polymers poly(caprolactone) (PCL) and 
poly(trimethylene carbonate) (PTMC). The size of these polymersomes was ~100 
nm with a membrane thickness of 14 nm. In human serum these polymersomes 
proved to be stable for at least 24 h, which favors their applicability in clinical 
settings.67
Another crucial requirement is that polymersomes can efficiently be loaded with 
cargo.68 Quantification of PEG22-b-(PCl50-g-TMC13) polymersome loading with 
eGFP revealed an average value of around 5 wt%, equivalent to approximately 
200 eGFP molecules per polymersome with an approximate [eGFP]internal in the 
region of 20-60 mg/mL.
In the case of enzyme-filled nanoreactors, the next step is to verify that 
substrate(s) and product(s) can cross the polymersomal wall.69,70 Comparison 
of Michaelis-Menten kinetic plots of free and encapsulated glucose oxidase 
(GOx) and horseradish peroxidase (HRP) revealed no difference in Vmax between 
free and encapsulated enzyme but an increase in Km for encapsulated enzyme. 
The latter was interpreted as likely to be due to a diffusive barrier experienced 
by encapsulated enzyme arising from the semipermeable (PEG-PCLgTMC) 
membrane hampering the diffusion of H2O2 and glucose into the nanoreactor. 
Importantly, proteinase K was unable to disrupt the self-assembled structures 
or to destroy encapsulated FITC-BSA, demonstrating the excellent shielding 
effectiveness of PEG22-b-(PCl50-g-TMC13) nanoreactors. 
A critical step in the development of polymersomes as intracellular nanoreactors 
is their ability to cross the plasma membrane.10,71,72 Because PEGylated 
polymersomes are hardly taken up by eukaryotic cells,68,73 their surface needs 
to be decorated with proteins that promote cell internalization. To this end, 
two variants of CPP TAT, the linear one and the cyclic one, were clicked at 
increasing density (0 %, 2.5 % and 5 %) onto the surface of the PEG22-b-(PCl50-
g-TMC13) polymersomes. Each condition was evaluated at two polymersome 
concentrations (0.05 mg/ml and 0.1 mg/mL). 
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The presence of CPP TAT proved to be obligatory for the uptake of the 
polymersomes in HEK293T cells, confirming previous results from our group.74 
In agreement with our findings, TAT was shown to efficiently promote the 
intracellular delivery of polymersomes in dendritic cells.75 Although cyclic 
TAT, in contrast to linear TAT, was demonstrated to deliver full-length proteins 
(GFP) directly into the cytosol,46 this was not observed for TAT-decorated 
PEG22-b-(PCl50-g-TMC13) polymersomes. Both variants caused exactly the same 
intracellular localization in vesicles of the endolysosomal system. Therefore, 
linear TAT was used in the remainder of the study. 
The aim of polymersome nanoreactor research is to substitute for missing 
or lost activity. To this end, polymersome nanoreactors should remain intact 
not only in the circulation, but also after cellular uptake.68 The data showed 
that with the treatment protocol used, namely 1 h pulse followed by a 24 h 
chase, the vast majority of the cargo (AF647BSA), ended up in LysoTracker 
Green-positive objects. Cells treated with TAT-free polymersomes showed the 
predominant presence of relatively small LysoTracker Green-positive objects, 
which completely lacked AF647 fluorescence. In contrast, cells treated with TAT-
polymersomes displayed enlarged LysoTracker Green-positive objects, which 
were brightly AF647 fluorescent, indicating the presence of AF647 in vesicles of 
the endolysosomal system. After treatment with free AF647BSA, a small amount 
of relatively faint AF647-fluorescent LysoTracker Green-positive objects was 
observed. Interestingly, however, these objects were also enlarged to the 
same degree as observed in TAT polymersome-treated cells. It is tempting 
to speculate that similar amounts of AF647 are present, but that free AF647, in 
contrast to polymersome-associated AF647, is not protected against lysosomal 
degradation. Einfalt et al. investigated the uptake and subcellular localization 
of PMOXA-PDMS-PMOXA polymersomes in HeLa cells and showed that these 
polymersomes were stable at acidic pH increasing the chance of endolysosomal 
escape.76 Cells treated for 24 h with these polymersomes containing labeled 
cargo showed very faint cytosolic aggregates. However, the PMOXA-PDMS-
PMOXA polymersomes did not contain a CPP, so uptake and endosomal release 
occurred in a CPP-independent manner. Obviously, endolysosomal escape of 
intact nanoreactors is the next hurdle to take if it comes to the generation of 
cytosolic synthetic organelles. 
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After having established the optimal polymer blend and self-assembly of PEG-
PCLgTMC copolymers into polymersomal vesicles using the direct hydration 
method, cellular integration towards acidic compartments was confirmed. 
This was a great challenge and important first step in the development of 
autonomous nanoreactors as promising therapy for patients suffering from 
mitochondrial disease. As next step, the functionality of enzyme-loaded 
polymersomes will be extensively evaluated in these patient cells.
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Abstract
The field of artificial organelles is interesting and of high potential impact. 
In chapter 2 we reported the synthesis and biophysical characterization of 
poly(ethylene glycol)-block-poly(caprolactone-gradient-trimethylene carbonate) 
(PEG-PCLgTMC) polymersomes and provided evidence for efficient cellular 
integration after surface decoration with cell penetrating peptide TAT into 
HEK293T cells. PEG-PCLgTMC polymersomes can readily be fabricated using the 
biocompatible direct hydration methodology and cell-free analysis revealed their 
semi-permeability and effective shielding capacity of encapsulated proteinaceous 
cargo. Although TAT-(PEG-PCLgTMC) polymersomes are readily internalized, 
robust data showing therapeutic efficacy in primary human cells are lacking. 
Here, we apply catalase-loaded PEG-PCLgTMC polymersomes to primary complex 
I-deficient patient skin fibroblasts and show full protection against exogenous 
H2O2-induced cell death. This effect was paralleled by complete prevention of the 
exogenous H2O2-induced increase in intracellular ROS. Taken together our results 
demonstrate that biocompatible catalase-nanoreactors successfully perform as 
a synthetic organelle, imparting activity-dependent antioxidant capacity to cells. 
Notably, for the first time, patient-derived human complex I-deficient primary 
fibroblasts are effectively protected against the toxicity of exogenous H2O2 by the 
action of internalized enzyme-loaded nanoreactors, showcasing this system in a 
therapeutically relevant context.
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Introduction
Polymersomes, synthetic replicas of liposomes, which are capable of 
encapsulating and stabilizing sensitive internal cargo such as enzymes,1,2 have 
great potential for cellular therapy.3,4 Cellular uptake is an essential feature to 
exert a therapeutic effect. In the previous chapter, cargo-loaded, biodegradable 
poly(ethylene glycol)-block-poly(caprolactone-gradient-trimethylene carbonate) 
(PEG-PCLgTMC) polymersomal nanoreactors have been shown to undergo 
cellular integration via the endolysosomal system mediated after surface 
decoration with the cell penetrating peptide TAT. Pioneering studies using 
nanoreactors in vivo have yielded interesting results, with superoxide dismutase-
loaded polymersomes functioning as antioxidants to reduce neuropathic pain 
(rat model) and β-galactosidase-loaded polyion complex vesicles (PICsomes) 
showing specific function within tumor tissue (mouse model).5,6
It is important to measure the effect of polymersomes towards an appropriate 
therapeutic target using a quantitative biochemical evaluation that will 
take us beyond proof-of-principle. In this respect, the pathological effect of 
hydrogen peroxide (H2O2) is a medically relevant topic of investigation. H2O2 is 
highly diffusible and relatively long-lived,7 serving as a key molecule in redox 
signaling, control and regulation.8 Mitochondria are an important source 
of intracellular H2O2, resulting from dismutation of superoxide produced at 
complexes I (CI) and III (CIII) of the oxidative phosphorylation system, which 
is subsequently reduced to water by the action of both cytosolic and mito-
chondrial peroxidases and peroxisomal catalase. When the native antioxidant 
capacity of a cell is overwhelmed by endogenous and/or exogenous reactive 
oxygen species (ROS), a condition of oxidative stress occurs.9 Oxidative stress 
is implicated in the pathogenesis of many human diseases including common 
neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Huntington’s, 
cancer and rare disorders of the mitochondrial oxidative phosphorylation 
system.10–12 Therefore, the generation of antioxidant nanoreactors (AONs), 
which can be integrated into cells that are experiencing heightened ROS levels, 
is a strategy that has great medical potential. Acatalasemia, an autosomal 
recessive condition that results in a >90 % reduction in cellular catalase activity, 
is an example where such a strategy could be highly effective. Individuals 
with inherited catalase deficiency have a high prevalence of diabetes mellitus 
(18.5 %) and of diseases related to oxidative stress (85 %).13 
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In mice models, studies show that catalase-deficiency leads to ROS sensitivity,14 
whereas catalase over-expression prolongs lifespan and attenuation of age-
related pathologies.15–17 
Mitochondrial CI deficiency is associated with neurodegeneration and studies 
using primary patient-derived skin fibroblasts indicate an imbalance between 
the production and scavenging of ROS.18,19 Studies on mice with malfunctioning 
CI also indicated that increases in neuronal ROS are an important part of the 
neurodegeneration process.20 
Currently, there is no cure for complex I deficiency disorders.21 Therefore, with 
increased attention being paid to the development of advanced therapeutic 
technologies to tackle these and age- and cancer-related diseases, attenuation 
of (cellular) ROS stress is an excellent niche to focus on. 
In this study we use primary skin fibroblasts from a patient with Mendelian 
complex I-deficient Leigh Syndrome and present, for the first time, catalase-
loaded, semipermeable polymersomes (comprising biodegradable copolymers) 
as antioxidant nanoreactors (AONs) in a medically relevant application. We 
demonstrate (and quantify) the capacity of AONs to function as synthetic 
organelles, providing effective shielding of patient-derived primary cells from 
ROS in vitro (Figure 1). Such unprecedented application of this technology 
makes the important step from proof-of-principle research to a biomedically 
relevant platform, which reflects the robustness and versatility of this approach 
and will, hopefully, inspire further development towards realization of synthetic 
organelles in clinical studies.
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Figure 1. Engineering and functioning of a biodegradable synthetic organelle. (a) Poly 
(ethylene glycol)-block-poly(caprolactone-gradient-trimethylene carbonate) (PEG-PClgTMC) 
copolymers were synthesized and, utilizing the direct hydration method, underwent controlled 
self-assembly into polymersomes that could be loaded with enzymatic cargo such as catalase. 
(b) PEG-PClgTMC polymersomes that possess a semi-permeable membrane facilitate trans-
membrane substrate diffusion for compartmentalized enzymatic reactions (e.g. X = H2O2 and 
Y = H2O + O2), functioning as autonomous nanoreactors. (c) Cellular integration is directed 
via covalent coupling of a cell-penetrating peptide (CPP) TAT to the polymersome surface. 
(d) Antioxidant polymersomes (containing catalase) demonstrate ROS shielding in both 
HEK293T and primary human skin fibroblasts. Figure adapted from reference 22. 
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Materials & Methods
Materials - Catalase from bovine liver (E.C. 232-577-1, E3289) and 
Corynebacterium glutamicum (E.C. 1.11.1.6, 02071) were supplied by Sigma-
Aldrich as were all chemicals, unless stated otherwise.
General procedure for polymersome formation and encapsulation of enzymes 
In a 5 mL vial, 20 μL of a 10 wt% PEG-PClgTMC block copolymer solution in 
oligo(ethylene glycol) (OEG, 350 Da) was added and a thin film of polymer 
solution was created by slow stirring. Subsequently, 80 mL of aqueous solution 
was added, followed by continuous stirring for 5 min. Polymersomes were 
subsequently diluted until the desired concentration was reached. In order to 
encapsulate enzymes, polymersomes were prepared by addition of 80 mL of 
aqueous solution containing the desired concentration of enzyme(s) (typically 
5-10 mg/mL) for encapsulation. The detailed synthetic and characterization 
procedure is described in Chapter 2 and by van Oppen et al.22
Catalase-loaded nanoreactor assays - Catalase activity was calculated from 
the initial rate of H2O2 break-down and the concomitant reduction in the 
absorbance at 240 nm. Measurements were performed with initial [H2O2] = 15 
mM (Abs240 ≈ 0.3) and polymersomes were diluted 1000-fold. 
Dynamic light scattering measurements (DLS) - DLS measurements were 
conducted using a Malvern Instruments Zetasizer (ZEN 1600), and Zetasizer 
Software (Malvern Instruments) was used for processing and analyzing the 
data.
Cryogenic transmission electron microscopy (cryo-TEM) - Experiments were 
performed using a JEOL TEM 2100 microscope (JEOL, Japan). Analysis and 
processing of the data was performed using ImageJ, a program developed by 
the NIH and available as public domain software at http://rsbweb.nih.gov/ij/. 
Samples for CryoTEM measurements were prepared by first treating the grids 
(Quantifoil R2/2 Cu 200 mesh grids) in a 208HR sputter coater for 20 seconds. 
Afterwards, 3 µL of sample was brought on the grid and blotted in a FEI Vitrobot 
Mark IV, at 100 % humidity. Subsequently, the grid was blotted and directly 
frozen in liquid ethane.
71
3
Cell culture - HEK293T cells were grown as a monolayer in DMEM with GlutaMax, 
high glucose and pyruvate (#31966 GIBCO, Life Technologies Invitrogen, Breda, 
the Netherlands) supplemented with 10 % v/v fetal calf serum (FCS) (GIBCO, Life 
Technologies Invitrogen) and 100 IU/mL penicillin/streptomycin (#15140122 
Life Technologies Invitrogen) in a humidified atmosphere of 95 % air – 5 % 
CO2 at 37 °C. Assay medium for HEK293T cells was without glucose, glutamine, 
phenol red and sodium pyruvate (#A14430-01, GIBCO, Life Technologies), 
supplied with 10 % FCS, 100 IU/mL penicillin/streptomycin, 2 mM L-Glutamine 
(#25030-024, Gibco, Life Technologies), 5 mM D-glucose (#8769 GIBCO, Life 
Technologies) and 10 mM HEPES (#15630056, Gibco, Life Technologies). Primary 
human skin fibroblasts were obtained following informed parental consent 
and according to the relevant Institutional Review Boards from skin biopsies 
of one healthy subject (C5120) and one patient in whom an isolated complex 
I deficiency was confirmed in both muscle tissue and cultured fibroblasts 
(S7-5175). Fibroblasts were grown in medium 199 (M-199) with Earle’s Salts, 
L-Glutamine, 25 mM HEPES, L-Amino Acids and phenol red (#12340030 GIBCO, 
Life Technologies Invitrogen) supplemented with 10 % v/v FCS and 100 IU/mL 
penicillin/streptomycin. Assay medium for fibroblasts contained no phenol red 
(#11043-023, GIBCO, Life Technologies Invitrogen).
Flow cytometry for measuring ROS levels - HEK293T cells were seeded in 24-
well plates (Sarstedt, Numbrecht, Germany) at 80,000 cells/well and patient 
fibroblasts at 40,000 cells/well, two days prior to measurement. Cells were 
incubated with the indicated concentration of polymersomes for 24 hours. 
After incubation, the cells were washed 2x with PBS and stained with 5 µM 
CM-H2DCFDA (#C6827, Invitrogen) in assay medium for 30 min in a humidified 
atmosphere of 95 % air – 5 % CO2 at 37 °C. The staining was aspirated and 
subsequently 500 µM H2O2 (Scharlau, 30% w/w) in assay medium was added 
for 5 min in a humidified atmosphere of 95 % air – 5 % CO2 at 37 °C. Next, cells 
were detached by trypsinisation for 2-3 minutes, spun down and resuspended 
in 100 µL assay medium. The fluorescent signal of H2DCF was measured using 
a FACSCalibur flow cytometer (BD BioSciences, Erembodegem, Belgium) and 
subsequently data was analyzed with FlowJo Software. The cells were gated on 
the live population by forward and side scatter and 10,000 cells were counted 
to determine cellular uptake by measure of mean cellular fluorescence in the 
FL-I channel.
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Crystal violet assay - Cells were seeded in 24-well plates and subjected to the 
various treatments (e.g. dose-dependency polymersomes, H2O2). Next, the cells 
were washed with PBS and incubated for 10 min at RT in a staining solution 
consisting of 0.5 % w/v crystal violet solution, 30 % v/v ethanol and 3 % v/v 
formaldehyde in MilliQ. After staining, plates are rinsed with water followed by 
addition of a 1 % w/v SDS solution for 30 min on an orbital shaker. The amount 
of re-solubilized crystal violet can be used as a readout of relative cell numbers 
by absorbance measurements (550 nm) using a microplate spectrophotometer 
(Benchmark Plus, Biorad, The Netherlands).23
Statistical Analysis - The number of independent experiments is marked by n, each 
experiment performed in duplicate. Average values are represented as mean ± SD. 
Values were tested for significance using the two-way analysis of variance (ANOVA) 
at 95 % confidence level (p < 0.05), followed by Tukey’s multiple comparisons 
test (Graph Pad Prism software, version 6), unless stated otherwise. Significant 
differences are indicated by *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Results
Evaluation of AONs in vitro
After establishing the conditions for efficient cellular uptake of TAT-
functionalized polymersomes (Chapter 2), the next step was to evaluate 
their function in vitro as a kind of ‘synthetic organelle’. Through encapsulation 
of catalase, which is an important enzyme in protecting cells from oxidative 
damage, biological functionality was bestowed upon the TAT-polymersomes, 
to generate an antioxidant nanoreactor (AON). As confocal laser scanning 
microscopy (CLSM) clearly showed the predominant presence of TAT-
polymersomes within the endolysosomal system, it is important to consider 
the function of such AONs at pH values ranging down to ~ 5. With this in mind, 
we chose to compare two isoforms of catalase, from bovine (CBOV) and bacterial 
(CBAC) sources, with the latter being more stable at lower pH values. Functional 
comparison between AONs, which had a catalase encapsulation efficiency of 
3.8 (± 0.4) %, demonstrated that CBAC -AONs were at least 8-fold more active 
than C BOV-AONs, at all pH values measured (Figure 2a). This difference in 
activity is most probably accounted for by a difference in intrinsic activity per 
unit enzyme. In accordance with the decreased sensitivity to pH, at pH 4.5 the 
CBAC-AONs were more active by a factor of 19-fold (Figure 2b). 
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Dynamic light scattering (DLS) and cryogenic transmission electron microscopy 
(cryo-TEM) were used to confirm the stability of AONs after catalase 
encapsulation, surface modification with 2.5 % TAT and purification (Figure 3a). 
It was also confirmed that addition of H2O2 (5 mM) did not disrupt AON 
morphology as no change in scattering behavior was observed (Figure 3b). 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison of the rate of H2O2 decomposition between polymersomal antioxidant 
nanoreactors (AONs), containing bacterial (CBAC) or bovine (CBOV) catalase. (a) Side-by-side 
comparison of the pH-dependence of H2O2 consumption in CBOV (black) and CBAC (red) AONs at 
[copolymer] = 40, 20 and 10 µg/mL (left to right in each column). (b) The average rate ratio 
between CBAC- and CBOV-AONs from pH 4.5 – 7.5.
Figure 3. (a) Cryo-TEM image confirming intact polymersome morphology of catalase-loaded 
AONs and (b) DLS correlograms (Z-average size = 150 nm and PDI = 0.2) before (black) and 
after (red) treatment with 5 mM H2O2.
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ROS-shielding by AONs in HEK293T cells
To address the functionality of the AONs as synthetic organelles we assessed their 
capability to shield HEK293T cells against the detrimental effects of exogenous 
H2O2. Cell integrity analysis (using crystal violet) showed that empty AONs 
were not cytotoxic when used for 24 h at a concentration up to 0.4 mg/mL 
(Figure 4a). However, a reduction in cell integrity was observed at a concentration 
of 2 mg/mL. Strikingly, neither the CBOV- nor the CBAC-AONs showed a cytotoxic 
effect at this higher concentration, suggesting a role for catalase-sensitive ROS 
in the cytotoxic effect of the AONs. In order to examine their ROS-shielding 
ability, HEK293T cells were pulse-treated with the indicated concentration of 
AONs for 1 h followed by washing and a 24 h challenge with or without 5 mM 
exogenous H2O2 (Figure 4b). Crystal violet analysis confirmed that under these 
conditions both AONs can fully protect against H2O2 cytotoxicity with the CBAC-
AONs being 10-15 times more potent than CBOV-AONs (EC50 values of 10.6 (SD = 
0.45) and 166.6 (SD = 58.8) µg/mL, respectively).
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Figure 4. Functional analysis of antioxidant nanoreactors (AONs) in HEK293T cells. (a) 
Cytotoxicity of empty, CBOV or CBAC loaded AONs (after 24 h incubation at concentrations of 
0-2.0 mg/mL) was assessed by crystal violet absorbance measurements (mean ± SD, n = 2). 
(b) Dose-dependence of the protection of cells against H2O2-induced cell stress by AONs. Cells 
were pulse-treated with AONs for 1 h prior to a challenge with or without 5 mM of exogenous 
H2O2 for 24 h. Data presented as ratio of crystal violet signal obtained with 5 mM H2O2 to that 
without (where n ≥ 3, mean ± SD, otherwise just the mean value is presented). (c) Effect of 
unloaded, CBOV and CBAC AONs on intracellular ROS assessed by CM-DCF fluorescence intensity 
measurements. Cells were treated with 0.4 mg/mL AONs for 24 h prior to loading with CM-
H2DCF and subsequent challenging with or without 0.5 mM of exogenous H2O2 for 5 min. 
Analysis was performed by flow cytometry with at least 10,000 cells per measurement. Data are 
presented as mean ± SD of 3 individual experiments after intra-experimental normalization to 
the sum of the values obtained. In panel c, significance was assessed using one-way ANOVA, 
followed by Tukey’s multiple comparisons test. Significant differences are indicated by *P < 
0.05, **P < 0.01.
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This difference in dose-dependence mirrors that determined in vitro (Figure 2), 
and demonstrates the robustness of this platform where function in vitro is 
directly translated in cellulo. Next, we used the chloromethyl (CM)-variant of 
the ROS-reactive fluorescent probe 2’,7’-dichlorodihydrofluorescein diacetate 
(CM-H2DCFDA) to demonstrate the H2O2 detoxifying effect of the AONs. CM-
H2DCFDA is intracellularly trapped as non-fluorescent covalently coupled 
CM-H2DCF and exogenous H2O2 induces its oxidation to fluorescent CM-DCF; 
a measure of intracellular ROS.24 Cells treated with 0.4 mg/mL AONs for 24 
h, and subsequently loaded with CM-H2DCF, were challenged for 5 min with 
0.5 mM exogenous H2O2 and subsequently analyzed by flow cytometry. The 
average fluorescence intensity of at least 10,000 counted cells was measured 
showing that exogenous H2O2 significantly increased intracellular ROS in 
both non-treated cells and cells treated with empty AONs, an effect that was 
completely reversed by the CBAC-AONs and partly by the CBOV-AONs (Figure 4c). 
In accordance with the results of the cytotoxicity study, AONs alone did not 
cause any increase in CM-H2DCF oxidation at the concentration used.
ROS-shielding by AONs in primary skin fibroblasts from patients with 
isolated mitochondrial complex I deficiency
Primary skin fibroblasts from patients with isolated mitochondrial complex I 
deficiency show an increased oxidation of ROS probes, suggesting a misbalance 
between ROS production and scavenging.18,19 Using primary skin fibroblasts 
from a healthy individual (C5120) and a patient with a mutation in the structural 
NDUFS7 subunit of CI (S7-5175), we assessed the ability of the CBAC-AONs to 
protect against H2O2 cytotoxicity. Evaluation of the CM-DCF signal after 24 h 
treatment with 0.4 mg/mL of AONs (followed by a 5 min challenge with 0.5 mM 
exogenous H2O2) showed that the H2O2-induced increase in fluorescence was 
virtually completely blunted (Figure 5). Both in non-treated cells and in cells 
treated with empty AONs the H2O2-induced increase in CM-DCF fluorescence was 
significantly higher in patient cells, suggesting a reduced capacity to detoxify this 
ROS. Critically, this difference was no longer observed following AON treatment, 
demonstrating a clear improvement of the ROS detoxifying capability. 
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Figure 5. Functional analysis of AONs using primary skin fibroblasts from a healthy individual 
(C5120) and a patient with isolated complex I deficiency (S7-5175). Intracellular ROS assessed 
by CM-DCF fluorescence intensity measurements after treatment with 0.4 mg/mL CBAC-AONs 
for 24 h prior to challenge with or without 0.5 mM H2O2 for 5 mins. Data are presented as mean 
± SD of 3 individual experiments after intra-experimental normalization to the sum of the 
values obtained. Significance was assessed using two-way ANOVA, followed by Bonferroni’s 
multiple comparisons test. Significant differences are indicated by **P < 0.01, ****P <0.0001.
To assess the effect of AONs on H2O2 cytotoxicity, fibroblasts were pulse-treated 
with AONs for 1 h followed by their removal and a chase period of 4 h prior to 
a 24 h challenge with or without 0.1 mM exogenous H2O2. Subsequent crystal 
violet analysis demonstrated the dose-dependence of the effect of CBAC-AONs 
in both healthy (Figure 6c) and patient fibroblasts (Figure 6d). In both cases 
complete prevention was obtained at an AON concentration of 0.3 mg/mL. In 
comparison, free CBAC at an equivalent concentration of 0.042 mg/mL had only 
a minor, if any, protective effect in both control and patient cells (Figure 6a-b). 
These results are in agreement with the above conclusion that 2.5 % TAT-
polymersomes possess strong uptake-facilitating properties.
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Figure 6. Functional analysis of free CBAC and CBAC-AONs using primary skin fibroblasts from a 
healthy individual (C5120) and a patient with isolated complex I deficiency (S7-5175). (a) 
C5120 and (b) S7-5175 fibroblasts were pulse-treated for 1 h with a range of free CBAC 
concentrations, followed by a chase period of 4 h and a subsequent challenge with or without 
0.1 mM H2O2 for 24 h. Cell viability was assessed by crystal violet staining. The data are 
presented as mean ± SD of duplo measurements performed in one experiment after 
normalization to the average value obtained with untreated (0 mg/mL free CBAC), unchallenged 
(0 mM H2O2) cells. (c) C5120 and (d) S7-5175 fibroblasts were pulse-treated for 1 h with a range 
of CBAC-AON concentrations, followed by a 4 h chase period and a subsequent 24 h challenge 
with or without 0.1 mM H2O2. Cell viability was assessed by crystal violet staining. Data are 
presented as mean ± SD from 2 experiments performed in duplo after intra-experimental 
normalization to the sum of the values obtained. Arrows indicate that 0.058 mg/mL free CBAC 
corresponds to 0.4 mg/mL AON.
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Surprisingly, when CBOV-AONs were tested according to the same protocol 
showing the protective ability of CBAC-AONs, i.e. 1 h pulse, wash, 4 h chase, 20 
h H2O2 challenge, no protection against H2O2-induced cell death was observed 
(Figure 7). However, when the protocol of figure 4b was used, i.e. 1 h pulse, 
wash, 24 h  H2O2 challenge, fibroblasts were dose-dependently protected by 
CBOV-AONs. This protection was lost again when a second H2O2 challenge was 
applied 4 h after the initial one. Together, these data show that CBOV-AONs, 
but not CBAC-AONs, rapidly lose their ability to detoxify H2O2. It is tempting to 
speculate that this time-dependent activity loss of CBOV, but not CCAT, reflects 
the increased acidification of the vesicles in which the AONs end up when 
they are internalized. In conclusion, it is important that the cargo of AONs is 
acid resistant unless strategies are employed to keep the polymersomes as 
nanoreactors in vesicles of the endolysosomal system that do not acidify or to 
induce their endolysosomal escape as nanoreactors into the cytosol. 
Figure 7. Effect of chase time after pulse treatment with CBOV-AONs on subsequent H2O2-
induced cell death in healthy control (C5120) and complex I-deficient patient (S7-5175) 
primary skin fibroblasts. (a) C5120 and (b) S7-5175 fibroblasts were pulse-treated with the 
indicated concentration of CBOV-AONs (mg/mL) for 1 h, washed, and subsequently challenged 
with 0 (light bars) or 0.1 mM H2O2 (dark bars) for 24 h or incubated for another 4 h in medium 
before challenging with 0 or 0.1 mM H2O2 for another 20 h. Cell viability was assessed by crystal 
violet staining. The data are presented as mean ± SD of duplo measurements performed in 
two independent experiments. 
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Discussion
This study shows for the first time a therapeutic effect of PEG-PCLgTMC 
polymersomes in primary human cells. The polymersomes were loaded with 
catalase, functioning as antioxidant nanoreactors (AONs), and the primary 
human cells were skin fibroblasts from a Mendelian complex I-deficient patient 
with Leigh Syndrome. Leigh Syndrome is one of the many rare mitochondrial 
disorders for which presently no cure is available.25 This urges researchers in the 
field of mitochondrial medicine to explore new avenues for the treatment of 
these diseases. Polymersomes form such a promising new approach because they 
possess the ability to effectively protect their cargo while being directed to and 
internalized by the cell of interest.26–29 In chapter 2 we showed that PEG22-b-(PCl50-
g-TMC13) polymersomes perform well in terms of biocompatibility, -degradability 
and -stability, size and loadability, and permeability and cargo shielding. We also 
showed that surface decoration with cell penetrating peptide TAT is obligatory 
for uptake into HEK293 cells, where they were shown to predominantly localize 
to vesicles of the endolysosomal system.
Here, we compared two isoforms of catalase as macromolecular cargo namely 
bovine (CBOV)- and bacterial (CBAC)-derived catalase. Because PEG-PCLgTMC 
polymersomes predominantly end up in endolysosomal vesicles, we first 
investigated the pH dependence of these isoforms in their polymersomal 
configuration. Enzyme activity measurements at different pH values showed a 
marked increase in CBAC-AONs to CBOV-AONs ratio from ~8 at pH values of 7.7 to 
5.5 to 19 at a pH value of 4.5, indicating that polymersomal CBAC is less sensitive to 
extrapolymersomal ambient acidification than polymersomal CBOV. It is tempting 
to speculate that this difference in pH sensitivity underlies the observation that 
polymersomal CBAC is still protective against exogenous H2O2-induced cell death 
after a chase of 4 h whereas polymersomal CBOV had lost its protective activity. 
If so, this means that 4 h after an AON pulse of 1 h, the AONs had moved to 
an acidic compartment, which is in agreement with the observation that 
polymersomes end up in LysoTracker Green-positive compartments as was 
shown in the previous chapter. Because it is expected that these proteinaceous 
molecules are rapidly degraded by lysosomal proteases,30 the observation that 
polymersomal CBOV retains its protective action in a lysosomal compartment 
indicates that the enzyme is still shielded by an intact polymersomal wall and 
that TAT PEG22-b-(PCl50-g-TMC13) polymersomes can be regarded as synthetic 
organelles within natural organelles. Although free CBAC was also able to protect 
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against exogenous H2O2-induced cell death, higher concentrations were required 
which is likely explained by a less effective uptake and the absence of a protective 
polymersomal wall. In agreement with our results, Singhal et al. demonstrated 
that catalase-loaded nanoparticles performed much better than free catalase in 
preventing H2O2-induced damage to human neurons.
31 
In the present study we did not perform experiments to determine the life-
time of polymersomal CBAC. One possibility is to increase the length of the chase 
period until exogenous H2O2 starts to kill the cells, indicating that polymersomal 
integrity is lost. Such information is crucial in deciding the next step on the road 
to a successful application in human disease. In case the functional life-time 
of the cargo-loaded polymersomes is too short, it might be decided to try and 
get them out of the endolysosomal sytem. Much research is devoted to tackle 
this problem of endolysosomal release.29,32–34 The idea is to finally get the AONs 
into the cytosolic compartment of the cell where they can act as true synthetic 
organelles. 
Another crucial aspect of the use of nanoparticles is their potential cyctotoxicity.35 
Cell viability analysis (using crystal violet) showed that empty AONs were not 
cytotoxic when used for 24 h at a concentration up to 0.4 mg/mL, whereas at a 
concentration of 2 mg/mL cell viability was clearly reduced. Interestingly, this 
cytotoxic effect was abolished upon inclusion of CBOV or CBAC in AONs, suggesting 
a role for catalase-sensitive ROS in the cytotoxic effect of the higher AON 
concentrations. 
To investigate the actual decrease in ROS levels, H2O2 detoxification was 
demonstrated using the fluorogenic ROS probe 2’,7’-dichlorohydrofluorescein 
diacetate (H2DCFDA). CM-H2DCFDA is widely applied as a “hydrogen peroxide 
(H2O2)-specific probe” in intact cells. However, the range of ROS that can oxidize 
this probe to fluorescent CM-DCF is much broader.36 The fluorescent protein-
based sensor “HyPer” was developed as a specific H2O2-biosensor,
37 but the usage 
of this biosensor is laborious because transfection is needed. Therefore, we 
decided to use CM-H2DCFDA. As next step, the therapeutic potential and efficacy 
of CBAC- AONs was evaluated in primary skin fibroblasts from a complex I-deficient 
patient. The intrinsic higher ROS levels of these cells, significant after a short pulse 
of exogenous H2O2, were demonstrated by measuring CM-DCF fluorescence with 
flow cytometry, and CBAC-AONs were demonstrated to be capable of nullifying 
these differences. 
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In conclusion, the protection of particularly sensitive human fibroblasts puts 
the application of synthetic organelles in a therapeutically relevant context 
using primary tissue, with significant evidence of the function in vitro. This work, 
therefore, constitutes the development of a realizable therapeutic technology, 
facilitated by the synergy between materials engineering and biochemical 
analysis.
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Abstract
Elastin-like polypeptide (ELP) nanoparticles are a versatile platform for targeted 
drug delivery. As for any type of nanocarrier system an important challenge 
remains the ability of deep (tumor) tissue penetration. In this study, ELP particles 
with controlled surface density of the cell-penetrating peptide (CPP) octa-
arginine (R8) were created by temperature-induced co-assembly. ELPs formed 
micellar nanoparticles with a diameter of around 60 nm. Cellular uptake in 
primary human skin fibroblasts was directly dependent on the surface density 
of R8 as confirmed by flow cytometry and confocal laser scanning microscopy. 
Remarkably, next to promoting cellular uptake, the presence of the CPP also 
enhanced penetration into spheroids generated from human glioblastoma 
U-87 cells. After 24 hours, uptake into cells was observed in multiple layers 
towards the spheroid core. ELP particles not carrying any CPP did not 
penetrate. Clearly, a high CPP density exerted a dual benefit on cellular uptake 
and tissue penetration. At low nanoparticle concentration, there was evidence 
of a binding site barrier as observed for the penetration of molecules binding 
with high affinity to cell surface receptors. In conclusion, R8-functionalized ELP 
nanoparticles form an excellent delivery vehicle that combines tunability of 
surface characteristics with small and well-defined size. 
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Introduction
The encapsulation of drugs into nanoparticles is gaining significance in 
targeted drug delivery for achieving a higher drug dose at the site of action 
and for increasing the bioavailability of drugs with poor water solubility. At 
this point, liposomes are still the most widely used drug carriers.1 However, 
liposomes are expensive to manufacture and have only limited stability. 
Alternatively, nanoparticles can be made from polymers and a great variety 
of polymers is being explored.2 For systemic application, biodegradability or 
elimination through excretion are important prerequisites. As a consequence, a 
major focus so far has been on polyester-based polymers such as the polylactic 
acid co-glycolides (PLGAs) or polycaprolactones.3
Protein-based nanoparticles are being pursued as a further strategy.4,5 In the 
same way as polyesters, these polyamides can also be degraded into non-toxic 
natural building blocks. However, in comparison to synthetic polymers, for 
the formation of nanoparticles, very different boundary conditions apply. For 
synthetic polymers, nanoparticle formation typically occurs by hydrophobic 
collapse, once a solution of organic solvent, containing the polymer, is diluted 
into an aqueous phase. For recombinant proteins whose intact tertiary structure 
defines functionality, this approach is not possible. They often have to be water 
soluble in their monomeric form in order to achieve high expression yields and 
purification. 
Elastin-like polypeptides (ELPs) are derived from human tropoelastin, a 
precursor of elastin, a component of the extracellular matrix.4,6 ELP consist of 
repeated valine (V) – proline (P) – glycine (G) – X – glycine (G) pentapeptides 
where the guest residue (X) can be any naturally occurring amino acid;7,8 ELPs 
with unnatural amino acids have been reported as well.9 These polymers show 
a reversible, temperature-dependent self-organization into coacervates. Upon 
raising the temperature above the lower critical solution temperature (LCST), 
they undergo a shape transition from a disordered, soluble state to a spiral-like 
state consisting of type-II β-turns, type-I β-turns and β-strands, exposing the 
(hydrophobic) side chains.10 This aggregation is thermodynamically driven. By 
changing the guest residue or length of the polymer it is possible to tune the 
LCST of ELPs.11,12 
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To direct this aggregation towards the formation of well-defined nanoparticles, 
diblock ELPs were designed with a hydrophilic ELP sequence (high LCST) and 
with a hydrophobic ELP sequence (low LCST) that differ in their guest residues. 
Between the two respective LCSTs these diblock ELPs exist as micellar structures.
ELP-based nanoparticles hold great potential for drug delivery.13–18 Drugs can 
be encapsulated either into the hydrophilic lumen or into the hydrophobic 
coacervate core, or via covalent coupling. In addition, ELPs can be extended 
by functional peptides to achieve cell-specific targeting or enhance cellular 
uptake.19 
As a means to enhance cellular uptake, cell-penetrating peptides (CPPs) are 
widely employed. CPPs are mostly cationic peptides of 8 to 30 amino acids in 
length that induce the cellular uptake of (macro-) molecules that otherwise only 
poorly enter cells.20 This capacity also extends to nanoparticles.21 Arginine-rich 
CPPs are a prominent class of CPPs. Oligoarginines between 6 and 12 arginine 
residues show optimal activity as CPPs.22 Interestingly, for functionalization of 
nanoparticles, multivalency afforded by coupling of many individual arginine 
building blocks shows less activity than coupling of an equivalent number of 
arginines in the form of oligopeptides.23 Very clearly, the structural arrangement 
of the arginine residues also plays a role.24 For nanoparticles, CPP density has a 
positive impact on uptake.25
To this point, the major part of CPP research has focused on delivery in 
two-dimensional (2D) tissue cultures. Very clearly, this setting bears little 
resemblance with the in vivo situation, where drug delivery systems need 
to penetrate tissues in three dimensions (3D). In 3D, particle size is a critical 
parameter. Moreover, particle binding and porosity of tissue are key parameters 
in effective nanoparticle treatment.26,27  For drug delivery systems that employ 
active targeting through incorporation of receptor ligands, the binding site 
barrier (BSB) effect can compromise penetration.28,29 High-affinity binding leads 
to capture of ligand-functionalized particles in the periphery of the cell mass. 
Further entry is a function of successive saturation of binding sites from the 
periphery, as demonstrated in vivo by Lee et al.30 
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Arginine-rich CPPs interact with the heparan sulfate proteoglycans of the 
glycocalyx. While each individual CPP binds with affinities in the lower 
micromolar to higher nanomolar range a polyvalent presentation may strongly 
increase interactions due to avidity effects.31
Here, we investigated the impact of CPP density on penetration of ELP 
nanoparticles in 3D cancer cell spheroids. Spheroids are excellent models 
for avascular regions of tumor tissue and can be generated with a highly 
reproducible morphology thus enabling a reliable determination of particle 
penetration.27 In particular, we were interested to learn whether a higher CPP 
density, which should yield more efficient uptake in 2D, would compromise 
penetration in 3D due to sequestration of particles in the outer cell layer. 
Nanoparticles of around 60 nm were formed with an ELP diblock copolymer. 
Octa-arginine density was varied by incorporating different molar fractions of 
ELP elongated with the CPP. To determine cellular uptake and localization in 
2D and 3D, AlexaFluor647 was incorporated as a fluorophore. In 2D, uptake 
was a direct function of CPP density. Interestingly, also in 3D CPP density 
benefitted penetration.
Materials and Methods
Materials - All chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The 
Netherlands) unless stated otherwise. 
Recombinant design of ELP constructs - The gene sequences coding for all ELP 
constructs were cloned into pET-24a(+) (Novagen, Amsterdam, The Netherlands) 
expression vectors, transformed into E.coli BLR(DE3) (Novagen) cells and grown 
on agar plates containing 30 µg/mL kanamycin overnight at 37 °C. A single 
colony was grown overnight at 30 °C, 250 rpm in LB medium containing 50 µg/
mL kanamycin and 0.5 % w/v D-glucose. The overnight culture was diluted to 
an OD600 of 0.1 in filter-sterilized AIM TB medium (Formedium, Hunstanton, UK) 
containing 6 g/L glycerol, 0.005 % Antifoam 204 and 50 µg/mL kanamycin. Cells 
were grown at 300 rpm at 37°C for 20 hours. For constructs containing R8, the 
culture was shifted to 30 °C after 4 hours of growth.
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ELP purification - Cells were collected by centrifugation at 2000 g, 4 °C for 30 min. 
For cytoplasmic extraction, 1 g of wet cell pellet was resuspended in 2 mL lysis 
buffer (50 mM Tris-HCl pH 8.0, 25 mM NaCl, 1 mM EDTA, 0.1 mM PMSF, Complete 
Protease Inhibitor Cocktail (1 tablet / 50 mL, 0.5 mg/mL lysozyme) and incubated 
for 4 h at 4 °C. Lysis was followed by sonication on a Branson Sonifier 250 (power 
level 2-4, 12 cycles of 10 s sonication, 10 s breaks). Cell debris was collected by 
centrifugation at 15,000 g, 4 °C for 15 min. Residual DNA was precipitated by 
adding 0.5 % w/v polyethylenimine and removed by centrifugation at 15,000 g, 4 
°C for 15 min. ELPs were precipitated by adding a saturated solution of (NH4)2SO4 up 
to 10-25  % v/v, depending on protein concentration. Proteins were collected (‘hot 
spin’) by centrifugation at 15,000 g at 4 °C for 15 min. The pellet was resuspended 
in phosphate-buffered saline (PBS) buffered saline and centrifuged to remove 
insoluble contaminants at 15,000 g, 4 °C for 20 min (‘cold spin’). The cycles of ‘hot’ 
and ‘cold’ spins were repeated until sufficient purity was achieved, usually after 2-4 
cycles. ELPs were resuspended in MilliQ, desalted on a HiPrep 26/10 column (GE 
Healthcare Life Sciences, Eindhoven, The Netherlands) with an AKTA Explorer 10 
(GE Healthcare Life Sciences) at 1 mL/min MilliQ. Residual salt concentration was 
below 0.001 mg/mL as determined by conductivity. The ELP solution was filter-
sterilized with 0.22 µm PES syringe filters (Nalgene) and freeze-dried. Yield was 
determined by weighting and varied around 20-200 mg/L culture.
Fluorophore conjugation - 3.86 mg freeze-dried ELPs were resuspended in 50 
mM NaHCO3, pH 7.8. 100 µg AlexaFluor647-NHS ester was dissolved in DMSO 
and added drop-wise to the protein solution to a stoichiometric ratio of 1 to 1. 
The reaction was allowed to proceed for 4 h at 21 °C, 300 rpm. Unreacted dye was 
removed by dialysis against MilliQ using 10 kDa MWCO Amicon Ultra-0.5 spin 
filter units (Millipore, Amsterdam, The Netherlands). The volume of the dialyzed 
protein samples was determined; efficiency of conjugation was determined by 
measuring dye concentration and weighing protein samples after freeze-drying. 
Concentration of dye was determined at 650 nm (ε = 270,000 cm-1M-1) and 
the molecular mass was confirmed by ESI-TOF. Coupling efficiency ranged from 
60 to 95 %.
Electrospray ionization – time-of-flight mass spectrometry (ESI-TOF) - Mass 
was determined by ESI-TOF on a JEOL AccuTOF (JEOL, Freising, Germany). 
Freeze-dried samples were resuspended in MilliQ to a concentration of 10 µM. 
Samples were acidified with 0.1 % formic acid upon injection. Deconvoluted 
spectra were obtained using MagTran 1.03 b2.
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Dynamic light scattering - Samples were diluted to a final concentration of 
10 µM in PBS. Measurements were performed on a Malvern Zetasizer Nano 
(Sysmex, Etten-Leur, The Netherlands). Samples were incubated for 5 min at 
37 °C before data collection. Reported values are averages of 3 independent 
measurements.
Spectroscopy - Freeze-dried samples were resuspended in PBS to a 
concentration of 10 µM. Absorbance at 350 nm was measured on a JASCO V630 
spectrophotometer (JASCO, Pfungstadt. Germany) with a cuvette path length 
of 1 mm. Temperature cycling was performed with a ramp rate of 0.2 °C/min. 
Cell culture - Primary human skin fibroblasts were obtained following 
informed parental consent and according to the relevant Institutional Review 
Boards from skin biopsies of one healthy subject (C5120). Fibroblasts were 
cultured in medium 199 (M-199) with Earle’s Salts, L-Glutamine, 25 mM HEPES, 
L-amino acids and phenol red (GIBCO, Life Technologies Invitrogen, Breda, The 
Netherlands) supplemented with 10 % v/v fetal calf serum (FCS) (GIBCO) in a 
humidified atmosphere of 95 % air – 5 % CO2 at 37 °C.
Confocal microscopy of uptake of ELP nanoparticles in a cell monolayer - One 
day prior to imaging, primary human skin fibroblasts were seeded at 40,000 
cells/well on an 8-well coverglass slide (Nunc Lab-Tek Chamber slide #1.0 
Borosilicate coverglass, Nunc, Wiesbaden, Germany). On the day of imaging, 
the medium was replaced by serum-containing medium containing 10 µM ELP 
nanoparticles (concentration refers to ELP) labeled with 5 % Alexa647-peptides 
including various fractions (0-25 %) of R8-ELP for an incubation time of 1, 2, 
4 or 24 hours. After incubation, the medium including particles was removed 
and the cells were washed three times with PBS and imaged in M-199 with 
Earl’s Salts, L-Glutamine, 2.2 g/L sodium bicarbonate and without phenol red 
(GIBCO), supplemented with 10 % v/v FCS. 
CellMask Green (Life Technologies Invitrogen) was used to stain the plasma 
membranes. Cells were incubated with the 1x working solution (provided 
solution is 1000 x) for three minutes, washed three times with PBS and imaged 
within 10 minutes in M-199 without phenol red, to prevent redistribution of the 
dye into the cytoplasm.
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To stain the lysosomes, the cells were incubated with 50 nM LysoTracker Green 
DND-26 (Thermo Fisher Scientific) for one hour. After staining, the cells were 
washed three times with PBS and imaged in M-199 without phenol red.
Imaging was performed with a TCS SP5 confocal microscope (Leica 
Microsystems, Mannheim, Germany) equipped with an HCX PL APO 63x N.A. 1.2 
water immersion objective. Cells were maintained at 37 ºC on a temperature-
controlled microscope stage. The ELP nanoparticles labeled with Alexa647 were 
excited with a 633 nm HeNe laser and emission was collected between 655 and 
750 nm. The green co-localization markers (CellMask Green, LysoTracker Green) 
were excited by an argon laser at 488 nm and emission was collected between 
500 and 550 nm. The obtained images were further processed using FIJI (http://
fiji.sc/).
Flow cytometry - Human primary skin fibroblasts were seeded in 24-well plates 
(Sarstedt, Numbrecht, Germany) one day (80,000 cells/well) or two days (40,000 
cells/well) prior to measurement. Cells were incubated with the indicated 
concentration of ELP nanoparticles for two hours. After incubation, the cells were 
washed with PBS and cells were detached by trypsinisation for 5 minutes, spun 
down and resuspended in 100 µL M-199 without phenol red. The fluorescent 
signal of the nanoparticles was measured using a FACSCalibur flow cytometer 
(BD BioSciences, Erembodegem, Belgium) and subsequently data was analyzed 
with Flowing Software (http://www.uskonaskel.fi/flowingsoftware/). The cells 
were gated on the live population by forward and sideward scatter and 10,000 
cells were counted to determine cellular nanoparticle uptake by measure of 
mean cellular fluorescence.
Inhibition of endocytic pathways - To study the contribution of endocytic 
pathways responsible for uptake of ELP nanoparticles, primary human skin 
fibroblasts were incubated with either 50 µM 5-(N-ethyl-N-isopropyl)amiloride 
hydrochloride, 50 µM monodansyl-cadaverine, and 100 µM genistein to inhibit 
macropinocytosis, clathrin-mediated endocytosis and caveolae-mediated 
endocytosis, respectively, followed by two hours incubation with the ELP 
nanoparticles (10 µM). Cell-associated fluorescence was measured by flow 
cytometry as described above.
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Cell death assay - Toxicity of ELP nanoparticles with different fractions of 
R8-ELP (0-90 %) was evaluated after 24 h using the propidium iodide assay. 
Two days prior to measuring cell death, 40,000 cells were seeded in 24-well 
plates (Sarstedt). The following day, cells were incubated with a range of 
concentrations (0-100 µM) of ELP nanoparticles. After 24 h of incubation, the 
cell medium was collected, the cells were washed three times with PBS, then 
trypsinized and spun down. Subsequently, the cells were resuspended and 
incubated for 30 min at 4 °C with 100 µL Nicoletti buffer (0.1 % Na3C6H5O7, 50 
µg/mL propidium iodide, 0.01 % Triton X-100) and no less than 10,000 cells 
were measured with flow cytometry to determine cell death.
Formation of spheroids - Human glioblastoma cells (U-87) (gift from Dr. Joost 
Schalkwijk, Department of Dermatology, RIMLS, Radboudumc, Nijmegen) were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 g/L 
D-glucose, GlutaMAX and pyruvate (GIBCO) and supplemented with 10 % v/v 
FCS (GIBCO) in a humidified atmosphere of 95 % air – 5 % CO2 at 37 °C. Spheroids 
were formed by plating 100 µL of a 10,000 cell/mL single cell suspension of 
U-87 cells onto agarose (0.75 % w/v in PBS) coated 96-well plates (Corning). 
Cells were allowed to aggregate for 5 days without motion, resulting in the 
formation of a single spheroid per well. On day 5, the spheroids were incubated 
with the appropriate concentration of ELP nanoparticles for the indicated 
incubation times. After incubation, the spheroids were washed three times 
with PBS. Subsequently, the spheroids were fixed in paraformaldehyde (4 % v/v 
in PBS). After fixation, the spheroids were carefully cut in half with a sharp razor 
blade and placed with the flat side (inner half ) on a coverslip in a drop of gelatin 
(4 % w/v in PBS). Nuclei were stained with DAPI (ThermoFisher Scientific), and 
the actin filaments with Alexa488 phalloidin (ThermoFisher Scientific).
Clearing was performed based on a protocol adapted from Ke et al.32 A 115 
% w/v fructose stock solution was prepared by dissolving fructose in MQ for 
30 minutes at 80 °C under stirring. Three solutions were prepared (28.75 % 
w/v, 57.5 % w/v, and 115 % w/v) and 0.5 % v/v 1-thioglycerol was added to all 
solutions. Cells were incubated with 200 µL preheated (60°C) fructose solutions 
in ascending order, each for 1 hour at RT. Spheroids were imaged in 115 % w/v 
fructose in an 8-well coverglass slide.
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The HeLa T-Rex Flp-in cell line (a kind gift of Dr. Stephen Taylor, Faculty of 
Life Science, Manchester, United Kingdom) stably expressing COX8-AcGFP133 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 4.5 
g/L D-glucose, GlutaMAX and pyruvate (GIBCO), supplemented with 10 % v/v 
fetal calf serum (FCS) (GIBCO), 1 % v/v penicillin/streptomycin (GIBCO), 4 µg/
mL blasticidin (GIBCO), 200 µg/mL hygromicin (Invitrogen) in a humidified 
atmosphere of 95 % air, 5 % CO2 at 37 °C. To induce expression of COX8-AcGFP1, 
1 µg/mL doxycyclin was added to the medium.  Spheroids were formed by 
plating 200 µL of a 12,500 cell/mL single cell suspension of HeLa-AcGFP1 onto 
agarose (0.75 % w/v in PBS) coated 96-well plates (Corning). Cells were allowed 
to aggregate for 4 days without motion, resulting in the formation of a single 
spheroid per well. On day 4, the spheroids were fixed and cut, or cleared as 
described above prior to confocal imaging.
Confocal microscopy of spheroids - Imaging of spheroids was performed using 
a TCS SP5 confocal microscope equipped with an HC PL FLUOTAR 20x N.A. 0.5 
dry objective. The ELP nanoparticles labeled with Alexa647 were excited with a 
633 nm HeNe laser and emission was collected between 655 and 750 nm. The 
COX8-AcGFP1 construct expressed in the HeLa cells was excited by an argon 
laser at 488 nm, and emission was recorded between 500 and 550 nm.  The 
samples co-stained with DAPI (Life Technologies) (excited with a 405 nm diode 
laser) and Alexa488 phalloidin (Life Technologies) were imaged with a Zeiss 
LSM510 META confocal microscope (Carl Zeiss, Sliedrecht, The Netherlands) 
using a 63x oil immersion objective (N.A. 1.4). Images were analyzed with 
Image Pro Plus 6.1 (Media Cybernetics, Rockville, MD, USA) and FIJI. 
Statistical Analysis - The number of independent experiments is marked by n, 
each experiment was performed in duplicate. Average values are represented 
as mean ± SD. Values were tested for significance using the two-way analysis 
of variance (ANOVA) at 95 % confidence level (p < 0.05), followed by Tukey’s 
multiple comparisons test (Graph Pad Prism software, version 6), unless stated 
otherwise. Significant differences are indicated by *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001.
97
4
Results
Characterization of ELP nanoparticles
ELPs consisted of a hydrophilic block [A3G2-60] (60 GXGVP pentarepeats with 
alanine and glycine as the guest residue X in a ratio of 3:2) and a hydrophobic 
block [I-60] (60 GXGVP pentarepeats with isoleucine as the guest residue X). 
To assess whether the orientation of the terminus with respect to the blocks 
had an impact on particle formation and uptake, ELPs were expressed with the 
hydrophilic block either at the N-terminus (n-ELP) or at the C-terminus (c-ELP). 
Either variant was extended with octa-arginine (R8) at the hydrophilic, outer 
block yielding nR8-ELP and cR8-ELP. Proteins were expressed and purified with 
yields ranging between 20-100 mg/L bacterial culture (Figure 1A). Masses 
measured by electrospray ionization – time of flight (ESI-TOF) mass spectrometry 
corresponded well to the theoretical values after cleavage of the N-terminal 
formylmethionine (Table 1). ELP nanoparticles (10 µM) were formed through 
self-organization by shifting the temperature from 4 to 37 °C, exceeding the 
LCST of the hydrophobic block [I-60] (22 °C). Dynamic light scattering (DLS) 
at physiological conditions showed monodisperse particles with a diameter of 
~60 nm for all four ELP variants (Figure 1B, Table 1). These data indicate that 
neither the position of the hydrophilic block in the ELP protein nor its extension 
with R8 had an effect on the formation and size of the ELP nanoparticles.
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Figure 1. Characterization of ELPs and ELP nanoparticles. (A) SDS-PAGE of c-ELP, n-ELP (silver-
stained) and cR8-ELP, nR8-ELP (coomassie-stained); (B) Dynamic light scattering results of 
particles consisting of 0 % or 100 % cR8-ELP and nR8-ELP, respectively.
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Table 1. Overview of proteins used in this study.
Protein Theoretical mass (Da)1 Measured mass (Da)2
Hydrodynamic diameter 
(nm)3
c-ELP 48198 48198 60.5 + 8.8
n-ELP 48198 48198 58.7 + 10.3
cR8-ELP 49505 49503 63.0 + 15.7
nR8-ELP 49505 49504 58.0 + 13.2
1The theoretical mass was determined with ExPASy (http://www.expasy.org/) excluding the N-terminal 
methionine. 2Mass found after deconvolution of the mass spectrum. 3Values are represented as mean 
+ SD from three independent measurements.
Uptake of ELP-R8 nanoparticles directly correlates with CPP density
First, we determined the dependence of the increase in cell-associated 
fluorescence on the position of the hydrophilic block and the R8 density on 
the surface of Alexa647-labeled ELP nanoparticles using primary human skin 
fibroblasts. To this end, ELP nanoparticles were formed without and with 
increasing percentages of N-terminal R8-ELP (nR8-ELP) by mixing n-ELP and 
nR8-ELP monomers in different ratios. A fixed ratio (5 %) of Alexa647-labeled ELP 
was incorporated for detection of fluorescence. Nanoparticles were added to 
the cell culture medium at a final ELP monomer concentration of 10 µM.
After two hours of incubation cellular uptake and subcellular distribution were 
determined by flow cytometry and confocal laser scanning microscopy. Cell-
associated fluorescence showed a strong linear increase with the ratio of nR8-
ELP in the particles (Figure 2A). This dependence of uptake was independent 
of the orientation of the CPP on the ELP, as C-terminal R8-ELP (cR8-ELP) showed 
a similar dependence on incorporated R8-ELP. However, at lower percentages 
of R8 (0 % - 25 %) cellular uptake tended to be lower for cR8-ELP than for nR8-
ELP (no statistical significant differences). In the remainder of this study we 
used n-ELP based nanoparticles. 
Whether cell-associated fluorescence reflected particles taken up into cells was 
investigated with confocal laser scanning microscopy. As for flow cytometry, 
only little cell-associated fluorescence was observed for ELP nanoparticles not 
containing any CPP. At 5 % nR8-ELP, the total fluorescence was localized inside 
cells. At 50 % nR8-ELP, fluorescence accumulated at the plasma membrane 
which was even more prominent at 90 % (Figure 2B). 
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This cellular uptake of ELP nanoparticles showed a strong time-dependence. 
After one hour of incubation with 10 % nR8-ELP nanoparticles, fluorescence 
was primarily observed at the plasma membrane. After two hours, particles 
were taken up and showed partial overlap with acidic vesicular structures 
as evident from colocalization with LysoTracker. This colocalization further 
increased towards four hours (Figure 2C).
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Figure 2. Cellular uptake of ELP nanoparticles by primary human skin fibroblasts. (A) Mean 
fluorescence intensity of cells incubated for 2 h with nanoparticles containing Alexa647-labeled 
c- or n-ELP without and with the indicated percentages of cR8- (red symbols) or nR8-ELP (black 
symbols) and added at a final monomer concentration of 10 µM. Mean cellular fluorescence 
intensity was quantified by flow cytometry. Values presented are the mean ± SEM of 3 independent 
experiments (red) or 2 independent experiments (black). Significance was assessed using two-
way ANOVA followed by Bonferroni’s multiple comparisons test (no significant differences).  (B) 
Subcellular distribution of ELP-associated fluorescence (red) after 2 h incubation with n-ELP 
nanoparticles containing the indicated percentages of nR8-ELP and added at a final monomer 
concentration of 10 µM as revealed by confocal laser scanning microscopy. Plasma membranes 
were visualized by Cell Mask Green (green) (scale bars 20 µm). (C) Lysosomal localization of ELP 
associated fluorescence (red) after 1 h, 2 h, and 4 h incubation incubation with 10% nR8-ELP 
nanoparticles added at a final monomer concentration of 10 µM. Acidic compartments were 
labeled with LysoTracker Green. ELP nanoparticles; red, lysosomes; green, scale bars 20 µm. 
Mander’s Overlap Coefficient was calculated as a measure for colocalization (n = 1).
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To obtain information about the endocytotic pathways that are involved 
in the uptake of the nR8-ELP nanoparticles, macropinocytosis, caveolae-
mediated endocytosis and clathrin-mediated endocytosis were inhibited 
with their respective inhibitors amiloride (50 µM), genistein (100 µM) and 
monodansylcadaverine (50 µM). Cells were incubated for 2 h with n-ELP 
nanoparticles containing the indicated percentages of nR8-ELP, added at a final 
monomer concentration of 10 µM, in the absence and presence of inhibitor. 
The mean cellular fluorescence intensity was measured by flow cytometry and 
for each percentage of nR8-ELP the value obtained with the untreated control 
was set at 100 % to which the inhibitor values were related. Up to 10 % nR8-
ELP all three inhibitors reduced the increase in mean cellular fluorescence 
intensity with amiloride being more effective than the other two inhibitors 
(Figure 3). The inhibitory effect of amiloride, but not that of the other two 
inhibitors, was also observed at the higher percentages (> 10 %) of nR8-ELP. 
Based on the observation that at 5 % nR8-ELP all cell-associated fluorescence 
was localized to intracellular punctate structures (Figure 2B), we conclude that 
macropinocytosis is the predominant uptake process of nR8-ELP nanoparticles.
Figure 3. Involvement of different endocytic routes in R8-ELP nanoparticle uptake. The 
endocytic pathways macropinocytosis, caveolae-mediated endocytosis, and clathrin-
mediated endocytosis were inhibited with amiloride, genistein and monodansylcadverine, 
respectively. Data are normalized to treatment without inhibitor. Error bars denote the 
standard error of the mean (SEM), n = 2. Significance was assessed using two-way ANOVA, 
followed by Tukey’s multiple comparisons test. Significant differences are indicated by 
 *P < 0.05.
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R8-ELP nanoparticles are non-toxic up to 25 % R8
The accumulation of ELP nanoparticles at 50 % nR8-ELP and higher at the plasma 
membrane could cause disturbance of membrane integrity. To investigate the 
potential toxicity of ELP nanoparticles, we measured propidium iodide (PI) 
positive cells as a hallmark of plasma membrane damage.34 The percentage of 
affected cells for concentrations of 0.5-10 µM ELP monomers was similar to the 
one of untreated cells, regardless of the percentage nR8 included (Figure 4). 
However, for concentrations of 50 µM ELP monomers and higher, significant 
cell death was observed for an nR8 content of 25 % and higher. 10 % nR8-ELP 
monomers were well tolerated even at a concentration of 100 µM.
Figure 4. Determination of nR8-ELP toxicity. Cell damage was determined via the fraction 
of propidium iodide positive fibroblasts (sub-G1 phase) after 24 h treatment with n-ELP 
nanoparticles containing the indicated nR8-ELP percentage and added at the indicated 
final monomer concentration. Error bars denote the standard error of the mean (SEM) of 3 
independent experiments. Significance was assessed using two-way ANOVA, followed by 
Tukey’s multiple comparisons test. Significant differences are indicated by *P < 0.05, **P < 0.01, 
***P < 0.001, ****P < 0.0001.
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Penetration of nR8-ELP nanoparticles into 3D tumor spheroids
The 2D experiments had shown a strong linear relationship of cell association/
uptake and R8 density. Next, we were interested to learn to which degree the 
nR8-ELP nanoparticles had the capacity to penetrate 3D tumor spheroids and 
how penetration was influenced by the density of the CPP. On the one hand, 
a high CPP density could promote association of ELP nanoparticles with the 
spheroid and thus entry, on the other hand nanoparticles could be captured 
and retained in the periphery of the spheroid forming a binding site barrier.
Using HeLa-Trex Flp-in Cox8 acGFP1 cells stably expressing a mitochondrially 
localized green fluorescent protein we first determined the capacity of standard 
confocal microscopy to penetrate the spheroid core. In this case, the GFP fusion 
protein only served as a cell tracer and the mitochondrial localization was 
without significance for our experiments. As expected for confocal microscopy, 
fluorescence could be detected into a penetration depth of up to 60 µm 
(Figure 5A). However, only spheroids with diameters larger than 400-500 μm 
generally display the typical, layered structure consisting of a necrotic core, 
surrounded by viable quiescent cells and an outer layer of proliferating cells.35,36 
Because of the need to detect the signal of nanoparticles in the core of a 
spheroid at a distance of at least 200 μm from the periphery, we fixed and cut 
the spheroid in halves followed by confocal laser scanning microscopy of the 
equatorial plane. Fluorescence was homogenously distributed over the whole 
central area of the spheroid (Figure 5B). Parallel to this strategy, we applied a 
clearing method adapted from Ke et al. for the visualization of the inner core 
of spheroids.32 As clearing agent, high-concentration fructose solutions were 
used to reduce light scattering within spheroids (Figure 5C). 
In the remainder of this chapter, we used spheroids grown from U-87 human 
glioblastoma cells as an in vitro 3D tumor model. To evaluate uptake and 
penetration capacity, U-87 spheroids were incubated for 5 h or 24 h with 
nR8-ELP nanoparticles (0 %, 10 % and 25 % nR8) added at a final monomer 
concentration of 10 µM. At the end of the incubation period, spheroids were 
fixed and bisectioned after which a confocal image was taken of the equatorial 
plane. Exposure to the nanoparticles had no impact on spheroid morphology 
in terms of area (Figure 6A) and aspect ratio (Figure 6B). 
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Figure 5. Penetration capacity of confocal microscopy in spheroids of Cox8-AcGFP1-
expressing HeLa cells. Pictures display fluorescent confocal sections from the bottom (red line) 
120 µm into the spheroid with sections recorded every 20 µm, scale bar represents 200 µm. (A) 
Confocal images of an intact spheroid. (B) Confocal images of a fixed and sectioned spheroid. 
(C) Confocal images of a spheroid after clearing.
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Figure 6. Impact of R8-ELP content and exposure time on the morphology of U-87 spheroids. 
Error bars denote the standard error of the mean (SEM). (A) Area of the spheroids. (B) Aspect 
ratio as a measure for the circularity of the spheroids, calculated as ratio of major and minor 
axis of spheroid. Data are from two independent experiments, with at least two spheroids per 
condition. Significance was assessed using a one-way ANOVA Kruskal-Wallis test and post-hoc 
Dunn’s multiple comparisons test (no significant differences).
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After an incubation time of 5 hours, the ELP nanoparticles were hardly visible in 
the peripheral cell layers of the spheroid. Only little penetration was observed 
for 10 % nR8-ELP nanoparticles, and a slight increase in penetration for 25 % 
nR8-ELP nanoparticles (Figure 7A, upper panel). In contrast, after 24 hours 
there was a clear dependence of fluorescence and penetration depth on 
nR8-ELP content (Figure 7A, lower panel). ELP nanoparticles containing 25 
% nR8-ELP displayed the highest fluorescence and the deepest penetration 
into the spheroid. The dot-like distribution of ELP nanoparticles indicated 
intracellular localization. This showed that on one hand the ELP nanoparticles 
functionalized with R8 were accumulated by cells as a result of the cell uptake-
inducing effect of octa-arginine. On the other hand, the CPP also promoted 
penetration into the spheroids. This is reflected in the fluorescence intensity 
as function of the distance from the outer edge (0 µm) to the core (200 µm) 
in a mean radial intensity profile displaying average values every 10 µm 
(Figure 7B). Interestingly, after normalization of the intensity profiles to 
the maximum fluorescence intensity value peak at 20 µm from the outer 
edge, penetration for 10 % and 25 % nR8-ELP nanoparticles was nearly 
indistinguishable after 24 h incubation (Figure 7C). Penetration depth of nR8-
ELP nanoparticles after 5 h and 24 h incubation was independent of the size of 
the spheroids (Figure 8).
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Figure 7. Distribution of fluorescence of nR8-ELP nanoparticles (0 %, 10 %, and 25 % nR8-
ELP) in U-87 spheroids after 5 h and 24 h incubation at 10 µM final concentration of ELP 
monomers. (A) Visualization of penetration depth of nR8-ELP nanoparticles (0 %, 10 %, and 
25 % nR8-ELP) after 5 h (upper panel) and 24 h incubation (lower panel). The fluorescence 
intensity is visualized by confocal laser scanning microscopy of the equatorial plane of fixed 
and bisectioned spheroids. Scale bar is 200 µm. (B) The fluorescence intensity of the nR8-ELP 
nanoparticles (0 %, 10 %, and 25 % nR8-ELP) in the spheroid after 5 h and 24 h incubation 
represented in a mean radial intensity profile. The average fluorescence was extracted every 
10 µm represented the distance from the outer edge of the spheroid (0 µm) to the inner core 
(200 µm). Error bars denote the standard error of the mean (SEM) from two independent 
experiments, with at least two spheroids measured per condition per experiment. (C) 
Background corrected (minimal fluorescence intensity) fluorescence of 10 % and 25 % nR8-ELP 
nanoparticles after 24 h incubation, normalized to the maximum fluorescence intensity of the 
peak at 20 µm from the outer edge of the spheroid.
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Figure 8. Penetration depth of nR8-ELP nanoparticles after 5 h and 24 h incubation displayed 
as function of the area of the spheroid. Penetration depth was determined based on the 
average intensity profile from images of the fixed and sectioned spheroids as the distance 
from the periphery at which the intensity had reached background levels. Error bars denote 
the standard error of the mean (SEM).
To determine the extent of cellular uptake, U-87 spheroids were treated for 5 
h and 24 h with n-ELP nanoparticles containing 0 %, 10 % or 25 % nR8-ELP at 
a final monomer concentration of 10 µM. At the end of the incubation period, 
the spheroids were fixed and cut into halves. Subsequently, the nuclei and actin 
skeleton were stained after which a confocal image was taken at the equatorial 
plane. After an incubation time of 5 h, for 0 % nR8-ELP nanoparticles no uptake 
was observed (Figure 9). For 10 % nR8-ELP nanoparticles after 5 h, a few faint 
dots were present in the cells of the outer layer of the spheroid. 25 % nR8-ELP 
nanoparticles showed the strongest uptake. After 5 hours, nanoparticles could 
be detected inside cells, three cell layers deep into the spheroid. After 24 h for 
0 % nR8-ELP nanoparticles hardly any uptake was present. For 25 % nR8-ELP 
nanoparticles extensive uptake was present five cell layers into the spheroid (~ 
80 µm). The data show that along with penetration, a fraction of ELPs is taken 
up by the cells.
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Figure 9. Intracellular uptake of ELP nanoparticles in U-87 spheroids. Spheroids of similar size 
(400 µm) were incubated with ELP nanoparticles containing 0 %, 10 % or 25 % of nR8-ELP for 5 
h and 24 h (red) and imaged by confocal laser scanning microscopy after fixation, sectioning 
and staining. The actin-skeleton of the cells was stained with phalloidin (green) and the 
nucleus with DAPI (cyan) to evaluate the intracellular distribution. The box in the overview 
indicates the approximate size of the enlargements.  Scale bar is 200 µm.
Concentration dependence of penetration depth
At this point, we wanted to learn whether penetration of 25 % nR8-ELP 
nanoparticles after 24 h incubation was dependent on ELP concentration as this 
would indicate the presence of a binding site barrier, either due to cellular uptake 
or due to binding to the extracellular matrix. For both cases, ELP nanoparticles 
should penetrate deeper into the spheroids at higher concentrations. We 
tested three different concentrations of 25 % nR8-ELP nanoparticles (2.5 µM, 
10 µM and 25 µM). Penetration was determined after fixation and clearing. 
For a reliable extraction of quantitative information on penetration depth, 
we developed a method to measure the mean radial intensity profile of the 
distribution of ELP nanoparticles across the equatorial plane of spheroids. The 
highest concentration of 25 µM displayed consistently the highest intensities 
inside the spheroids (Figure 10A). However, after normalization of the mean 
radial profiles of 2.5 µM and 10 µM 25 % nR8-ELP nanoparticles to the maximum 
fluorescence intensity of the peak at 30 µm, both 10 µM and 25 µM displayed 
very similar intensity profiles, demonstrating that for these concentrations the 
penetration was independent of nanoparticle concentration (Figure 10B). In 
contrast, for 2.5 µM 25 % nR8 ELP nanoparticles fluorescence was only present 
in the periphery indicative of a binding site barrier. 
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Figure 10. Distribution of different concentrations of 25 % nR8-ELP nanoparticles in cleared 
U-87 spheroids. (A) Mean radial intensity profiles at the equatorial plane of cleared U-87 
spheroids for 2.5 µM, 10 µM and 25 µM Alexa647-labeled 25 % nR8-ELP nanoparticles after 24 
h incubation. Values represented as mean of three independent experiments (three spheroids 
per experiment) ± SEM (B) The fluorescence intensity of 2.5 µM, 10 µM  and 25 µM nR8-ELP 
nanoparticles after 24 h incubation represented after background correction (minimal 
fluorescence intensity) and normalized to maximum fluorescence intensity of the peak at 30 
µm from the outer edge of the spheroid.
nR8-ELP nanoparticles display highest penetration depth after 24 h 
After the evaluation of concentration of ELP nanoparticles on penetration 
depth, we measured the impact of incubation time on penetration depth of 25 
µM 25 % nR8-ELP nanoparticles. U-87 spheroids were incubated with 25 µM 25 
% nR8-ELP nanoparticles varying from 0.5 h to 48 h and subsequently fixed and 
cleared. An incubation time of 24 h displayed the highest penetration depth 
(Figure 11A). In the outer layers, fluorescence of ELP nanoparticles increased 
over time with a maximum at 4 h. When the incubation time was increased to 
48 h, intensities decreased. This observation may be attributed to degradation 
of ELP nanoparticles, however, the coherence and regularity of spheroids 
decreased from 24 to 48 h, as well (Figure 12). After normalization of the mean 
radial profiles for the different incubation times to maximum fluorescence peak 
intensities at 30 µm from the outer layer, the intensity profiles of 24 h and 48 
h demonstrate high fluorescence intensities towards the central parts of the 
spheroid (Figure 11B).
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Figure 11. Distribution of 25 µM 25 % nR8-ELP nanoparticles in cleared U-87 spheroids after 
different incubation times (0.5 h – 48 h). (A) Mean radial intensity profiles of the equatorial 
plane of cleared U-87 spheroids. Values represented as mean of three independent experiments 
(three spheroids per experiment) ± SEM (B) The fluorescence intensity of 25 µM 25 % nR8-
ELP nanoparticles after different incubation times represented after background correction 
(minimal fluorescence intensity) and normalized to maximum fluorescence intensity of the 
peak at 30 µm from the outer edge of the spheroid.
Figure 12. Confocal images of equatorial plane of cleared spheroids at different time points 
after incubation with 25 µM Alexa647-labeled 25 % R8-nELP nanoparticles. Scalebar is 200 µm 
(for 0 h imaging with 10x objective).
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Discussion
Here, we show that functionalization of ELP nanoparticles with the cell-penetrating 
peptide (CPP) octa-arginine (R8) simultaneously conferred two functional 
characteristics which are highly relevant for future in vivo drug delivery applications. 
On the one hand, the CPP mediated the cellular uptake of the nanoparticles, on the 
other hand, the CPP also promoted the penetration of nanoparticles into 3D tumor 
spheroids. Both activities positively correlated with the density of the CPP on the 
surface of the nanoparticles. 
By swapping the orientation of the hydrophilic and hydrophobic protein block, 
we evaluated both C-terminal (cR8-ELP nanoparticles) and N-terminal conjugation 
of the CPP (nR8-ELP nanoparticles). Uptake of nR8-ELP nanoparticles was slightly 
higher which may be attributed to the negatively charged C-terminus counteracting 
the positive charge of octa-arginine. Investigating the accompanying mechanism 
of uptake suggested macropinocytosis as the major endocytic pathway, as has 
been reported before for octa-arginine mediated uptake.37,38 Octa-arginine by itself 
has little cytotoxicity, which may be attributed to the low membrane-activity of 
this CPP.39 Also for ELP nanoparticles containing R8 up to a ratio of 25 % R8, toxicity 
was low. This observation is in contrast to the multivalent presentation of nona-
arginine on a linear backbone,25 demonstrating that geometry of presentation has 
a major impact on the toxicity of oligoarginines.  
The promotion of penetration by conjugation of R8 was not necessarily to be 
expected as R8 was primarily selected as a cell-penetrating peptide and the ability 
to induce cellular uptake was confirmed in 2D tissue cultures. Uptake of R8 is 
associated with binding to glycosaminoglycans40 and this interaction has also been 
associated with triggering of endocytosis.41  In our view, the best view to explain 
this counterintuitive finding may be that exchange between glycosaminoglycans 
between adjacent cells is faster than induction of endocytosis. 
To describe the penetration of high-affinity binders into three-dimensional tissues, 
the concept of the binding site barrier has been formulated. Even though the 
affinity of individual CPPs for glycosaminoglycans is only in the upper nanomolar 
range,42–44 the multivalent display on the surface of particles can strongly increase 
affinity through avidity effects.25 We addressed the potential presence of a binding 
site barrier by varying the density of the CPP as well as the concentration of the 
ELP nanoparticles. 
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The first intervention affected the avidity, and both should promote the saturation 
of binding sites. After normalization of the fluorescence intensities, penetration was 
independent of peptide density. There was, however, a concentration dependence. 
For 2.5 µM ELP-nanoparticles, also after 24 h fluorescence was restricted to 
the periphery of the spheroids. In contrast, for 10 µM and 25 µM ELPs, efficient 
penetration to the same degree was observed. 
Further support for the presence of a binding site barrier came from an experiment 
in which we incubated spheroids for a 30 min pulse followed by a 24 h chase. No 
spreading of fluorescence from the brightly fluorescent rim at the periphery of the 
spheroids could be observed (not shown).  The observation that ELP nanoparticles 
not carrying any R8 did not show any penetration suggests that the binding site 
barrier is a consequence of uptake rather than saturation of binding sites on 
the glycosaminoglycans. At higher concentrations the endocytic capacity may 
become increasingly exhausted. Rapid exchange between a bound and unbound 
state should promote percolation of the particles through the interstitial space. 
Apparently, even with an avidity effect in place, the interaction with the glycocalyx 
still has a high enough off-rate. 
Outside the field of cell-penetrating peptides, positive charge has been 
demonstrated to enhance penetration. For dendrimers that were significantly 
smaller than the ELP-nanoparticles, positively charged terminal groups provided 
increased tumor penetration compared to neutral or negatively charged terminal 
groups.45 Regardless of this addition, smaller dendrimers seemed to penetrate 
more quickly. Addition of R8 to somewhat larger dendrimers significantly boosted 
the penetration of dendrimers.46 Also for lipid nanoparticles similar observations 
were made.47,48 However, in these and other studies penetration was inferred at 
best from confocal images of uncleared spheroids so that in fact, no information on 
penetration behavior could be derived.49,50 With the use of cleared and sectioned 
spheroids, we quantified the cellular uptake and 3D penetration of R8-conjugated 
ELP-nanoparticles to disclose the CPP’s role as dual functionality charge carrier. 
Surprisingly, starting after 4 h fluorescence in the periphery decreased. By 
comparison, it still increased in the central parts of the spheroids. A possible 
explanation could be degradation of ELP-nanoparticles. In this case, however, ELP-
nanoparticles that were only externally associated with the cells in the periphery 
still had to diffuse further towards the center. 
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Alternatively, the extended presence of R8-ELP nanoparticles could lead to a 
dissociation of cells from the periphery, a hypothesis that is supported by the 
rugged appearance of spheroids after a 48 h incubation. Further research will 
be required to address how in vivo heterogeneity in the composition of the 
extracellular matrix, presence of different cell types and interstitial fluid pressure 
affect particle penetration.51 In addition, the formation of protein corona 
surrounding nanoparticles could influence penetration and accumulation.52 
ELP-based nanoparticles are being pursued as a strategy for targeted drug 
delivery and represent excellent candidates for this purpose because of their 
biodegradability, biocompatibility, and the presence of both hydrophobic 
and hydrophilic components in the same system that provide flexibility in 
drug formulation.5 Moreover, proteins can be easily extended with targeting 
moieties such as nanobodies,19 and also variation of the CPP may further tune 
penetration.53 
Mixing of ELPs carrying different functionalities allows for a highly flexible 
adjustment of the density of the delivery moiety. It will be highly interesting 
to which degree the combination of CPP-conjugated ELPs with ELPs carrying 
receptor-specific targeting ligands will enable a fine-tuning of activities 
mediating uptake and targeting.
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Abstract
Evidence is accumulating that oxidative stress plays a key role in the pathology 
of a broad range of mitochondrial dysfunction-related disorders, including 
isolated NADH:ubiquinone oxidoreductase or complex I (CI) deficiency. This 
opens the possibility of treatment with drugs that counter oxidative stress such 
as KH176, a novel small molecule ROS-redox modulator. Because disturbances in 
the central nervous system are predominant in isolated CI deficiency, adequate 
blood-brain barrier penetration is a prerequisite for optimal therapeutic 
efficacy. Nanoparticles offer a promising tool to increase drug accumulation 
in brain tissues for higher therapeutic efficacy. As proof of concept, we here 
evaluate the therapeutic potential of elastin-like polypeptide (ELP)-based 
nanoparticles functionalized with the cell-penetrating peptide octa-arginine 
(5 % R8-ELP) and KH176 (95 % ELP-KH176) (ELPKH176 nanoparticles) in primary 
skin fibroblasts from a patient with complex I deficiency and Leigh syndrome. 
We show that 24 h co-treatment with ELPKH176 nanoparticles dose-dependently 
prevents the L-buthionine-(S,R)-sulfoximine (BSO)-induced reduction in cell 
viability, as assessed by calcein-AM staining, with an EC50 closely resembling 
that of free KH176. BSO induces oxidative stress through depletion of reduced 
glutathione (GSH) and reduces cell viability in patient, but not healthy, 
human skin fibroblasts. Taking into account that ELP-based nanoparticles are 
highly versatile, the present findings stimulate further research towards the 
incorporation of targeting functionalities that endow ELP nanoparticles with 
e.g. the ability to penetrate the blood-brain barrier.
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Introduction
Complex I or NADH:ubiquinone oxidoreductase is the first enzyme of the 
mitochondrial oxidative phosphorylation (OXPHOS) system. The enzyme 
oxidizes NADH to NAD+ and transfers the released electrons through flavin 
mononucleotide (FMN) and a chain of iron-sulfur (FeS) clusters to the ubiquinone 
binding site, where it reduces ubiquinone to ubiquinol.1 This intramolecular 
electron transfer is energetically coupled to the translocation of four protons 
across the inner mitochondrial membrane, thus contributing to the build-up of 
the electrochemical proton gradient or proton motive force that is used by ATP 
synthase or complex V to convert ADP + Pi into ATP. Human complex I consists 
of 44 different subunits, together forming a 45 subunit functional assembly, 
the amount and/or activity of which is reduced in human complex I deficiency.2 
Complex I-deficient patients present with a wide variety of signs and symptoms, 
which can appear in any organ and tissue and at any time of age.3 
Leigh syndrome is a mitochondrial disorder characterized by dying tissue, 
mainly in the midbrain and brainstem, resulting in a progressive loss of mental 
and movement abilities and, typically, patients die within 2 to 3 years from the 
onset of symptoms. In most cases, this disorder is inherited, with mutations 
in both the nuclear and, less frequent, the mitochondrial DNA. Frequently, 
deficiency of complex I is the underlying cause of this disease.4–6 The first signs 
and symptoms are usually observed within a few months to two years of age 
but also teens and adults can develop this devastating disorder. Although a 
number of small molecules with potential for treatment of mitochondrial 
disorders are under clinical investigation, no cure is currently available.7–10 One 
of these molecules is the clinical stage small molecule KH176 harboring ROS-
redox modulating activity.11,12
In our studies on the cell biological consequences of human complex I 
deficiency we have used a large panel of primary skin fibroblasts from patients 
with nuclear-inherited isolated complex I deficiency and showed, among 
others, that these fibroblasts exhibit markedly increased oxidation rates of the 
ROS-sensitive dyes 5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein 
(CM-H2DCF) and hydroethidine (HEt).
13,14 Although complex I and III are well-
established sites of ROS production, it remains to be determined where exactly 
these ROS originate from in complex I deficiency.15,16 
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Based on these initial results, KH176, a novel small molecule ROS-redox 
modulator, was developed.17 KH176 was shown to effectively prevent the 
L-buthionine-(S,R)-sulfoximine (BSO)-induced reduction in cell viability, as 
assessed by calcein-AM staining, in complex I-deficient patient fibroblasts. 
BSO treatment is one of the few interventions that can effectively discriminate 
between healthy fibroblasts and fibroblasts from mitochondrial disease 
patients.17,18
Studies with mice genetically engineered to lack the NDUFS4 subunit of 
complex I (Ndufs4-/- mice) revealed a phenotype that closely resembled that of 
Leigh syndrome patients including a predominant role of the central nervous 
system.19–21 Intraperitoneal injection of KH176 slightly, though significantly, 
improved motor performance in Ndufs4-/- mice.21 Similar results were obtained 
after intraperitoneal injection of these complex I-deficient mice with the 
blood-brain barrier penetrating antioxidant N-acetyl cysteine amide (AD4).22 
Analysis of the pharmacokinetic parameters of KH176 indicated the need for 
improvement of plasma half-life and blood-brain barrier penetration.17 Taken 
together, the results obtained with KH176 demonstrate that a nanoparticle 
platform for targeted delivery to the brain may further increase the potential of 
this compound for counteracting brain degeneration.
In the present study we used primary skin fibroblasts from a complex I-deficient 
Leigh syndrome patient with a V122M mutation in the NDUFS7 gene (S7-
5175 cells) to evaluate the usefulness of elastin-like polypeptide (ELP)-based 
nanoparticles for cellular delivery of KH176.23 We show that these nanoparticles 
when functionalized with the cell-penetrating peptide (CPP) octa-arginine (R8) 
at the hydrophilic site and KH176 at the hydrophobic site, referred to as ELPKH176 
nanoparticles, can prevent the BSO-induced reduction in cell viability in these 
patient fibroblasts.
Materials and Methods
Materials - All materials were obtained from Sigma-Aldrich (Saint Louis, MS, 
USA) unless stated otherwise. KH176 [(S)-6-hydroxy-2,5,7,8-tetramethyl-N-
((R)-piperidin-3-yl)chromane-2-carboxamide hydrochloride] was provided 
by Khondrion BV (Nijmegen, The Netherlands). Imidazole-1-sulfonyl azide 
hydrochloride was synthesized as described previously.24 
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Electrospray ionization – time-of-flight mass spectrometry (ESI-TOF) - Mass 
was determined by ESI-TOF on a JEOL AccuTOF (JEOL, Peabody, Massachusetts, 
USA). Freeze-dried samples were resuspended in Milli-Q to a concentration of 
10 µM. Samples containing buffer were first desalted with Milli-Q using Amicon 
Ultra-0.5 spin filter units with 10 kDa MWCO (Merck, Burlington, Massachusetts, 
USA). All samples were acidified with 0.1 % formic acid upon injection. 
Deconvoluted spectra were obtained using MagTran 1.03 b2.
Expression and purification of elastin-like polypeptides (ELPs) - The constructs 
were cloned by recombinant DNA technology as previously described.25 pET24(+) 
plasmids containing the respective coding sequence were transformed into 
E. coli BLR(DE3) (ThermoFisher Scientific, Waltham, Massachusetts, USA) and 
grown on agar plates containing 30 µg/mL kanamycin overnight at 37 °C. A 
single colony was grown overnight at 23 °C, 250 rpm in LB medium containing 
50 µg/mL kanamycin and 0.5 % w/v D-glucose. The overnight culture was diluted 
to an OD600 of 0.1 in filter-sterilized AIM TB medium (Formedium, Norfolk, UK) 
containing 6 g/L glycerol, 0.005 % v/v Antifoam 204 and 150 µg/mL kanamycin. 
Cells were grown at 30 °C and 300 rpm for 20 hours. Cells were collected by 
centrifugation (4000 g, 4 °C, 30 min). For cytoplasmic extraction, 1 g of wet 
cell pellet was resuspended in 10 mL phosphate-buffered saline (PBS; pH 7.2-
7.4). Cells were lysed by homogenization using an EmulsiFlex-C3 homogeniser 
(Avestin, Ottawa, Canada). Cell debris was collected by centrifugation (15,000 g, 
4 °C, 15 min). Residual DNA was precipitated by adding 0.5% w/v poly(ethylene 
imine) and removed by centrifugation (15,000 g, 4 °C, 15 min). ELPs were 
precipitated by adding a saturated solution of (NH4)2SO4 up to 10-25 % v/v 
either at room temperature or at 4 °C depending on the construct. Proteins 
were collected by centrifugation (15,000 g, 4 °C or RT, 15 min). The pellet 
was resuspended in PBS and centrifuged to remove insoluble contaminants 
(15,000 g, 4 °C, 20 min). This inverse-transition cycling (ITC) was repeated until 
sufficient purity was achieved, usually after 2-4 cycles. ELPs were resuspended 
in Milli-Q that was purified using a HiLoad 16/600 Superdex 200 column and 
desalted using a HiPrep 26/10 column (GE Healthcare Life Sciences, Eindhoven, 
The Netherlands). 
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Next, the proteins were purified using an AKTA Explorer 10 FPLC (Fast Protein 
Liquid Chromatography) system (GE Healthcare Life Sciences) at 1 mL/min PBS 
and desalted at 4 mL/min Milli-Q, respectively. Residual salt concentration was 
below 0.01 mg/mL as determined by conductivity. The ELP solution was filter-
sterilized with 0.22 µm PES syringe filters (ThermoFisher Scientific) and freeze-
dried. Yield was determined by weighing and varied between 25-100 mg/L 
bacterial culture. 
Synthesis of ELP-(S)-N-((R)-1-(1-(1H-1,2,3-triazol-4-yl)-2,5,8,11-tetraoxate-
tradecan-14-oyl)piperidin-3-yl)-6-hydroxy-2,5,7,8-tetramethylchromane-2-
carboxamide - The ELP diblock copolymers 1 (50 mg each, 1.04 µmol) were 
dissolved in Milli-Q and imidazole-1-sulfonylazide hydrochloride 2 was added 
to a 50 fold excess (10.5 mg, 50 µM) to yield ELP-N3 3 (Figure 1). The reaction 
proceeded for 4 hours at room temperature. The ELPs were purified by inverse 
transition cycling as described above, dialysed against Milli-Q and lyophilised. 
(S)-6-hydrox y-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chromane -2-
carboxamide hydrochloride (300 mg) was partitioned between saturated 
aqueous sodium carbonate solution (20  mL) and CH2Cl2 (20 mL). The organic 
layer was dried with Na2SO4 and evaporated to dryness to afford (S)-6-
hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chromane-2-carboxamide 
free base 4 as off-white solid. Under inert-gas atmosphere, (S)-6-hydroxy-
2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chromane-2-carboxamide free base 
(122 mg, 0.37 mmol), alkyne-PEG(4)-COOH 5 (149 mg, 0.57 mmol), OxymaPure® 
(11 mg, 0.08 mmol) and EDCI (109 mg, 0.57 mmol) were dissolved in dry DMF 
(5 mL). The reaction mixture was cooled on an ice-water bath and N-ethyl-
N’-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 86 mg, 0.449 
mmol) was added in one portion. The cooling bath was removed and stirring 
was continued at room temperature overnight. Then, the reaction mixture 
was quenched by adding saturated aqueous ammonium chloride solution 
and the aqueous phase was extracted with EtOAc (3x 10 mL). The combined 
organic extracts were consecutively washed with saturated aqueous sodium 
bicarbonate solution and brine (20 mL each), dried (Na2SO4) and evaporated to 
dryness. 
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After purification via flash column chromatography (EtOAc/MeOH 98/2→95/5), 
((S)-N-((R)-1-(3,6,9,12-tetraoxapentadec-1-yn-15-oyl)piperidin-3-yl)-6-hydroxy-
2,5,7,8-tetramethylchromane-2-carboxamide 6 was obtained as light yellow 
oil (mixture of rotamers, 176 mg, 82 %). Rf = 0.40 (EtOAc/MeOH 9/1); 
1H NMR 
(CDCL3, 400MHz): δ = 6.52 - 6.73 (m, 1 H), 5.38 (br. s., 1 H), 4.17 - 4.21 (m, 2 H), 
4.03 - 4.10 (m, 1 H), 3.84 - 3.99 (m, 1 H), 3.27 - 3.77 (m, 16 H), 3.16 - 3.25 (m, 1 H), 
2.94 - 3.10 (m, 2 H), 2.44 - 2.69 (m, 3 H), 2.42 (t, J=2.3 Hz, 1 H), 2.06 - 2.39 (m, 11 
H), 1.43 - 1.92 ppm (m, 11 H); ESI-MS m/z: 575.3 [M+H]+, 597.3 [M+Na]+. 
ELP-N3 3 (45 mg, 0.93 µmol) was dissolved in 10 mM potassium phosphate 
buffer pH 7.0. Subsequently, three molar equivalents of 6 (1.6 mg, 2.8 µmol) 
were dissolved in 10 mM potassium phosphate buffer pH 7.0 and added to 
3. Additionally, CuSO4 (final concentration 3 mM), sodium ascorbate (final 
concentration 50 mM) and tris(3-hydroxypropyltriazolylmethyl)amine (final 
concentration 12 mM) were added to the reaction. The reaction was performed 
at RT for 2 hours, after which the ELP-KH conjugate was purified with ITC and 
desalted as described above. Mass was confirmed by ESI-TOF (data not shown). 
Dynamic light scattering - Samples were diluted to 10 µM in PBS (pH 7.2-
7.4). Measurements were performed on a Malvern Zetasizer Nano (Malvern 
Panalytical, Malvern, UK). Samples were incubated for 5 minutes at 37 °C before 
data collection. Reported values are averages of 3 independent measurements. 
Cell culture of primary human skin fibroblasts - Primary human skin fibroblasts 
were obtained following informed parental consent and according to the 
relevant Institutional Review Boards. To this end, a skin biopsy was taken from a 
patient (S7-5175) displaying an isolated mitochondrial complex I (CI) deficiency 
in muscle tissue and cultured fibroblasts. This patient harbored a mutation 
(V122M) in the NDUFS7 subunit of CI. Fibroblasts were cultured in Medium 
199 (M199; #22340-020; Thermo Fisher Scientific, Waltham, MA, USA) in a 
humidified atmosphere (95 % air, 5 % CO2) at 37 °C. This medium contained 25 
mM HEPES, 5.5 mM D-glucose, 0.7 mM L-glutamine, 0.05 mM phenol red and no 
pyruvate. To this medium was added: 10 % v/v Fetal Bovine Serum (FBS; Greiner 
Bio-One, Kremsmünster, Austria) and 100 IU/mL penicillin/streptomycin (#30-
002-CI; Corning, NY, USA). Assay medium was as specified above but contained 
no phenol red (#11043-023, GIBCO, Life Technologies Invitrogen). 
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Live-cell high-content microscopy - Cells were seeded at a density of 3500 
cells/well into 96-well black plates (665090, Greiner Bio-one) and cultured in 
a humidified atmosphere of 95 % air - 5 % CO2 at 37 °C. After 24 h, the cells 
were treated with culture medium containing semi-logarithmic concentrations 
of BSO, ELP nanoparticles and 1 µM KH176 for 24 h in a humidified atmosphere 
of 95 % air - 5 % CO2 at 37 °C. Fluorescence microscopy images were acquired 
using a BD Pathway 855 High-Content Bioimager (Becton Dickinson, Franklin 
Lakes, NJ, USA) using a protocol described previously.26 For viability analysis, 
cells were stained with a combination of calcein-AM (#65-0853-39; Thermo 
Fisher) and Hoechst 33258 (#94406, Invitrogen). Calcein-AM is membrane-
permeable and accumulates in the cytosol upon esterase-mediated cleavage 
of its AM (acetoxymethyl) ester groups. Different from our previous protocol,26 
an air 10× objective was used instead of an air 40× objective. To accommodate 
this change, we applied a different cut-off value (i.e. a gray value of 420) and 
changed the size-dependent filter (i.e. an area of the objects between 20-750 
pixels) for the Hoechst images.26 
Results
The ELP monomers used in the present study were diblock copolymers 
consisting of a hydrophilic block [A3G2-60] (60 VPGxG pentarepeats with alanine 
and glycine as the guest residue x in a 3:2 ratio) and a hydrophobic block [I-60] 
(60 VPGxG pentarepeats with isoleucine as the guest residue x). We recently 
reported that these ELP monomers readily self-assemble into monodisperse 
nanoparticles with a diameter of ~60 nm upon shifting the temperature from 
4 °C to 37 °C (van Oppen et al., manuscript submitted).27 ELP monomers are 
highly versatile in that the guest residues and terminal extensions can be 
chosen according to the needs. This makes ELP-based nanoparticles suitable 
tools for biomedical applications.
Covalent modification of ELPs with KH176 via copper-catalyzed click 
reaction
KH176 was covalently attached to ELPs by copper-catalyzed click reaction 
(CuAAC). Due to the lack of reactive side chains within the ELP, the N-terminal 
amino acid was converted into an azide group by utilizing imidazole-1-
sulfonylazide (Figure 1). 
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KH176 was modified on the piperidine group via standard peptide chemistry 
with an alkyne group on a short poly(ethylene glycol) (PEG) spacer. The CuAAC 
was performed in buffered aqueous medium between KH176-alkyne and 
ELP-N3 with adequate yield after purification. The reaction went to completion 
and yielded 70-80 % of the functionalized ELP after inverse-transition cycling 
purification to remove excess KH176 and sodium ascorbate.
Figure 1. Scheme of ELP-KH176 synthesis. The ELP diblock copolymer 1 was first modified 
with imidazole-1-sulfonylazide 2 to yield ELP-N3 3. (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-
piperidin-3-yl)chromane-2-carboxamide 4 was modified with alkyne PEG(4)-COOH 5 to (S)-
N-((R)-1-(3,6,9,12-tetraoxapentadec-1-yn-15-oyl)piperidin-3-yl)-6-hydroxy-2,5,7,8-tetrame-
thylchromane-2-carboxamide 6. The final product 7 was reached by copper(I)-catalyzed azide-
alkyne cycloaddition.
Encapsulation of KH176 and R8 is orientation dependent
Particle formation was tested with 10 % R8-[A3G2-60]-[I-60] (for efficient 
cell uptake) and different ratios of KH176-[A3G2-60]-[I-60] and KH176-[I-60]-
[A3G2-60] (Table 1). Aggregation was observed when particles displayed both 
KH176 and R8 on the outer surface (Figure 2). It is likely that an interaction 
between KH176 and R8 induced aggregation of micelles, since particles formed 
from only KH176-[A3G2-60]-[I-60] were stable with low polydispersity. In order 
to achieve maximum loading of particles with KH176, a combination of 5 % 
R8-[A3G2-60]-[I-60] with 95 % KH176-[I-60]-[A3G2-60] was used as the final 
formulation.
126
Chapter 5 | ELP-nanoparticle mediated import of the ROS-redox modulator KH176 prevents the 
decrease in cell viability in response to induced GSH depletion 
 
Figure 2. Nanoparticle formation probed by dynamic light scattering. Different ratios of 
KH176-modified ELPs were mixed with R8-modified ELPs. All formulations resulted in stable 
nanoparticles, with the exception of particles displaying both KH176 and R8 on the surface. 
Measurements were done in PBS pH 7.2-7.4 at 10 µM.
Table 1. Hydrodynamic radii of different particle compositions. Compositions are displayed 
as molar percentages. Hydrodynamic radii and standard deviations are derived from 3 
independent measurements.
Particle composition Hydrodynamic radius (nm)
KH176-[I-60]-[A3G2-60] 21.3 + 9.6
10 % R8-[A3G2-60]-[I60], 90 % KH176-[I-60]-[A3G2-60] 24.6 + 11.5
10 % R8-[A3G2-60]-[I60], 40 % KH176-[I-60]-[A3G2-60] 28.9 + 9.7
10 % R8-[A3G2-60]-[I60], 20 % KH176-[I-60]-[A3G2-60] 22.1 + 7.8
KH176-[A3G2-60]-[I60] 23.3 + 9.3
10 % R8-[A3G2-60]-[I60], 90 % KH176-[A3G2-60]-[I60] 277.8 + 160.3
10 % R8-[A3G2-60]-[I60], 40 % KH176-[A3G2-60]-[I60] 22.4 + 13.7
10 % R8-[A3G2-60]-[I60], 20 % KH176-[A3G2-60]-[I60] 22.1 + 7.8
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BSO treatment decreases calcein-AM and Hoechst 33258 staining in 
complex I-deficient patient fibroblasts
We recently developed a live cell microscopy protocol for unbiased and 
automated quantification of a variety of cellular and nuclear parameters in 
primary human skin fibroblasts.26 Using this protocol, we next investigated 
the effect of BSO pretreatment on subsequent calcein-AM and Hoechst 33258 
staining in S7-5175 patient fibroblasts. Up to a concentration of 1 µM, 24 h 
treatment with BSO did not visibly alter the fluorescence intensity of the two 
stains (Figure 3). However, at a concentration of 3 µM, BSO treatment caused 
a maximal decrease in calcein and Hoechst 33258 fluorescence. Since BSO was 
washed away before addition of the stains, it can be excluded that the presence 
of BSO affected the labeling. 
Co-treatment with ELPKH176 nanoparticles reduces the BSO-induced 
decrease in cell viability in complex I-deficient patient fibroblasts
Automated quantitative image analysis revealed that 24 h treatment with 
BSO dose-dependently decreased the number of calcein-positive pixels per 
well (Figures 4A and 4B, red line) and the number of Hoechst 33258-positive 
pixels per nucleus (Figures 4C and 4D, red line). In addition, there was a slight 
reduction in the number of nuclei per well. However, this effect showed a strong 
variation between the replicates (Figures 4E and 4F, red line). In all three cases, 
no effect was observed at 1 µM BSO, whereas the maximal effect was reached 
already at a BSO concentration of 3 µM. 
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Figure 3. Visualization of the effect of BSO pretreatment on subsequent calcein-AM- and 
Hoechst 33258 staining in complex I-deficient patient fibroblasts. (A) Unprocessed (RAW) 
and processed (BIN) images of calcein-AM- and Hoechst 33258-stained S7-5715 fibroblasts 
after 24 h treatment with the indicated concentration of BSO. Scalebar represents 400 µm. (B) 
Overlay of unprocessed images of S7-5715 cells pretreated with 3 µM BSO for 24 h, washed, 
and subsequently stained with calcein-AM (green) and Hoechst 33258 (blue).
129
5
Co-treatment with 1 µM free KH176, as a positive control, resulted in complete 
reversal of the BSO-induced decrease in calcein-positive pixels per well over 
the entire range of BSO concentrations tested (Figure 4A, purple line). By 
comparison, co-treatment with ELPKH176 nanoparticles significantly reduced 
the decrease in calcein-AM staining caused by 3 µM BSO, whereas this effect 
gradually disappeared with increasing BSO concentrations. The effect of the 
ELPKH176 nanoparticles was dose-dependent and a maximum recovery of 
viability amounting to 60 % of the value obtained with 1 µM free KH176 was 
reached at an ELPKH176 nanoparticle concentration of 3 µM (Figure 4A, black 
line). Thereafter, the effect of the ELPKH176 nanoparticles decreased again with 
increasing ELPKH176 nanoparticle concentration (Figure 4A, dark and light green 
lines). The latter observation argues against the possibility that the significant 
effect obtained with the ELPKH176 nanoparticles is due to contamination of 
the ELPKH176 nanoparticle preparation with free KH176, as in that case one 
would expect a further prevention of the BSO effect with increasing ELPKH176 
nanoparticle concentration. Co-treatment of the cells with ELP nanoparticles 
consisting of ELP monomers not functionalized with KH176 failed to show the 
beneficial effect of the ELPKH176 nanoparticles (Figure 4B). Moreover, the finding 
that higher concentrations of these nanoparticles did not affect cell viability, 
when tested in the presence of BSO concentrations at or below 1 μM, makes 
it unlikely that the decrease of the beneficial effect at these higher ELPKH176 
nanoparticle concentrations was due to unspecific effects.
The same results were obtained regarding the effect of co-treatment with 
ELPKH176 nanoparticles on the BSO-induced decrease in the number of Hoechst 
33258-positive pixels per nucleus (Figures 4C and 4D). On the other hand, we 
were unable to demonstrate a beneficial effect of co-treatment with ELPKH176 
nanoparticles on the BSO-induced decrease in the number of nuclei per well 
(Figure 4E). This lack of effect is likely explained by the relatively small decrease 
evoked by BSO in combination with a relatively large standard deviation. 
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Figure 4. Effect of ELPKH176 nanoparticles on restoring the effects of BSO treatment. Cells were 
co-treated with the indicated concentrations of ELPKH176 nanoparticles and BSO for 24 h, washed, 
and stained with calcein-AM and Hoechst 33258. Next, the cells were imaged and the images were 
processed according to our recently published protocol to extract (A,B) the number of calcein-positive 
pixels per well, (C,D) the number of Hoechst 33258-positive pixels per nucleus and (E,F) the number of 
nuclei per well.26 The ELP nanoparticles used in A,C and E consisted of ELP monomers functionalized 
with either KH176 (95 %) or R8 (5 %), those used in B,D and F consisted of ELP monomers not 
functionalized with KH176 (95 %) and ELP monomers functionalized with R8 (5 %). Error bars denote 
the standard error of the mean of 3 independent experiments for the ELPKH176 nanoparticles (A,C and 
E) and 2 independent experiments for the ELP nanoparticles (B,D and F). Significance was assessed 
at 3 µM BSO using two-way ANOVA, followed by Tukey’s multiple comparisons test. Significant 
differences are indicated by *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Discussion
Here, we show that the ROS-redox modulator KH176 covalently coupled to cell-
penetrating ELP nanoparticles reduces the BSO-induced decrease in cell viability 
in primary skin fibroblasts from a complex I-deficient patient with Leigh syndrome. 
The effect of 24 h co-treatment with ELPKH176 nanoparticles was significant at a 
BSO concentration of 3 μM, shown before to be the lowest BSO concentration that 
completely depleted both healthy and complex I-deficient patient fibroblasts of 
GSH within this time frame.17 The maximal effect, ~60 % reduction of the effect 
of 3 μM BSO, was reached with 3 μM ELPKH176 nanoparticles and calculation of the 
ELPKH176 nanoparticle concentration for the half-maximal effect yielded a value of 
~0.37 µM. This value closely resembled that of free KH176, which, under the same 
conditions as used in the present study, was determined to be ~0.27 µM.17 
Macropinocytosis has been reported as the main endocytotic pathway for R8-
mediated uptake.28,29 Accordingly, confocal microscopy of fibroblasts treated 
with ELP-based nanoparticles consisting of 5 % Alexa647-ELP, 5 % R8-ELP and 90 % 
ELP revealed that Alexa647 fluorescence primarily localized to punctate structures 
corresponding to endolysosomal vesicles (van Oppen et al., manuscript 
submitted). The latter study furthermore demonstrated that uptake of ELP 
nanoparticles completely depended on the inclusion of R8-ELP. It is therefore 
reasonable to assume that ELP-KH176 applied through ELPKH176 nanoparticles 
predominantly ends up in endocytic vesicles.
The likely presence of ELP-KH176 in vesicles of the endolysosomal pathway leaves 
the question of how vesicular ELP-KH176 can reduce the GSH depletion-induced 
decrease in cell viability. Recently, we reported that catalase-encapsulating TAT-
polymersomes, which, similarly to ELP-KH176, were demonstrated to be mainly 
present in endolysosomal vesicles, can effectively protect S7-5175 patient 
fibroblasts against exogenous H2O2-induced cell death.
30 Accordingly, vesicular 
ELP-KH176 may exert its beneficial effect by promoting the detoxification of 
intracellularly produced H2O2 that is no longer neutralized by the glutathione 
antioxidant system. 
Beyrath and co-workers showed that healthy control fibroblasts and S7-
5175 patient fibroblasts were equally sensitive to GSH depletion by 24 h BSO 
treatment.17 However, in sharp contrast to patient fibroblasts, healthy control 
fibroblasts showed no decrease cell viability. 
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These results indicate that fibroblasts possess a mechanism that can compensate 
for the loss in GSH. Such a putative compensatory mechanism would then be 
inactive in patient fibroblasts. Further reasoning along this line of thought leads 
to the idea that KH176 can activate this putative compensatory mechanism in 
patient fibroblasts as can be deduced from its ability to completely prevent the 
GSH depletion-induced decrease in cell viability in these cells.17 Importantly, this 
effect of KH176 was not paralleled by any detectable increase in GSH. Regarding 
the nature of this putative compensatory mechanism, Beyrath and co-workers 
provided evidence that KH176 acts at the level of the thioredoxin system. 
This system oxidizes NADPH to reduce oxidants such as H2O2. Using a coupled 
enzyme assay containing thioredoxin reductase, thioredoxin and peroxiredoxin, 
Beyrath and co-workers showed that not KH176 itself, but its major metabolite 
KH176m, mediated the oxidation of NADPH in the presence of H2O2.
17 In addition, 
they showed that well-characterized inhibitors of thioredoxin reductase largely 
decreased the beneficial effect of both KH176 and KH176m on the GSH depletion-
induced decrease in cell viability. Because they also showed that cells produced 
substantial amounts of KH176m during a 24 h incubation in the presence of 
KH176, it cannot be ruled out that KH176m is responsible for the beneficial effect 
of extracellularly supplied KH176. With this in mind, the observation that the 
effect of 3 µM ELPKH176 nanoparticles was dose-dependently reduced at higher BSO 
concentrations may be explained by increasing rates of GSH depletion gradually 
exceeding the rate at which ELP-KH176 is converted into ELP-KH176m. Currently, 
it is unknown by which mechanism and in which cellular compartment KH176 is 
converted into KH176m. If this would be the cytosolic compartment, the present 
findings would be compatible with the idea of a gradual appearance of vesicular 
ELP-KH176 in the cytosol, where it is converted into ELP-KH176m, resulting in a 
gradual build-up of a sufficient concentration to significantly reduce the effect of 
3 μM BSO during a 24 h co-incubation with 3 μM ELPKH176 nanoparticles. However, 
if ELP-KH176 does not escape the endolysosomal system its conversion into 
KH176 needs to take place in this system. Regarding the presence of components 
of the thioredoxin system in vesicles of the endolysosomal pathway, evidence 
has been provided for the presence of peroxiredoxin in redox-active endosomes 
or redoxosomes and exosomes.31,32 Further research is required to elucidate 
whether vesicular ELP-KH176 is converted into vesicular ELP-KH176m and as 
such may act through a vesicular thioredoxin system to prevent the cytotoxic 
effects of GSH depletion. 
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The potential of ELP-based nanoparticles as a drug delivery platform has been 
demonstrated both in vitro and in vivo. Particularly ELP nanoparticles carrying 
anti-cancer drugs such as doxorubicin,33 paclitaxel,34 rapamycin and docetaxel 
have been extensively investigated.35,36 Other examples of ELP-based drug 
delivery are ELPs containing antibiotic payloads for antimicrobial therapy,37 
growth factors and tissue-protective molecules to increase wound-healing 
and rapamycin to treat Sjogren’s syndrome.38,39 Regarding the delivery of 
antioxidants, chitosan nanoparticles loaded with Trolox exerted a protective 
effect against hypoxia-mediated oxidative stress and formulations have been 
optimized for the inclusion of mitochondrial therapeutics such as curcumin and 
coenzyme Q10 in Food and Drug Administration (FDA)-approved polymeric 
poly(lactic-co-glycolic acid) (PLGA) nanoparticles.40–43
In conclusion, we demonstrated that ELPKH176 nanoparticles can prevent GSH 
depletion-induced reduction in cell viability in primary skin fibroblasts from a 
complex I-deficient patient with Leigh syndrome. Taking into account that ELP-
based nanoparticles are highly versatile, the present findings stimulate further 
research towards the incorporation of targeting functionalities that endow ELP 
nanoparticles with e.g. the ability to penetrate the blood-brain barrier.
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Abstract
The blood-brain barrier (BBB) severely hampers entry of drugs to treat 
neurodegenerative disease into the central nervous system. Still, endothelial 
cells of the BBB express a variety of specific receptor-mediated transport systems, 
which could be used to induce transcytosis of carrier-mediated drugs. In this 
chapter, we explored the potential of ELP-nanoparticles including 25 % peptide 
G23 (ELPG23) to induce transcytosis within 24 h in an in vitro BBB model. Upon 
switching the temperature from 4 °C to 37 °C, mixtures of ELP and ELP-G23 
formed nanoparticles of a well-defined size of ~60 nm. The BBB model in this 
study was a monolayer of human brain microvascular endothelial cells (HBMEC/
ciβ) on collagen-coated filter inserts. Tightness of the monolayer was established 
by quantification of the permeability coefficient of paracellular tracers and 
measurement of the transendothelial resistance (TEER). The transcytosis capacity 
of ELPG23 nanoparticles was significantly pronounced after 4 h incubation 
onwards compared to ELP nanoparticles. This finding confirms the potential of 
ELPG23 nanoparticles for the targeted delivery of KH176 to the brain.
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Introduction
Improper functioning of mitochondria can have dramatic effects on neuronal 
survival, since neurons have enormous energy demands and limited 
regenerative capacity.1 However, treatment of neurodegenerative diseases, 
in general, is severely hampered by the presence of the blood-brain barrier 
(BBB). The BBB entails nonfenestrated brain capillary endothelial cells with low 
pinocytotic activity intimately linked by protein complexes forming of tight 
and adherent junctions.2 The BBB restricts entry of 98 % of small molecule 
drugs, unless molecules are lipid-soluble with a molecular weight of 400 – 
600 Da or less, and ~100 % of large-molecule neurotherapeutics.3 Although 
KH176 is a small-size molecule and thus able to enter the brain,4 targeted 
delivery of KH176 could increase pharmacokinetics and enhance therapeutic 
efficacy. In the previous chapter, ELP nanoparticles covalently functionalized 
with KH176 (ELPKH176 nanoparticles) exerted a significant therapeutic effect in 
patient cells with isolated complex I deficiency. The efficiency might be further 
enhanced through functionalization with a specific BBB targeting peptide that 
would be able to enhance transcytosis across the BBB. Brain endothelial cells 
express a variety of specific receptor-mediated transport systems including the 
transferrin receptor, insulin receptor and low density lipoprotein receptors for 
transcytosis.5 Generally, a blood circulating ligand interacts with its specific 
receptor at the apical side of the plasma membrane of endothelial cells. 
After binding, endocytosis is initiated and intracellular vesicles transport the 
receptor-ligand complex, or dissociated ligands, to the basolateral side of the 
endothelial cell where release takes place.5 
Currently, only few robust cellular model systems to mimic the BBB are available.6 
Access to human primary endothelial cells is limited and immortalized human 
brain microvascular endothelial cells show poor barrier formation.6 One cell line 
that has been developed, characterized and validated as a functional human in 
vitro BBB model are primary human brain microvascular endothelial cells which 
were conditionally (temperature-sensitive) immortalized by both tsSV40T and 
hTERT (HBMEC/ciβ).7 
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ELP nanoparticles are a peptide-based drug delivery system, and this feature 
makes them suited to include peptide-based ligands which could interact with 
receptors specifically expressed at the BBB. Peptide shuttles offer advantages 
such as low cost, reduced immunogenicity and high chemical versatility 
compared to traditional monoclonal antibodies.8 Examples of brain targeting 
peptides which are under clinical development are Angiopep-2, which acts on 
low density lipoprotein receptor-related protein 1 (LRP1) and glutathione (GSH), 
an endogenous peptide which acts on many transporters mediating influx 
an efflux in the central nervous system.8 In this study, we used a dodecamer 
peptide called G23 with ganglioside GM1 as target. This peptide was identified 
by means of phage display, and has been demonstrated to promote transport 
over the BBB in vitro and in vivo.9,10 
ELP nanoparticles consist of ELP monomers, which form nanoparticles 
upon reaching the lower critical solution temperature (LCST). The effect of 
incorporating different amounts of ELP-G23 monomers on particle formation 
and size was measured with dynamic light scattering. The functionality of ELP 
nanoparticles including 25 % G23 (ELPG23 nanoparticles) was evaluated in a 
two-dimensional cellular model mimicking the endothelial membrane of the 
BBB. The model in our study consisted of a layer of conditionally (temperature-
sensitive) immortalized primary human brain microvascular endothelial cells 
(HBMEC/ciβ). We assessed whether the monolayer of HBMEC/ciβ cells cultured 
on collagen-coated filter inserts fitted the permeability characteristics as 
previously described by Kamiichi et al.7 Furthermore, we evaluated whether 
ELPG23 nanoparticles were more efficiently transcytosed in HBMEC/ciβ cells 
than ELP nanoparticles by tracking the fluorescence of 10 % ELP-Alexa647 at the 
apical and basolateral side of the filter insert. We found that ELPG23 nanoparticles 
promote transcytosis over a monolayer of HBMEC/ciβ cells. These results are 
a further relevant step preceding in vivo studies for the development of the 
targeted delivery of KH176 towards the brain as therapy for neurodegenerative 
disease induced by mitochondrial defects.
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Materials and Methods
Dynamic light scattering - Samples were diluted to a final concentration of 
10 µM in PBS. Measurements were performed on a Malvern Zetasizer Nano 
(Sysmex, Etten-Leur, The Netherlands). Samples were incubated for 5 min at 
37 °C before data collection. Reported values are averages of 3 independent 
measurements.
Cell culture – Human Brain Microvascular Endothelial Cells/conditionally 
immortalized, clone β (HBMEC/ciβ) kindly provided by Dr. Tomomi Furihata 
(Laboratory of Pharmacology and Toxicology, Chiba University, Japan) were 
cultured to confluency at 33 °C in a humidified atmosphere of 95 % air – 5 % 
CO2. The culture medium used was CSC complete medium (CSC Certified, Bio-
Connect, Huissen, The Netherlands) supplemented with 2% v/v CSC CultureBoost 
(CSC Certified) containing CSC Non-Recombinant Growth Factors (CSC Certified). 
Culture flasks were coated with coating solution containing 1.15% v/v collagen 
Type l solution (Sigma-Aldrich, Zwijndrecht, The Netherlands) in 0.12% v/v 
acidified MQ with acetic acid (Sigma-Aldrich) for 30 min at 37˚C.
Permeability coefficients of paracellular tracers and trans-endothelial 
resistance (TEER) – Prior to seeding, filter inserts (ThinCerts, Pore size 3.0 µm, 
Frickenhausen, Germany) were coated with coating solution as described 
above. The appropriate amount of cells was seeded apically in 500 μL culture 
medium on coated filter inserts in a 12-well polystyrene culture plate (Cellstar, 
Greiner Bio-One, Kremsmünster, Austria). The plate was incubated overnight 
in a humidified atmosphere of 95% air – 5% CO2 at 33 ˚C and subsequently 
transferred to a humidified atmosphere of 95% air – 5% CO2 at 37 °C for 11 
days. Three days post-seeding onwards, the culture medium was replaced 
both on the apical and basolateral side for culture medium containing 200 
nM hydrocortisone (Sigma-Aldrich) every other day. The trans-endothelial 
resistance (TEER) was measured using a Volt-Ohm meter (EMD Millipore Millicell-
ERS2 Volt-Ohm Meter, Billerica, Massachusetts, USA). The assay to determine 
permeability coefficients was initiated by adding 5 µM of paracellular tracers 
10-kDa Rhodamine-Dextran (Molecular probes, Thermo Fisher Scientific, Breda, 
The Netherlands) and sodium fluorescein (Molecular probes, Thermo Fisher 
Scientific, Breda, The Netherlands) apically in a humidified atmosphere of 95% 
air – 5% CO2 at 37 °C. 
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Immediately after initiation (t0), the medium was collected from the basolateral 
side of the well at the indicated time points. Fluorescence of each sample then 
was measured in triplicate using black flat-bottomed microplates (#353219, 
Falcon-corning, Thermo Fisher Scientific) and a Synergy 2 micoplate reader 
(BioTek, Abcoude, The Netherlands) with excitation and emission for sodium 
fluorescein at 485/20 and 528/20, respectively. For 10-kDa Rhodamine-
Dextran excitation and emission wavelengths were 540/25 nm and 620/40. The 
permeability coefficients were calculated as described by Kamichii et al.7
Transcytosis assay – Prior to seeding, filter inserts (ThinCerts Pore size 3.0 µm) 
were coated with coating solution as described above. 50,000 / cm2 HBMEC/ciβ 
cells were seeded apically on filter inserts in a 12-well polystyrene culture plate 
(Cellstar). The plate was incubated overnight in a humidified atmosphere of 95% 
air – 5% CO2 at 33 ˚C and subsequently transferred to a humidified atmosphere 
of 95% air – 5% CO2 at 37 °C for 11 days. Three days post-seeding onwards, 
the culture medium was replaced both on the apical and basolateral side for 
culture medium containing 200 nM hydrocortisone (Sigma-Aldrich) every other 
day. Twelve days post-seeding, ELPG23 nanoparticles and ELP nanoparticles were 
added apically at a final concentration of 10 µM in a humidified atmosphere of 
95% air – 5% CO2 at 37 °C for 24 h. At t0, fluorescence of samples from the apical 
and basolateral side was measured, and subsequently at different time points 
samples were taken from the basolateral side and replenished with medium 
without fluorescence. Fluorescence of samples was measured in triplicate 
using black flat-bottomed microplates (#353219, Falcon-corning, Thermo 
Fisher Scientific) and the Tecan Spark 10M microplate reader (Tecan, Giessen, 
The Netherlands) with excitation and emission at 640/9 nm and 675/20 nm, 
respectively.
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Results
Characterization of ELP nanoparticles
ELPs consisted of a hydrophilic block [A3G2-60] (60 GXGVP pentarepeats with 
alanine and glycine as the guest residue X in a ratio of 3:2) and a hydrophobic 
block [I-60] (60 GXGVP pentarepeats with isoleucine as the guest residue X). 
ELP nanoparticles (10 µM with respect to ELP in PBS) were formed through self-
organization by shifting the temperature from 4 to 37 °C, exceeding the LCST 
of the hydrophobic block [I-60] (22 °C). Dynamic light scattering (DLS) showed 
monodisperse particles with a diameter of ~60 nm for ELP nanoparticles 
including G23-ELP monomers up to 25 % at 37 °C (Figure 1, red and green line). 
For ELP nanoparticles including 100 % G23-ELP monomers, large aggregates 
were formed (Figure 1, black line). For this reason, in the experiments hereafter 
ELPG23 nanoparticles mentioned are ELP nanoparticles including 25 % G23-ELP 
monomers and 10 % ELP-Alexa647 monomers for visualization.
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Figure 1. Characterization of ELPG23 nanoparticles with dynamic light scattering. 
ELP nanoparticles (green line), ELPG23 nanoparticles containing 25 % G23-ELP monomers 
(red line) and ELPG23 nanoparticles containing 100 % G23-ELP monomers (black line).
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Tightness of HBMEC/ciβ layer is intact based on permeability 
coefficients of paracellular tracers
The tightness of the monolayer of HBMEC/ciβ on collagen-coated filter inserts 
was assessed 12 days post-seeding (cellular passage 9), by determining the 
permeability coefficients (Pe) for paracellular tracers 10-kDa Rhodamine-
Dextran and sodium fluorescein (Na-F) (Figure 2A). We were interested to 
learn whether an increase in cell density at the time of seeding would increase 
tightness of the monolayer of HBMEC/ciβ and seeded two different cell densities, 
namely 50,000 cells/cm2 and 100,000 cells/cm2. After 24 h incubation of 5 µM 
paracellular tracers, the Pe for Rhodamine-Dextran was 0.13 ± 0.0009 ×10
-3 cm/
min (50,000 cells/cm2) and 0.16 ± 0.0003 ×10-3 cm/min (100,000 cells/cm2). For 
Na-Fluorescein, the Pe values were 1.7 ± 1.0 × 10
-3 cm/min (50,000 cells/cm2) 
and 2.3 ± 0.72 × 10-3 cm/min (100,000 cells/cm2). In addition, the monolayer 
integrity was assessed by measuring the transendothelial resistance (TEER). 
TEER values were equally low (in range of few hundreds of Ω×cm2) between 
collagen-coated inserts, 50,000 cells/cm2 and 100,000 cells/cm2 of HBMEC/ciβ 
cells on collagen-coated inserts (Figure 2B). Since both Pe and TEER values 
were similar to previously established in vitro monoculture BBB models, for 
experiments hereafter a cell density of 50,000 cells/cm2 was used.7
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Figure 2. Validation of tightness of the monolayer of HBMEC/ciβ on collagen-coated 
filter inserts. (A) Permeability coefficients (Pe) for paracellular tracers Rhodamine-Dextran 
(10 kDa) and sodium fluorescein (332,2 Da). Error bars represent standard error (SD) of 
duplicate measurements within one experiment. (B) Trans-endothelial resistance (TEER) at 
t = 0. Error bars represent standard error of the mean (SEM) of triplicate measurements within 
one experiment.
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ELPG23 nanoparticles promote transcytosis over a monolayer of  
HBMEC/ciβ
In order to assess the transcytosis capacity, a monolayer of HBMEC/ciβ cells was 
incubated with 10 µM ELPG23 nanoparticles on the apical side in a humidified 
atmosphere of 95% air – 5% CO2 at 37 ˚C for 24 h. At various time points, the 
fluorescence of the ELP-Alexa647 monomers in the medium of the basolateral 
side was analyzed and expressed as percentage of the total apical fluorescence 
at t0 (Figure 3). After 24 h, 64.6 ± 6.3 % fluorescence of ELPG23 nanoparticles 
was in the basolateral medium and 45.6 ± 13.7 % fluorescence was in the 
apical medium. In contrast, for ELP nanoparticles 52.8 ± 4.1 % fluorescence was 
detected in the basolateral medium and 45.5 ± 8.1 % fluorescence in the apical 
medium. Importantly, no difference in fluorescence at the basolateral medium 
between ELPG23 nanoparticles and ELP nanoparticles could be measured for the 
collagen-coated filter inserts. For ELPG23 nanoparticles, 62.8 ± 0.6 % fluorescence 
was in the basolateral medium and 32.3 ± 7.6 % fluorescence was in the apical 
medium after 24 h. For ELP nanoparticles, these values were 62.1 ± 3.2 % and 
28.7 ± 5.0 %, respectively. 
Figure 3. Transcytosis of ELP and ELPG23 nanoparticles. 10 µM ELP nanoparticles were added 
to the apical side of HBMEC/ciβ cells or collagen and incubated for 24 h. Fluorescence was 
measured at the basolateral side at different time points and expressed as percentage of the 
t0 molar fraction at the apical side. Values represented are the mean ± SEM of 3 independent 
experiments. Significance was assessed using two-way ANOVA, followed by Tukey’s multiple 
comparisons test. Significant differences are indicated by *P < 0.05 and **P < 0.01. 
148
Chapter 6 | Evaluation of elastin-like polypeptide nanoparticles functionalized with the G23 
peptide in a human in vitro blood-brain barrier model
Discussion
In this study, we evaluated the potential of ELPG23 nanoparticles to transcytose 
over a monolayer of HBMEC/ciβ cells on collagen-coated filter inserts. This cell 
line was extensively characterized by Kamichii et al. and proposed to be used as 
in vitro model for the blood-brain barrier.7 Targeted brain delivery using drug-
loaded ELPG23 nanoparticles would be a relevant step towards the treatment of 
neurodegenerative disease.
First we recapitulated and optimized experimental conditions to create a tight 
monolayer of HBMEC/ciβ as published.7 Common characteristics to assess 
tightness are permeability coefficients for paracellular tracers and TEER values.11 
Using differently sized fluorescent tracers which are spectrally distinguishable 
such as 10-kDa Rhodamine-Dextran and sodium fluorescein allowed 
simultaneous analysis of the two tracers in the same culture.12 We quantified the 
permeability coefficients for 10-kDa Rhodamine-Dextran and sodium fluorescein 
(MW = 332.2 Da) in relation to initial cell densities of 5 × 104 cells / cm2 and 1 × 
105  cells / cm2 on collagen-coated filter inserts. Not only the physical dimensions 
of the cells dictate the efficacy of paracellular restriction,11 but also the height 
of the monolayer has an impact on the path length which needs to be crossed 
by the ELP nanoparticles.13 The permeability coefficients of 0.1 – 2.5 × 10-3 cm 
s-1 were within the range of previously established in vitro monoculture BBB 
models at similar passage number.7,14 The cell passage number is an important 
aspect,15 as we observed that a monolayer of HBMEC/ciβ with a higher passage 
number displayed higher permeability coefficients (data not shown). Of note, 
these permeability coefficients are a composite of  paracellular and transcellular 
routes.12 In general, primary brain capillary endothelial cultures provide a 
phenotypic resemblance to the in vivo BBB with permeability coefficients for 
paracellular tracers in the order of  10-6 cm s-1.11  For example, for the extracellular 
marker sucrose an in vivo permeability of as low as 2.5 – 3.0 × 10-8 cm s-1 was 
measured.16 For the cell density of 5 × 104 cells / cm2, we measured lower 
permeability coefficients for both paracellular tracers than for 1 × 105  cells / cm2. 
Based on these values, we continued the transcytosis studies using 5 × 104 cells 
/ cm2. In addition, transendothelial resistance (TEER) is a quantitative technique 
to evaluate integrity of the endothelial monolayer.6 Regarding TEER values, no 
differences between collagen, 5 × 104 HBMEC/ciβ / cm2 and 1 × 105  HBMEC/ciβ 
/ cm2 could be observed. These values did not exceed 200 Ω cm2 and are in line 
with the findings previously reported on this cell line.7 
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In comparison, values of ~1800 Ω cm2 have been measured in rats in vivo, 
however, for humans this value is difficult to measure.17 A next step in optimizing 
in vitro blood-brain barrier models could be the extension of the HBMEC/ciβ 
monolayer with perfusable brain-specific capillaries and surrounding pericytes 
and astrocytes within a matrix.18,19 Quadruple culture models including four 
types of primary cell types achieved a TEER value as high as 2,500 Ω cm2.20
The main goal of this study was to evaluate whether 25 % ELP-G23 monomers 
within ELP nanoparticles would increase transcytosis in the HBMEC/ciβ 
monolayer. The maximum amount of targeting peptide G23 to be included in 
the hydrophilic corona of ELP nanoparticles was 25 %, as higher amounts led 
to aggregation due to the hydrophobic nature of G23. Size of nanoparticles 
is an important feature for BBB transport, and an average size of 65 nm for 
ELPG23 nanoparticles offers a good probability of crossing the BBB.
21 After 
addition at the apical side, ELPG23 nanoparticles were present in a higher 
percentage at the basolateral side at each time point measured compared to 
ELP nanoparticles. At time points t = 240 min (4 h) and t = 1440 min (24 h) the 
differences in transcytosis between ELPG23 nanoparticles and ELP nanoparticles 
were statistically significant. A G23-mediated increase in transcytosis capacity 
after 4 h and 18 h in vitro was reported before.9,10 Of note, these studies used 
an alternative human brain endothelial cell line, different filter inserts and 
polymersomes as carrier for transport across the BBB. In the work of Georgieva 
et al., reducing the peptide density of G23 from 10 to 5 mol % incorporated into 
polymersomes, demonstrated a two-fold reduction in transcytosis.
It is important to determine the rate of uptake of circulating ELPG23 nanoparticles 
from the blood to the brain, since chronic treatment would be required for 
alleviation of neurodegenerative symptoms linked to complex I deficiency. 
As the drug molecule of interest KH176 would be active in the brain at low 
concentrations,4 a slow rate of transcytosis might prevent accumulation of ELPG23 
nanoparticles in the brain.22 Important to keep in mind is that the degradation 
kinetics of ELPG23 nanoparticles could drastically impact the pharmacokinetics 
of KH176.
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Mitochondria play an important role in maintaining BBB integrity. Large 
numbers of mitochondria are present in brain endothelial capillary cells, which 
subsequently lead to a high metabolic capacity in the BBB.23 The inhibition 
of mitochondrial function using complex I inhibitor rotenone increased cell 
permeability and disrupted cell-cell junctions in a primary cerebrovascular 
endothelial cell (cCVEC) monolayer transwell system in vitro and in vivo.24 While 
opening the BBB, at the same time, it could also reduce the rate of transcytosis. 
For this reason, it would be important to mimic the effects of complex I 
deficiency in an in vitro BBB model for the prediction of therapeutic efficacy of 
ELP-mediated drug delivery in vivo.
In conclusion, we presented the potential of ELPG23 nanoparticles in transcytosis 
over a human in vitro BBB model consisting of a tight monolayer of HBMEC/
ciβ cells on collagen-coated filter inserts. After 4 h, ELPG23 nanoparticles in 
comparison to ELP nanoparticles showed a significant increase in transcytosis. 
Thus these ELPG23 nanoparticles have the potential to function as a carrier for 
the targeted delivery of KH176 to the brain.
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Introduction
Nanomedicine involves the application of nanotechnology for prevention, 
diagnosis and treatment of disease.1 Within the field of nanomedicine, 
nanoreactors and drug delivery systems provide many advantages compared to 
current treatments.2 Both nanoreactors and nanoparticle-based drug delivery 
systems can be specifically targeted to tissues and cells of interest. Nanoreactors 
or artificial organelles typically contain enzymes or enzyme systems aimed at 
normalizing aberrant cellular processes and should remain intact after cellular 
uptake. Nanoparticle-based drug delivery systems are aimed at local or cellular 
drug delivery and should therefore release the drug either extracellularly 
or intracellularly and most preferentially in a controlled manner. They are 
designed to improve unfavorable pharmacokinetic properties, such as poor 
tissue distribution and high inactivation and excretion rates of conventional 
drugs. Moreover, they should increase the therapeutic efficacy of these drugs 
by enhancing their accumulation in tissues or cellular compartments they are 
destined for, preventing, in the meantime, adverse effects in non-targeted 
tissues and cells.3 In this thesis we described the synthesis, properties and live 
cell functional testing of catalase containing polymersomes, as a representative 
of an intracellular nanoreactor, and antioxidant delivering elastin-like 
polypeptide (ELP)-based nanoparticles, as a representative of a nanoparticle 
drug delivery system. The cell systems used include 2D cell cultures of HEK293 
cells and primary human skin fibroblasts from a patient with Leigh syndrome, 
3D cultures or spheroids of a tumor cell line and a blood brain barrier (BBB) 
model. The latter model specifically addresses the process of transcytosis which 
is crucial for nanoparticles aimed at reaching the cells of the central nervous 
system. 
Despite the high expectations based on results obtained in cell and animal 
models, thus far relatively few nanoreactors and nanoparticle drug delivery 
systems have made it to a successful evaluation in the clinical setting.4 The 
reasons are manifold but center around the poor understanding of the 
behaviour of these nanoparticles in the human body. Nanoparticles should 
be biocompatible and, depending on their intended role as nanoreactor or 
nanoparticle drug delivery system, to a more or lesser extent biodegradable. 
Furthermore, there is a need of predictive outcome measures in cell and animal 
models that can bridge the translational gap to the clinic. 
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The delivery of enzymes and drugs to a specific tissue or type of cell is 
challenging, all the more because nanoreactors and nanoparticle drug delivery 
systems are supposed to cross endothelial barriers, such as the BBB, to facilitate, 
if required, their uptake by target cells and to promote, if needed, lysosomal 
escape. Importantly, prematurely clearing by the mononuclear phagocytic 
system which results in reduced half-life and, consequently, higher dosing 
regiments to reach the effective plasma concentration should be prevented 
and, finally, nanoparticles should not induce unwanted toxicity.5 Nanoparticles 
are highly versatile which allows optimal fine-tuning to the requirements 
described above.
The aim of this thesis is to evaluate the potential of two types of nanoparticles, 
polymersomal nanoreactors and elastin-like polypeptide (ELP)-based 
nanoparticles, in terms of BBB passage, spheroid penetration, cellular uptake, 
intracellular localization and providing patient-derived cells with the required 
biological activity.
Polymersomes – composition, preparation and (bio)physical properties 
Polymersomes are polymer vesicles which are fabricated via self-assembly of 
amphiphilic block copolymers. The advantages of polymersomes in drug delivery 
are their high encapsulation efficiency, long blood circulation, tunable chemistry 
and flexible structure. Polymersomes are excellent candidates to include an active 
moiety such as an enzyme. Because of the polymersomal semi-permeability, 
enzymes are able to interact with the external environment while being 
protected against degradation.6  For effective functioning as nanoreactor, semi-
permeability, biodegradability and biocompatibility are crucial requirements.7 
In chapter 2, the direct hydration method for the preparation of poly 
(ethylene glycol)-block-poly(caprolactone-gradient-trimethylene carbonate) 
(PEG-PCLgTMC) polymersomes was presented including their physical 
characterization highlighting the semi-permeability of their membrane and 
their ability to shield enzymatic cargo.
Regarding the biodegradability of the copolymers involved, the polymer PCL is 
biodegradable and FDA-approved for use in drug delivery.8 The polymer PTMC 
has been reported before to display unique degradation behaviour with resistance 
to non-enzymatic hydrolysis and generation of non-acidic degradation products. 
These properties reduce the risk of adverse reactions in vivo.9 
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Although PEG is not biodegradable, this polymer is generally considered to be 
nontoxic. PEG increases the hydrodynamic volume of the nanoparticles, which 
retards glomerular filtration and, thus, prolongs the blood circulation time. On 
the other hand, an important disadvantage of PEG is the reduced cellular uptake 
because of the hydrophilic corona surrounding polymersomes.8,10 PEGylated 
therapeutics have reached the market, but unexpected immune-mediated 
side-effects, probably caused by anti-PEG antibodies, are receiving increased 
attention. The FDA recently updated their guidelines to screen for anti-PEG 
antibodies in clinical trials.11 In vitro data demonstrated that the structure of 
polymersomes was preserved in human serum and no signs of degradation 
were observed within a time period of 24 h. Moreover, proteinase K was not 
able to disrupt the self-assembled structures and polymersomes were able 
to shield encapsulated fluorescent FITC-BSA substrate. However, it should be 
realized that experimental conditions cannot mimic the harsh degradative 
environment of lysosomes.
Polymersomes – cellular uptake and intracellular localization
To function as nanoreactors inside living cells, efficient cellular uptake is a 
crucial feature for polymersomes. Therefore, we first focused on directing 
the cellular integration of polymersomes. This is a crucial step in obtaining 
a relevant therapeutic effect inside cells. Cell penetrating peptides (CPPs) 
are described to be efficient in mediating a wide range of cargoes such as 
nanoparticles into living cells.12 To this end, we conjugated the CPP TAT derived 
from the human immunodeficiency virus (HIV) to polymersomes.13 TAT is known 
to direct endocytotic uptake of proteinaceous cargo, leading to entrapment 
in endocytotic vesicles.14 In previous studies, TAT-conjugated polymersomes 
were shown to be efficiently internalized through macropinocytosis and to, 
subsequently, colocalize primarily with lysosomes.15,16 In our study, we were 
especially interested to learn, whether the cyclic form of TAT (cTAT) would 
be able to induce endosomal escape of the internalized polymersomes. This 
because the cTAT was reported to direct cytosolic delivery of green fluorescent 
protein (GFP) in HeLa cells.17 We compared the efficacy of the linear and cyclic TAT 
variants in facilitating polymersomal uptake in HEK293T cells. Flow cytometry 
revealed that, as expected, cell uptake was virtually absent for polymersomes 
without TAT or cTAT, whereas TAT- and cTAT-polymersomes were readily taken 
up in a concentration-dependent manner. Confocal laser scanning microscopy 
visualized intracellular punctate structures within the cell membrane for (c)TAT-
polymersomes. 
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Since our data could not confirm an advantage in uptake from cyclic TAT over 
linear TAT, subsequent studies were performed using TAT-polymersomes. 
To visualize the content of nanoreactors inside living HEK293T cells, 
AlexaFluor647-labelled bovine serum albumin (AF647BSA) was included in TAT-
polymersomes. The data obtained show that with the treatment protocol used, 
1 h pulse followed by a 24 h chase, the vast majority of the cargo, AF647BSA, 
ends up in LysoTracker Green-positive objects. Similarly, incubation with free 
AF647BSA showed accumulation in LysoTracker Green-positive compartments 
and not in the cytosol. Therefore, the absence of detectable amounts of AF647BSA 
in the cytosolic compartment of cells treated with AF647BSA encapsulating TAT-
polymersomes does not unambiguously prove that the endolysosomal system 
contains intact polymersomes. More advanced microscopy techniques are 
required to provide information at sufficiently high resolution about the fate of 
polymersomes in the endolysosomal pathway.18,19 A polymersomal membrane 
disrupting agent can be used to check whether the cargo after disruption of 
the polymersomes is able to reach the cytosolic compartment resulting in a 
homogeneous distribution rather than a punctate endolysosomal pattern as 
demonstrated by Einfalt et al, 2018.20 
However, these strategies are not quantitative in determining whether the 
payload is inside polymersomes or whether it is released intracellularly. To 
quantify  intracellular release from polymersomes, Scarpa et al. developed a 
method using fluorescein.21 When fluorescein is highly concentrated in aqueous 
solution, it self-quenches. After encapsulation of fluorescein inside the aqueous 
core of polymersomes above the quenching concentration, polymersomes 
are non-fluorescent. If the cargo is released in the cytosol, dequenching will 
occur and fluorescence will increase. Generally, it is hard to accurately define 
the amount of nanoparticles inside cells. For this reason, measuring the cell-
culture supernatant solution after incubation would be a control for the 
presence of polymersomes in the remaining medium.4 More information about 
the number of polymersomes internalized and the concentration of cargo in 
the various compartments is required for further optimization and control of 
the polymersome-mediated cargo delivery.
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Polymersomes – endosomal escape
Several strategies can be employed to induce endosomal escape or, if the 
cargo is pH sensitive, to inhibit endolysosomal acidification. Polymersomes 
are formulated through self-assembly of amphiphilic diblock copolymers. If 
required, these copolymers can be designed to undergo disassembly upon an 
external stimulus so that the polymersomes function as a drug delivery system. 
Examples of release-triggering stimuli are redox conditions,22–24 light,25 and 
pH.26,27 Especially the latter can be a strategy to release polymersomal cargo 
into the cytosol. This because polymersomes get internalized via endocytosis 
and once inside vesicles of the endolysosomal system, the vesicular pH will 
lower, resulting in polymersomal disintegration and rupture and the release 
of cargo.28 Depending on its ability to cross the membrane, the cargo will end 
up in the cytoplasm. Yang et al. demonstrated selective targeting to human 
lung cancer and endosomal escape of fluorescent cargo in vivo using cell 
penetrating peptide-functionalized polymersomes.29 Chemical compounds 
such as chloroquine and nordihydroguaiaretic acid (NDGA), which cause the 
release of endosomal content into the cytoplasm, can be used to check whether 
intracellular activity will be increased upon successful endosomal escape.30 
Polymersomes – intracellular antioxidant nanoreactors prevent 
exogenous H2O2-induced cell death 
After having established that TAT-polymersomes and their content reside in 
lysosomes, the next step was to investigate whether polymersomes can act as 
nanoreactors in healthy and diseased cells (chapter 3). Thus far, most research 
on polymersomes as drug delivery systems focuses on cancer therapy.31 Based 
on the promising results in vitro and in vivo, steps are undertaken to explore the 
potential of polymersomes beyond oncology.28,32 
In this thesis, the disease model of interest is human complex I deficiency. 
Complex I or NADH:ubiquinone oxidoreductase is the first enzyme complex of 
the mitochondrial oxidative phosphorylation (OXPHOS) system. It reoxidizes 
NADH to NAD+ and transfers the released electrons through a chain of redox 
centers to the ubiquinone binding site where ubiquinone is reduced to 
ubiquinol. This intramolecular electron transfer is energetically coupled to the 
translocation of four protons across the inner mitochondrial membrane, thus 
contributing to the build-up of the electrochemical proton gradient that is 
used by ATP synthase or complex V of the OXPHOS system to convert ADP + Pi 
into ATP. 
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Three major forms of complex I deficiency exist: myopathy, mitochondrial 
encephalomyopathy and fatal infantile multisystem disorder (for details, see 
https://www.umdf.org/types/). Complex I deficiency is the most frequently 
occurring OXPHOS system defect in childhood. In most cases, the deficiency 
is inherited with mutations in both the nuclear and, less frequent, the 
mitochondrial DNA. Despite many efforts, no cure is currently available.33 
Studies on the cell biological consequences of human complex I deficiency, 
using primary skin fibroblasts from complex I-deficient patients and complex 
I-deficient mouse and fly models, increasingly provide evidence that oxidative 
stress is a major contributor to the pathogenesis of this devastating disease. 
A detailed summary of the experimental data obtained with primary skin 
fibroblasts of the patient used in this study is provided in the last section of 
this chapter. Mitochondria are an important source of intracellular reactive 
oxygen species (ROS), starting with the production of superoxide at OXPHOS 
complexes I (CI) and III (CIII), located at the inner mitochondrial membrane, 
which is dismutated by mitochondrial matrix and cytosolic superoxide 
dismutase (SOD) into H2O2 .
34 H2O2 is subsequently oxidized into water by 
cytosolic and mitochondrial peroxidases and peroxisomal catalase. When the 
native antioxidant capacity is overwhelmed by ROS,35 a condition of oxidative 
stress occurs. Oxidative stress is implicated not only in the pathogenesis of 
complex I deficiency but also in that of many other disorders such as Alzheimer’s, 
Parkinson’s and Huntington’s, depression and anxiety disorders, atherogenesis 
and heart failure and cancer.36–38 Relevant to this thesis is that primary skin 
fibroblasts from patients with isolated complex I-deficiency show increased 
ROS levels, thus providing an excellent human cell system for the evaluation 
of antioxidant-loaded polymersomes or antioxidant nanoreactors (AONs).39,40
In chapter 3, the functioning of catalase-loaded, semi-permeable polymer-
somes (comprising biodegradable copolymers) as antioxidant nanoreactors 
(AONs) is characterized by providing effective shielding of complex I- deficient 
patient-derived primary fibroblasts displaying increased ROS levels. 
As confocal laser scanning microscopy (CLSM) clearly showed the predominant 
presence of TAT-polymersomes within the endolysosomal system, it is 
important to consider the function of such AONs at pH values ranging down to 
~ 5. Therefore, we compared two isoforms of catalase, from bovine (CBOV) and 
bacterial (CBAC) sources, with the latter being more stable at lower pH values. 
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In order to examine their ROS-shielding ability, HEK293T cells were pulse-
treated with polymersomes in a dose-dependent manner for 1 h followed by 
washing and a 24 h challenge with or without exogenous H2O2. Crystal violet 
analysis confirmed that under these conditions both AONs can fully protect 
against H2O2 cytotoxicity with the CBAC-AONs being 10-15 times more potent 
than CBOV-AONs. At first sight, this suggested that both catalase isoforms 
remain active during 24 h treatment with H2O2 due to their presence inside 
polymersomes which protect them against lysosomal degradation. However, 
when C5120 healthy control fibroblasts and complex I-deficient S7-5175 patient 
fibroblasts were pulse-treated with CBOV-AONs for 1 h and then challenged with 
H2O2 followed by a second H2O2 challenge 4 h after the first challenge, cells 
appeared not protected anymore. This demonstrates that CBOV-AONs are able 
to sufficiently neutralize a first H2O2 challenge but not a second one 4 h later. 
When cells were pulse-treated with CBOV-AONs for 1 h, followed by a chase of 
4 h, and then a H2O2 challenge, no protection was observed either. Together, 
these data show that CBOV-AONs rapidly lose their ability to detoxify H2O2. In 
sharp contrast, when cells were pulse-treated with CBAC-AONs for 1 h, followed 
by a chase of 4 h, and then a H2O2 challenge, the level of protection remained 
unimpaired. These data indicate that CBAC remains active, whereas CBOV rapidly 
(within 4 h) loses its activity. It is tempting to speculate that this activity loss 
of CBOV but not CCAT reflects the increased acidification of the vesicles in which 
the polymersomes end up when they are internalized. Experiments to test this 
hypothesis by preventing endolysosomal acidification through inhibition of 
the activity of the V(acuolar)-ATPase with bafilomycin A1 failed because the 
latter compound alone prevented H2O2-induced cell death (Figure 1). Finally, 
we did not perform experiments in which we increased the chase time after 
the 1 h pulse with CBAC-AONs beyond 4 h to test whether CBAC remained active 
for prolonged periods of time. In conclusion, it is important that the cargo of 
polymersomes is acid resistant unless strategies are employed to keep the 
polymersomes as nanoreactors in vesicles of the endolysosomal system that 
do not acidify or to promote their endolysosomal escape towards the cytosol.  
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Figure 1. Effect of Bafilomycin A1 (Baf A1) on the functional analysis of AON + CBov using primary 
skin fibroblasts from a healthy individual (C5120). Cells were pulse treated for 1 h with PBS (0) or 
0.4 mg/mL AON + CBov, followed by a challenge with or without 0.1 mM H2O2 for 24 h. Cells were 
pulse treated for 1 h with PBS (0) or 0.4 mg/mL AON + CBov, followed by a chase period of 4 h and 
a subsequent challenged with or without 0.1 mM H2O2 for 20 h and cells were pulse treated for 
1 h with PBS (0) or 0.4 mg/mL AON + CBov, followed by a challenge with or without 0.1 mM H2O2 
for 24 h, while continuously incubated with 100 nM Baf A1. Cell viability was assessed by crystal 
violet staining. The data are presented as mean ± SD of duplo measurements performed in one 
experiment. 
 
Polymersomes – intracellular antioxidant nanoreactors neutralize 
exogenous H2O2 
We used the chloromethyl (CM)-variant of the ROS-reactive fluorescent probe 
2’,7’-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) to demonstrate the 
H2O2 detoxifying effect of the AONs. This ROS-reactive probe is widely used as a 
“hydrogen peroxide (H2O2)-specific probe”. However, the range of ROS detected by 
this probe is much broader. H2DCFDA freely passes the plasma membrane. In the 
cytosol it is hydrolysed to the DCFH carboxylate anion form,41,42 the oxidation of 
which results in the formation of the fluorescent product (DCF). Upon excitation at 
495 nm DCF emits fluorescence at 520 nm.41 Mechanistically, the oxidation of H2DCF 
to DCF is a two-step reaction. First, a DCF radical is formed, which is then oxidized 
by reacting with molecular oxygen to form fluorescent DCF.43 DCF formation is also 
induced by other radical species including hydroxyl, carbonate and thiyl radicals, 
as well as nitrogen dioxide.41,44,45 
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Importantly, H2O2 does not directly react with H2DCF but requires the presence 
of peroxidases (e.g. horseradish peroxidase). Moreover, the superoxide radical 
generated in the second step during H2DCF oxidation can be enzymatically 
dismutated by superoxide dismutases (SODs) to form H2O2 and thereby 
stimulate auto-amplification of the DCF signal.46 Relative to H2DCFDA, oxidation 
of its chloromethyl derivative, CM-H2DCFDA, yields a product, CM-DCF, that is 
trapped within the cell thus allowing longer duration measurements.47
Although CM-H2DCFDA staining is relatively easy to perform and applicable to 
most cell types, its oxidation is not specific for a particular type of ROS and 
therefore can best be used to assess cellular oxidant levels. The fluorescent 
protein-based sensor “HyPer” was developed as a specific H2O2-biosensor.
48 
Structurally, HyPer consists of a circularly permuted cpYFP inserted into the 
H2O2-sensitive regulatory domain of the E. coli transcription regulator OxyR.
49,50 
Upon an increase in ambient H2O2 level the reduced form of HyPer becomes 
oxidized and an S=S bridge is formed between Cys199 and Cys208 (Figure 2a). 
This conformational change in the HyPer protein is sensed by cpYFP, thereby 
inducing a change in the HyPer spectral properties. The reduced form of HyPer 
can specifically be detected using fluorescence microscopy by measuring 
its 520 nm emission intensity following 420 nm excitation (Figure 2a). The 
oxidized form of HyPer is specifically detected by measuring its 520 nm emission 
intensity following 480 nm excitation. The ratio between the emission signal 
at 480 nm excitation and 420 nm excitation (i.e. the 480/420 nm ratio signal) 
can then be used as a measure of the ambient H2O2 level. Although HyPer is 
not responsive to various other tested oxidants like superoxide, oxidized 
glutathione, nitric oxide, and peroxinitrite,48 it does display pH-sensitivity.51,52 
This necessitates the use of an H2O2-insensitive HyPer variant to rule out that 
pH-changes are erroneously interpreted as alterations in H2O2 level. To this end, 
the critical HyPer cysteine residue (C199) is mutated into a serine (C199S) to 
obtain the biosensor “SypHer” (Figure 2b). SypHer is H2O2-insensitive and can 
be used as HyPer-control and pH sensor.51–53 Since HyPer and SypHer require 
transfection, making its usage more laborious, we use CM-H2DCFDA in the ROS 
measurements described in this thesis.
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Figure 2. Structure and spectral properties of HyPer and SypHer. (A) Schematic structure 
and principle of ambient H2O2 level detection by the protein-based sensor HyPer (blue). The 
reduced and oxidized forms of HyPer display different spectral properties, allowing their 
independent detection (see main text for details). Grx indicates glutaredoxin. (B) SypHer is a 
mutated form of HyPer that is pH-sensitive but H2O2-insensitive. SypHer is created from HyPer 
by mutating a cysteine residue (Cys199) involved in H2O2-induced S=S bridge formation. The 
spectral properties of SypHer are similar to that of Hyper. Figure adapted from reference 54. 
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The work presented in chapter 3 shows that exogenous H2O2 significantly 
increased intracellular ROS in both non-treated HEK293T cells and HEK293T 
cells treated with empty TAT-polymersomes. This effect was completely 
prevented by CBAC-AONs and partly by CBOV-AONs. Evaluation of the CM-DCF 
signal in C5120 control fibroblasts and S7-5175 patient fibroblasts showed 
that CBAC-AONs virtually completely blunted the effect of exogenous H2O2 in 
these cells as well. Both in non-treated fibroblasts and fibroblasts treated with 
empty TAT-polymersomes, the H2O2-induced increase in CM-DCF fluorescence 
was significantly higher in the S7-5175 cells, suggesting a reduced capacity to 
detoxify ROS. Critically, this difference was no longer observed following CBAC-
AON treatment, demonstrating a clear improvement of the capacity of these 
patient cells to detoxify ROS.
Future perspectives – polymersomes crossing the blood-brain barrier
In many cases, human CI deficiency is associated with progressive neuronal 
deterioration in specific areas of the central nervous system. Animal studies 
using complex I-deficient mice and flies have implicated increases in neuronal 
ROS in the process of neurodegeneration.54,55 The experiments described in this 
thesis show that catalase encapsulating polymersomes can efficiently prevent 
exogenous ROS-induced increases in intracellular ROS in primary fibroblasts 
from complex I-deficient patients. A relevant next step is to use these 
polymersomes for the delivery of mitochondrial therapeutics across the blood-
brain barrier (BBB). To this end, specific antibodies can be used such as anti-
human insulin receptor antibody 83-14. Polymersomes conjugated with this 
antibody were shown to specifically bind to human brain capillary endothelial 
hCMEC/D3 cells and to be taken up by these cells.56 Another target for both 
the BBB and glioma cells is low density lipoprotein receptor-related protein 1 
(LRP1). This protein has been reported to be highly expressed on the BBB and 
glioma cells.57,58 Conjugation of polymersomes with angiopep-2, which binds 
with affinity to LRP1, has been demonstrated to successfully promote uptake in 
human glioblastoma U87MG cells, rat C6 cells and in vivo.59–61 Finally, previous 
work successfully used the G23 peptide to target polymersomes to the BBB and 
to promote their transport across this barrier.62,63 In this thesis, we explored the 
ability of G23 to transport elastin-like polypeptide (ELP) nanoparticles across a 
human in vitro BBB model.
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Elastin-like polypeptide nanoparticles – composition, preparation and 
(bio)physical properties
Elastin-like polypeptides (ELPs) are inspired from human tropoelastin, a 
precursor of elastin, a component of the extracellular matrix.64,65 ELPs consist 
of pentameric repeats of GXGVP, where the guest residue (X) can be any 
naturally occurring amino acid.66,67 A characteristic feature of these peptides 
is their ability to reversibly and temperature-dependently self-organize into 
coacervates. The ELP monomers used in the present study (chapters 4-6) are 
diblock copolymers consisting of a hydrophilic block [A3G2-60] (60 VPGxG 
pentarepeats with alanine and glycine as the guest residue in a 3:2 ratio) and a 
hydrophobic block [I-60] (60 VPGxG pentarepeats with isoleucine as the guest 
residue). We recently reported that these ELP monomers readily self-assemble 
into monodisperse nanoparticles with a diameter of ~60 nm upon shifting 
the ambient temperature from 4°C to 37°C (van Oppen et al., manuscript 
submitted). ELP monomers are highly versatile in that the guest residues and 
terminal extensions can be chosen according to the needs. This makes ELP-
based nanoparticles highly suitable tools for biomedical applications. Since 
ELP nanoparticles consist of natural polypeptide chains, their biocompatibility 
and biodegradability is ensured as their metabolic byproduct are only small 
peptides and amino acids.68
Points of concern regarding ELP nanoparticles, as for protein and peptide 
formulations in general, are their stability in vivo,64 their low bioavailability due 
to serum enzyme degradation and their poor tissue penetration.69 Since ELP 
nanoparticles are held together by non-covalent interactions, their stability 
in serum or in the presence of serum proteins is crucial for their application as 
drug delivery system. ELPs in solution are susceptible to protein degradation 
by trypsin, elastase and collagenase, especially ELPs that contain lysine.70 Sha 
et al. performed a proteolytic biodegradation study on a small library of ELPs, 
concluding that ELPs are prone to extra- and intracellular proteolytic breakdown.71 
The use of polypeptides instead of synthetic polymers has several advantages, 
such as protein engineering without chemical modifications, high tunability at 
the genetic level and a high level of biodegradation. Introduction of the polymer 
PEG is a widely established approach to prolong the half-life of nanoparticles. 
Because of an increase in the hydrodynamic volume of the particles, glomerular 
filtration will be retarded. As already discussed for polymersomes, PEGylation 
has certain drawbacks. 
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A biological alternative to PEGylation has been presented in the form of a 
polypeptide chain consisting of three small residues: proline (P), alanine (A) 
and serine (S). PAS sequences are biocompatible, hydrophilic and uncharged 
and their biophysical properties have been reported to be very similar to PEG.72 
Since PAS sequences are non-immunogenic and stable in blood plasma,73 they 
have the potential to form a good substitute to PEG in increasing the stability 
of nanoparticles. Another alternative in the field of recombinant polypeptides 
is the 864 amino acid long sequence XTEN.74
ELP nanoparticles can be stabilized through formation of disulfide bonds during 
the assembly process.75 Another crosslinking strategy involves the use of strain-
promoted azide-alkyne cycloaddition (SPAAC).64,76 However, careful evaluation 
of cytotoxicity is crucial, specifically in the latter case where chemicals are used 
for crosslinking.
Elastin-like polypeptide nanoparticles – crossing the blood-brain 
barrier
Since ELP nanoparticles are a versatile peptide-based drug delivery system, 
this feature makes them suited to include peptide-based ligands which can 
interact with receptors specifically expressed at the BBB. Brain endothelial cells 
express a variety of specific receptor-mediated transport systems including 
the transferrin receptor, insulin receptor and LRP1 receptor for transcytosis.77 
Examples of brain targeting peptides which are under clinical development are 
the above-mentioned Angiopep-2, which acts on LPR1, and glutathione (GSH), 
an endogenous peptide which interacts with many in- and efflux transporters 
of the central nervous system.78 
In chapter 6 of this thesis, we evaluated G23, a dodecamer peptide which targets 
ganglioside GM1. The design of in vitro BBB models is a huge research area, as 
access to human primary endothelial cells is limited and immortalized human 
brain microvascular endothelial cells show poor barrier formation.79 The in vitro 
BBB model used in this thesis has been developed, characterized and validated 
as a functional human BBB model. The model consists of primary human 
brain microvascular endothelial cells which were conditionally immortalized 
(HBMEC/ciβ cells).80 Important indicators of the tightness of the HBMEC/ciβ 
monolayers on collagen-coated filter inserts include permeability coefficients 
for paracellular tracers and transendothelial resistance (TEER) values.81 
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The permeability coefficients of rhodamine-dextran and sodium-fluorescein 
were within the range of previously established monoculture BBB models at 
similar passage number.80,82 TEER values did not exceed 200 Ω per cm2 and are 
in line with findings previously reported for this cell line.80
The main objective of the study presented in this chapter was to evaluate whether 
ELP nanoparticles containing G23-ELP monomers (ELPG23 nanoparticles) could 
promote transcytosis across the HBMEC/ciβ monolayer. The maximum amount 
of G23-ELP monomers was 25 %, as higher values led to aggregation due to the 
hydrophobic nature of G23. Nanoparticle size is essential for BBB transport,83 
and, in this respect, an average size of 65 nm offered a good probability for 
ELPG23 nanoparticles to cross the HBMEC/ciβ monolayer. At time points t = 4 h 
and t = 24 h the difference in transcytosis between ELPG23 nanoparticles and 
ELP nanoparticles was statistically significant. This result is in agreement with 
previous studies using hCMEC/D3 cells showing an increase in G23-mediated 
transcytosis after 4 h and 18 h.62,63 Of note, these latter studies used another 
human brain endothelial cell line, different filter inserts and polymersomes as 
carrier for transport across the BBB. In the work of Georgieva et al., reducing 
the G23 peptide surface density from 10 to 5 mol % into polymersomes 
resulted in a two-fold reduction in transcytosis.62 Future studies should give 
more insight in the behaviour of ELPG23 nanoparticles in relation to transcytosis, 
such as reducing the amount of G23-ELP monomers in ELPG23 nanoparticles, 
or conjugating a second fluorescent label to G23-ELP monomers to gain 
more insight in the stability of the nanoparticles. Moreover, the efficiency of 
G23 in transcytosis should be compared with that of angiopep-2. Angiopep-2 
conjugated to three molecules of the anti-cancer agent paclitaxel, known as 
ANG1005, completed the phase II clinical phase in September 2017 (www.
clinicaltrials.gov).84 In general, specific ligands such as Angiopep-2 targeting 
for receptor LRP-1 and G23 targeting for ganglioside GM1 can enhance the 
transport of drugs across the BBB. However, these ligands are not efficient 
enough in tissue penetration, for example to enhance solid tumor penetration. 
Elastin-like polypeptide nanoparticles – crossing the cellular plasma 
membrane
Important obstacles in drug delivery are protective, physiological barriers such 
as tumor tissue, BBB and the cellular plasma membrane. As a means to facilitate 
bypassing of biological barriers or enhance cellular uptake, cell-penetrating 
peptides (CPPs) are widely employed.69 
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CPPs are mostly cationic peptides of 8 to 30 amino acids in length that induce 
the cellular uptake of (macro-) molecules that otherwise only poorly enter cells. 
Arginine-rich CPPs are a prominent class of CPPs, especially oligoarginines 
between 6 and 12 arginine residues show optimal CPP activity.85 Fusion proteins of 
the CPP octa-arginine and ELP monomers are readily generated through genetic 
engineering. In chapter 4 we swapped the orientation of the hydrophilic and 
hydrophobic blocks of ELP monomers to investigate whether C-terminal (cR8-
ELP) or N-terminal (nR8-ELP) conjugation of octa-arginine differentially affected 
the uptake of ELP nanoparticles by healthy human skin fibroblasts.  Confocal 
laser scanning microscopy showed only little cell-associated fluorescence for 
ELP nanoparticles not containing any CPP. At 5 % nR8-ELP, all fluorescence was 
localized inside the cells. Uptake of nR8-ELP nanoparticles was slightly higher 
which may be attributed to the negatively charged C-terminus counteracting 
the positive charge of octa-arginine. Investigation of the underlying uptake 
mechanism suggested macropinocytosis as the major endocytic pathway, as 
has been reported before for octa-arginine-mediated uptake.86,87 After two 
hours of incubation, internalized particles showed partial overlap with acidic 
vesicular structures as evident from colocalization with LysoTracker Green. 
CPP families vary in their way of binding to the plasma membrane and their 
translocation mechanism. This means that a particular CPP may bind to a type 
of cell which displays a preferred membrane composition.69 For example, Lim 
et al. successfully designed several CPP derivatives with specificity to cancer 
cells.88
Elastin-like polypeptide nanoparticles – penetration in spheroids
Cancer tissues often suffer from poor drug penetration because of a dense 
connective stroma that hinders the entry of molecules.89 After having 
established CPP-mediated uptake of nR8-ELP nanoparticles in 2D tissue 
cultures, we next investigated the impact of CPP density on the penetration 
of 3D cancer cell spheroids by ELP nanoparticles (chapter 4). In particular, we 
were interested to learn whether a higher CPP density, which in 2D was shown 
to yield more efficient uptake, would compromise penetration in 3D due to 
sequestration of particles in the outer cell layer. To describe the penetration of 
high-affinity binders into 3D tissues, the concept of the binding site barrier was 
used. We addressed the potential presence of a binding site barrier by varying 
the density of the CPP as well as the concentration of the ELP nanoparticles. 
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Presence of the CPP promoted the penetration of nanoparticles into 3D tumor 
spheroids, the depth of which positively correlated with the density of the CPP 
on the surface of the nanoparticles. The observation that ELP nanoparticles 
not carrying any R8 did not show any penetration suggests that the binding 
site barrier is a consequence of uptake rather than saturation of the binding 
sites on the glycosaminoglycans. We showed that at higher concentrations the 
endocytic capacity may become increasingly exhausted.
To increase the specificity of CPPs, so called activatable CPPs (ACPPs) were 
developed by the research group of the late Nobel Prize-winning chemist 
Dr. Roger Tsien. They developed a construct composed of a polycationic CPP 
connected via a cleavable linker to a neutralizing polyanion. This polyanion 
shields the construct from adsorption and uptake into cells, until the linker is 
proteolyzed by specific proteinases such as matrix metalloproteinases (MMPs) 
MMP-2 and MMP-9, upregulated in most types of solid tumors.90,91
An alternative strategy is to combine CPPs with targeting peptides for a 
synergetic effect during the specific binding and penetrating process. Targeting 
peptide Angiopep-2 acts on LRP1, expressed on brain endothelial cells and is 
overexpressed in human glioma cells. Li et al. successfully combined Angiopep-2 
with the CPP TAT to improve cell permeability in solid tumors.84 Other examples 
are conjugation of AHNP, which specifically binds to oncoprotein ErbB2, to a 
variant of TAT and conjugation of targeting peptides DV1 and DV3, acting on 
chemokine receptor 4, to TAT.92,93
Elastin-like polypeptide nanoparticles – potential therapeutic efficacy
Although CPP R8-mediated uptake of ELP nanoparticles is efficient, strategies 
can be explored to release vesicular entrapped ELP nanoparticles into the 
cytosol. In combination with CPP-mediated uptake, endo- or lysosomolytic 
agents such as sucrose, calcium and chloroquine can be used to destabilize 
the endosomal membrane. These agents induce osmotic swelling and thus 
promoting the disruption of vesicular compartments.94 Unfortunately, it is not 
possible to use this strategy in vivo.
Similarly to chloroquine, the amino acid histidine can act as a weak base inducing 
the so-called proton sponge effect inside endosomal vesicles. By protonation at 
pH = 6.0, histidine becomes positively charged and attracts anions resulting in an 
increase in osmolarity. 
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The vesicles swell and their content is released into the cytosol.95 Elongation 
of CPP TAT with 10 histidine residues yielded a 7000-fold improvement in 
gene expression following addition of the modified TAT/DNA complex.96 The 
contribution of the histidines was demonstrated by means of the proton-
pump inhibitor bafilomycin A. Similarly, the histidine-rich peptide LAH4-L1 
showed an endosomal destabilization effect in complex formation with cationic 
poly(amidoamine) dendrimers and components of non-viral vectors.97 
Callahan et al. designed histidine-rich hydrophobic ELP blocks to create pH-
responsive ELP nanoparticles.98 However, rather than endosomal escape, the goal 
of this latter approach was the disassembly of the nanoparticles at the slightly 
lower extracellular pH in tumors (6.2 – 6.9).
Using ELP nanoparticles, drugs can be conjugated with a pH-sensitive bond 
to ELP monomers. After endosomal uptake, the drug is then released as was 
successfully demonstrated by MacKay et al.99 This work showed that the anti-
cancer agent doxorubicin coupled to ELP nanoparticles with a short pH-labile 
linker not only displayed a four-fold higher maximum tolerated dose than the 
free drug but in addition caused nearly complete tumor regression after a single 
dose in vivo. Similarly, Moktan et al. described an acid-sensitive ELP doxorubicin 
conjugate which displayed efficient targeting and complete tumor growth 
inhibition by making use of hyperthermia-induced tumor accumulation of ELP 
nanoparticles.100 An alternative and successful approach can be the decoration 
of ELP nanoparticles with a small protein possessing a binding domain for small 
molecules, such as FK-506 binding protein 12 (FKBP12) which is the obligatory 
binding partner of rapamycin.101 Highlighting the versatility of the ELP toolbox, 
an RGD ligand for integrin binding was included for the formation of bifunctional 
ELP nanoparticles. This complex showed superior target cell binding and tumor 
growth repression in vivo. 
In chapter 5 we demonstrate that ELP-based nanoparticles functionalized 
with the cell penetrating peptide R8 at the hydrophilic site and the ROS-redox 
modulator KH176 at the hydrophobic site, referred to as ELPKH176 nanoparticles, 
can prevent the GSH depletion-induced abolishment of calcein-AM staining in 
S7-5175 cells.
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BSO depletes cells from GSH by irreversible inhibition of γ-glutamyl cysteine 
synthase, which is the rate limiting enzyme in GSH synthesis. Many studies have 
shown that BSO induces a progressive increase in cell death and that cell death 
time and BSO concentration are inversely related. Using primary skin fibroblasts 
from a healthy subject (C-5120 fibroblasts), we previously showed that 72h 
treatment with BSO at concentrations of 1 µM and 12.5 µM caused an oxidative 
shift of both the cytosolic and mitochondrial thiol/disulfide redox status.102 
This effect was paralleled by a decrease in HEt oxidation, increases in H2DCF 
oxidation and NAD(P)H autofluorescence and mitochondrial shrinking.39,40,102 
The latter study showed that BOLA1 overexpression partially reversed the 
effect of BSO on the mitochondrial thiol/disulfide redox status and completely 
abolished the BSO-induced change in mitochondrial morphology without 
having any effect on the BSO-induced decrease in intracellular GSH levels. 
It was suggested that BOLA1 exerted its effect by increasing the activity of 
GLRX5, a mitochondrial enzyme involved in the formation of iron-sulfur clusters. 
Analysis of the effect of BSO on cell death of S7-5175 patient fibroblasts, as 
determined by crystal violet staining, revealed that BSO concentrations at 
or below 10 µM did not significantly affect crystal violet staining up to 48h 
but dose-dependently decreased the crystal violet signal by 13% and 23% at 
72h and 96h, respectively (data not shown). However, at 30 µM and beyond 
(100 µM), BSO maximally decreased crystal violet staining by 24%, 59% and 
76% at 48h, 72h and 96h, respectively. These data suggest that BSO exerts a 
dual effect in these patient fibroblasts. Up to 10 µM, it completely depletes 
GSH and abolishes calcein-AM staining with only a minor effect on cell death, 
while at 30 µM and beyond it causes massive cell death. Co-treatment for 96h 
with increasing concentrations of KH176 showed a maximal restoration by 
50% of the effect of 30 µM BSO on crystal violet staining (data not shown). 
This effect was already reached at 0.3 µM KH176. Previous studies showed 
similar results for fibroblasts from mitochondrial disease patients with either 
polymerase γ deficiency or Kearns-Sayre syndrome.103 In the latter case, the 
effect of 88h treatment with 50 µM BSO was found to be reversed by EPI-743 
with an EC50 of ~20 nM. Experiments to test the effect of ELPKH176 nanoparticles 
on BSO-induced cell death would be a relevant next step in the evaluation of 
therapeutic efficacy.
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Detailed summary of the experimental data obtained with primary 
fibroblasts of the S7-5175 patient 
In the present study we evaluated the usefulness of polymersomal nanoreactors 
containing catalase and ELP-based nanoparticles for cellular delivery of KH176 
in primary skin fibroblasts from a complex I-deficient patient with a V122M 
mutation in the NDUFS7 gene (S7-5175 cells). There is ample evidence that 
disturbances in ROS detoxification and consequent ROS damage and/or changes 
in ROS- and/or redox signaling play a role in the pathogenesis of mitochondrial 
complex I deficiency. The complex I-deficient patient fibroblasts used in the 
present study were from a patient with Leigh syndrome harboring a disease-
causing mutation in the nuclear NDUFS7 gene encoding the NDUFS7 core 
subunit of NADH:ubiquinone oxidoreductase or complex I of the mitochondrial 
oxidative phosphorylation (OXPHOS) system.104 Thorough investigation 
of these fibroblasts, referred to as S7-5175 fibroblasts, revealed that the 
consequent V122M amino acid substitution caused a proportional decrease 
in complex I expression and activity associated with increased oxidation rates 
of CM-H2DCF and HEt.
40,105,106 However, no significant changes in cellular GSH, 
GSSG, GSH+GSSG and GSH/GSSG ratio and/or cytosolic or mitochondrial thiol 
redox status were observed in S7-5175 fibroblasts and fibroblasts from 9 other 
complex I-deficient patients as compared to C5120 healthy fibroblasts and 
fibroblasts of 9 other healthy subjects.107 
On the other hand, analysis of whole blood from Leigh syndrome patients, 
revealed a significant decrease in total glutathione by ~18% and a borderline 
significant decrease in GSH/GSSG ratio,108 whereas Pastore and co-workers 
reported marked decreases in total glutathione (58%) and GSH/GSSG ratio in 
lymphocytes from another panel of Leigh syndrome patients.109 Finally, a 60% 
decrease in reduced glutathione was reported in skeletal muscle from a patient 
with isolated complex I deficiency.110 Taken together, these data suggest that 
cellular glutathione levels and GSH/GSSG ratios might be decreased in clinically 
relevant tissues including skeletal muscle, heart and brain, thus warranting 
the use of complex I-deficient patient fibroblasts with artificially reduced 
glutathione levels to study possible beneficial effects of ELPKH176 nanoparticles 
on the consequences of reduced glutathione levels.
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Conclusions
To minimize errors in the biological responses towards drug delivery systems 
and increase the chance of clinical success, more detailed examination 
of nanoparticles in their biological environment should be performed as 
summarized in  Figure 3.
When nanoparticles are in contact with biological media such as blood or 
serum in media, biomolecules (mainly proteins) are known to adsorb on the 
nanoparticles and form a so-called biomolecular corona. This formation could 
influence various properties of nanoparticles, such as cellular interaction, 
cellular targeting, toxicity and in vivo clearance. In the development of 
nanotechnology for biomedical applications, understanding this interaction 
between nanoparticles and a complex physiological environment is crucial for 
effective drug delivery strategies.111 Importantly, each protein source could lead 
to a different composition of the biomolecular corona, often influenced by the 
stage and type of disease, so the best option would be to choose the protein 
source which could be directly connected to the in vivo model.4 A strategy to 
visualize the protein corona to optimize the design of nanostructures has been 
demonstrated by Feiner-Gracia et al. This was done by in vitro measurements 
using Förster Resonance Energy Transfer (FRET) to prove close interaction 
between blood serum proteins and different types of nanostructure.112 
Alternatively, advanced microscopy techniques could be used to visualize 
the protein corona.113 An array of accurate techniques for protein analysis and 
corona activity is reviewed by Wang et al., 2018.114 Apart from the identification 
of the proteins forming the biomolecular corona and vice versa the parameters 
of nanoparticles such as size and charge impacting the corona, the interaction 
between proteins and biochemical cascades should be assessed.115
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Figure 3. Schematic representation of features contributing to artifacts in nanotoxicology. 
Figure taken from reference 116.116
In conclusion, in this thesis an array of cell biological assays has been presented 
to evaluate two drug delivery systems in their ability to cross biological barriers, 
facilitate cellular uptake, and their therapeutic potential in human complex 
I-deficient skin fibroblasts. Based upon the results obtained, more insight and 
understanding in the biological mechanism behind the precise mode of action 
of nanoparticles in mitochondrial disease could be gained as a primary step in 
developing nanoparticle drug delivery systems as future therapy for patients 
suffering from mitochondrial disease.
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Summary
Nanomedicine involves the application of nanotechnology for prevention, 
diagnosis and treatment of disease. Especially the field of drug delivery has high 
potential to advance current treatment options, as specific targeting of drugs 
could improve unfavorable tissue distribution of (conventional) drug molecules 
and increase their therapeutic efficacy by achieving higher accumulation 
levels in the target tissue. However, biological challenges, such as the need to 
cross endothelial barriers like the blood-brain barrier (BBB) and (intra)cellular 
barriers, limit successful clinical application so far. To address these challenges, 
nano-sized materials with unique physicochemical properties were formulated 
into structures such as nanoparticulate drug carriers able to cross endothelial 
and cellular barriers. 
In chapter 1, the background and challenges of two types of nanoparticles, 
being polymersome-based nanoreactors (polymersomes) and elastin-like 
polypeptide (ELP)-based nanoparticles, are generally described in terms of BBB 
passage, spheroid penetration, cellular uptake and intracellular localization. 
The potential of these nanoparticles could be particularly beneficial for a 
variety of pathologies related to mitochondrial defects. Patients with defects 
in complex I (NADH-ubiquinone oxidoreductase), the first and largest enzyme 
of the mitochondrial oxidative phosphorylation system, present a wide 
variety of signs and symptoms. In this thesis, we use primary skin fibroblasts 
from a complex I-deficient patient with Leigh syndrome harboring a V122M 
mutation in the nuclear NDUFS7 gene to evaluate the therapeutic potential of 
polymersomes and ELP-based nanoparticles.
In chapter 2, biodegradable, semi-permeable polymersomes were physically 
characterized and their cellular uptake properties were evaluated in HEK293T 
cells. Poly(ethylene glycol)-block-poly(caprolactone-gradient-trimethylene 
carbonate) (PEG-PCLgTMC) polymersomal nanoreactors were fabricated 
using the biocompatible direct hydration methodology. Subsequent physical 
characterization demonstrated the effectiveness of the semi-permeable 
membrane of these nanoreactors in protecting encapsulated enzyme while 
permitting the diffusion of its substrate(s) and product(s). A critical step in the 
development of polymersomes as intracellular nanoreactors is their ability to 
cross the plasma membrane. 
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Because PEGylated polymersomes are hardly taken up by eukaryotic cells, 
their surface was coated with cell penetrating peptides (CPPs) to promote 
cell internalization. The data presented show that the presence of CPP TAT, 
derived from human immunodeficiency virus (HIV), is obligatory for the 
uptake of the polymersomes in HEK293T cells and that this CPP directed their 
integration towards acidic compartments of the endolysosomal system. This 
is an important first step in the development of autonomous nanoreactors as 
promising therapy for patients suffering from mitochondrial disease.
In chapter 3 the ability of TAT-mediated catalase-loaded polymersomes, to 
function as intracellular antioxidant nanoreactors (AONs), was evaluated 
in primary skin fibroblasts from a complex I-deficient patient with Leigh 
syndrome harboring a V122M mutation in the nuclear NDUFS7 gene. Complex 
I is considered an important site of reactive oxygen species (ROS) production, 
especially under pathological conditions. The capacity of AONs to function 
as synthetic organelles, providing effective shielding in patient-derived 
primary cells from ROS in vitro, was demonstrated by a full protection against 
exogenous H2O2-induced cell death. This effect was paralleled by a complete 
prevention of the exogenous H2O2-induced increase in intracellular ROS. These 
results demonstrate for the first time, that patient-derived human complex 
I-deficient primary fibroblasts can be effectively protected against exogenous 
H2O2 toxicity by the action of internalized AONs. 
In chapter 4, protein-based nanoparticles were explored as drug delivery 
system as they can be degraded into non-toxic natural building blocks. Elastin-
like polypeptides (ELPs) are derived from human tropoelastin and demonstrate 
reversible, temperature-dependent self-organization into coacervates. 
Drugs can be encapsulated either into the hydrophilic lumen or into the 
hydrophobic coacervate core, or via covalent coupling. In addition, ELPs 
can be extended by functional peptides to achieve cell-specific targeting or 
enhance cellular uptake. In this chapter, special attention is paid to the density 
and configuration of the cell penetrating peptide octa-arginine (CPP R8) 
incorporated in ELP nanoparticles. Cellular uptake and penetration into three 
dimensional (3D) tumor spheroids are two functional characteristics which 
are highly relevant for future in vivo drug delivery applications. Spheroids are 
excellent models for avascular regions of tumor tissue and can be generated 
with a highly reproducible morphology thus enabling a reliable determination 
of particle penetration. On the one hand, CPP R8 mediated the cellular uptake 
185
7
of the nanoparticles, on the other hand, it promoted the penetration of the 
nanoparticles into 3D tumor spheroids. Both activities positively correlated 
with the density of the CPP on the surface of the nanoparticles. It will be highly 
interesting for future applications to which degree the combination of CPP-
conjugated ELPs with ELPs carrying receptor-specific targeting ligands will 
enable a fine-tuning of activities mediating uptake and targeting in 3D tumor 
spheroids.
Chapter 5 evaluates the therapeutic potential of ELP nanoparticles for cellular 
delivery of KH176, a potent intracellular reduction-oxidation-modulating 
compound developed by Khondrion to treat mitochondrial disease. KH176 
was previously demonstrated to effectively prevent the L-buthionine-(S,R)-
sulfoximine (BSO)-induced reduction in viability of patient cells. Here we 
used Leigh syndrome patient fibroblasts harboring a V122M mutation in the 
NDUFS7 gene of complex I to evaluate the usefulness of ELP nanoparticles 
for cellular delivery of KH176. We demonstrate that these nanoparticles, 
when functionalized with CPP R8 at the hydrophilic site and KH176 at the 
hydrophobic site (ELPKH176 nanoparticles), prevent the BSO-induced reduction 
in patient cell viability. Since ELP-based nanoparticles are highly versatile, 
these results stimulate further research towards the incorporation of targeting 
functionalities that endow ELP nanoparticles with e.g. the ability to penetrate 
the BBB.
Mitochondrial dysfunction can dramatically impact on neuronal survival, since 
these cells have large energy demands and limited regenerative capacity. 
However, small-molecule treatment of neurodegenerative diseases is hampered 
by the presence of the BBB. In chapter 6, we evaluated the dodecamer peptide 
called G23 in ELP nanoparticles (ELPG23) with ganglioside GM1 as target to 
induce transcytosis in a human in vitro BBB model. Monolayer tightness was 
established by determining the permeability coefficient of paracellular tracers 
and transendothelial resistance (TEER). The transcytosis capacity of ELPG23 
nanoparticles was significantly enhanced after 4 h incubation onwards relative 
to ELP nanoparticles. This suggests that ELPG23 nanoparticles can be used for 
targeted delivery of KH176 to the brain. 
In chapter 7, the above results regarding polymersomes and elastin-like 
polypeptide nanoparticles are put into perspective along with conclusions 
regarding the biological challenges for nanomedicine. 
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Samenvatting
Nanogeneeskunde betreft het toepassen van nanotechnologie op de preventie, 
diagnose en behandeling van ziektes. Met name de mogelijkheid van gerichte 
medicijnafgifte heeft veel potentie om huidige behandelstrategieën te 
verbeteren. Het gericht afgeven van medicijnen aan ziek weefsel kan ongewenste 
bijwerkingen in gezond weefsel voorkomen en tegelijkertijd de therapeutische 
werkzaamheid van medicijnen in het zieke weefsel vergroten. Echter, om het 
medicijn op de juiste plek te krijgen moet het kunnen doordringen in compacte 
celmassa’s zoals tumoren en andere biologische barrières kunnen passeren. Het 
gaat hierbij om bloed-weefsel barrières, met als meest prominente de bloed-
hersenbarrière. Als deze barrières zijn gepasseerd dan moet, wanneer men de 
extracellulaire concentratie van het medicijn zo laag mogelijk wil houden, de 
buitenste begrenzing van de zieke cel worden gepasseerd. Afhankelijk van het 
cellulaire opnamemechanisme en het intracellulaire doelorganel, moet vervolgens 
soms ook nog een of meerdere intracellulaire membranen gepasseerd worden. Dit 
zijn grote uitdagingen die tot dusver in veel gevallen (mede) beperkend zijn voor 
een klinisch succes van de nanogeneeskunde. Om bij te kunnen dragen aan het 
oplossen van deze problemen, hebben wij nanomaterialen met unieke fysisch-
chemische eigenschappen gebruikt om zogenaamde nanodeeltjes te maken. Het 
doel van dit proefschrift is om te onderzoeken hoe we deze nanodeeltjes het beste 
biologische barrières kunnen laten passeren en door zieke cellen kunnen laten 
opgenomen worden, om vervolgens een therapeutisch effect te bewerkstelligen.
In hoofdstuk 1 wordt de opbouw en eigenschappen van de twee soorten 
nanodeeltjes die in dit proefschrift centraal staan beschreven. Dit zijn 
polymeerachtige nanoreactoren, ook wel polymersomen genoemd, en 
peptideachtige nanodeeltjes. Tevens worden de strategieën met betrekking tot 
het passeren van de bloed-hersenbarrière, de opname door doelcellen, en de 
eventuele passage van intracellulaire membranen beschreven. Beide nanodeeltjes 
zouden met name geschikt kunnen zijn voor de behandeling van ziekten die 
gerelateerd zijn aan mitochondriële defecten. Patiënten met een defect in complex 
I, het eerste en grootste enzymcomplex van het mitochondriële oxidatieve 
fosforyleringssysteem, presenteren zich met een grote diversiteit aan symptomen. 
In dit proefschrift gebruiken we primaire huidfibroblasten van een complex 
I-deficiënte patiënt met het syndroom van Leigh als model om de therapeutische 
potentie van polymersomen en peptideachtige nanodeeltjes op cellulair niveau 
te onderzoeken.
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In hoofdstuk 2 wordt de synthese, karakterisatie en celopname van 
biologisch afbreekbare, semipermeabele polymersomen geëvalueerd. Het 
uitgangsmateriaal van de polymersomen bestond uit poly(ethyleenglycol)-
block-poly(caprolacton-gradient-trimethyleencarbonaat) (PEG-PCLgTMC) 
en de synthese van de polymersomen vond plaats via de directe hydratie 
methode. Fysische karakterisatie van de aldus gevormde nanoreactoren liet 
zien dat deze in staat zijn om relatief grote cargomoleculen, zoals enzymen, 
in te sluiten. Bovendien werden enzymen afgeschermd tegen afbraak door 
relatief grote proteolytische enzymen in de omgeving van de nanoreactor, 
terwijl de kleinere substraat- en productmoleculen van het ingesloten 
enzym vrijuit kunnen diffunderen door het semipermeabele membraan. Een 
kritische stap voor het bereiken van een therapeutisch intracellulair effect is 
het vermogen om de plasmamembraan te passeren. Omdat polymersomen 
met een gePEGyleerde buitenwand niet of slecht worden opgenomen door 
eukaryotische cellen, hebben we de buitenwand gecoat met een zogenaamd 
cel-penetrerend peptide (CPP). Inderdaad liet de aanwezigheid van CPP TAT, 
afkomstig van het humaan immuundeficiëntievirus (HIV), zien dat een dergelijk 
peptide onmisbaar is voor de opname van polymersomen in HEK293T cellen. Na 
celopname komen de polymersomen primair in verzuurde celcompartimenten 
van het endolysosomale systeem terecht. Deze bevindingen zijn een belangrijke 
eerste stap in de ontwikkeling van nanoreactoren als therapie voor patiënten 
met mitochondriële defecten. 
Als volgende stap, wordt in hoofdstuk 3 de functionaliteit van de hierboven 
beschreven TAT-polymersomen onderzocht in primaire huidfibroblasten 
afkomstig van een complex I-deficiënte patiënt met een V122M mutatie in het 
NDUFS7 gen. In de polymersomen was het enzym katalase ingesloten, wat hen 
tot zogenaamde antioxidant nanoreactoren (AONs) maakt. Complex I wordt 
beschouwd als een belangrijke plek voor de productie van zuurstofradicalen, 
met name onder pathologische omstandigheden. We lieten zien dat de door 
de primaire huidfibroblasten opgenomen AONs als synthetische organellen 
kunnen functioneren, omdat ze de cellen effectief beschermden tegen celdood 
ten gevolge van het toedienen van waterstofperoxide (H2O2). Tevens konden 
we laten zien dat in cellen met AONs na toediening van H2O2 geen stijging 
optrad van het intracellulaire niveau van zuurstofradicalen. Voor de eerste 
keer laten deze resultaten laten zien dat complex I-deficiënte patiëntencellen 
effectief beschermd kunnen worden tegen toxische effecten van extracellulair 
H2O2 door intracellulaire AONs.
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In hoofdstuk 4 wordt de potentie van peptideachtige nanodeeltjes onderzocht 
als mogelijkheid voor medicijnafgiftesysteem, omdat ze in biologische, niet-
toxische bouwsteentjes afgebroken kunnen worden. Deze bouwsteentjes 
zijn elastine-achtige peptiden (ELPs) afkomstig van tropoelastine, en hebben 
de handige eigenschap om op een tempartuurafhankelijke en reversibele 
manier coacervaten te vormen. In deze ELP coacervaten of ELP nanodeeltjes 
kunnen medicijnen bedoeld voor afgifte op verschillende manieren worden 
ingesloten, bijvoorbeeld in de hydrofobe kern of in de hydrofiele lumen, of 
via covalente koppeling aan de ELPs vastgemaakt worden. ELPs zijn in het 
bijzonder geschikt vanwege de mogelijkheid om functionele peptiden hierin 
te verenigen, bijvoorbeeld peptiden die zorgen voor cel-specifieke “targeting” 
of die celopname bevorderen. In dit hoofdstuk hebben we onderzocht wat 
de optimale dichtheid en configuratie is van het cel-penetrerende peptide 
octa-arginine (CPP R8) in ELP nanodeeltjes. Een belangrijke in vivo toepassing 
van ELP nanodeeltjes is die van carrier van anti-kanker medicijnen. Hiervoor 
is van essentieel belang dat deze nanodeeltjes niet alleen goed worden 
opgenomen door de tumorcellen, maar ook diep in de tumor kunnen 
doordringen. Voor dit onderzoek zijn driedimensionale (3D) tumormodellen 
geschikt, omdat ze de avasculaire regio’s van tumorweefsel nabootsen en hun 
morfologie heel reproduceerbaar is. Met behulp van een goed gedefinieerd 
3D tumormodel hebben we aangetoond dat de aanwezigheid van een zeker 
percentage R8 noodzakelijk is voor zowel de opname als de penetratie van de 
ELP nanodeeltjes. Dit is een essentiële bevinding in de ontwikkeling van ELP 
nanodeeltjes als toekomstige therapeutische toepassing voor specifieke en 
effectieve medicijnafgifte in tumoren.
In hoofdstuk 5 evalueren we de therapeutische potentie van ELP nanodeeltjes 
door te onderzoeken of deze deeltjes KH176 af kunnen leveren aan primaire 
huidfibroblasten van de in hoofdstuk 3 genoemde complex I-deficiënte patiënt 
met het syndroom van Leigh. KH176 bezit een potente intracellulaire reductie-
oxidatie-modulerende werking en is door Khondrion ontwikkeld met het oog 
op de behandeling van mitochondriële ziekten. In eerdere studies bleek KH176 
bijzonder effectief in het voorkomen van celdood in complex I-deficiënte 
patiëntencellen, geïnduceerd door behandeling met L-buthionine-(S,R)-
sulfoximine (BSO). Hier laten we zien dat ELP nanodeeltjes gefunctionaliseerd 
met KH176 en het cel-penetrerende peptide R8 (ELPKH176 nanodeeltjes), de 
toename in celdood geïnduceerd door BSO kunnen voorkomen. 
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Deze resultaten stimuleren verder onderzoek naar het effect van het combineren 
van diverse gefunctionaliseerde ELPs in ELP nanodeeltjes, om bijvoorbeeld ook 
specifiek de bloed-hersenbarrière te kunnen passeren.
 Het slecht functioneren van mitochondriën kan een dramatisch effect hebben 
op het voortbestaan van neuronen, omdat met name deze cellen een enorme 
energiebehoefte hebben gepaard met een beperkt herstellend vermogen. 
Echter, het behandelen van neurodegeneratieve ziekten wordt gehinderd 
door de aanwezigheid van de bloed-hersenbarrière. In hoofdstuk 6 hebben 
we het “targeting” peptide G23 in combinatie met ELP nanodeeltjes (ELPG23 
nanodeeltjes) onderzocht. Dit peptide heeft ganglioside GM1 als target, en we 
hebben gemeten in hoe verre ELPG23 nanodeeltjes in staat zijn om transcytose 
over een in vitro model van de bloed-hersenbarrière te bewerkstelligen. De 
belangrijkste eigenschap van dit model is de zeer geringe doorlaatbaarheid 
van de cellaag waaruit het bestaat. Deze doorlaatbaarheid hebben we bepaald 
aan de hand van de permeabiliteitscoefficiënt van paracellulaire fluorescerende 
tracers en de transendotheliale weerstand (TEER). De ELPG23 nanodeeltjes waren 
significant beter in staat tot transcytose dan de ELP nanodeeltjes zonder G23, na 
een incubatietijd van 4 uur. Deze bevinding suggereert dat ELPG23 nanodeeltjes 
geschikt zouden kunnen zijn voor gerichte afgifte van KH176 naar het brein.
In hoofdstuk 7 worden de hierboven beschreven resultaten betreffende 
polymersomen en ELP nanodeeltjes in perspectief geplaatst. Tevens worden 
conclusies getrokken wat betreft biologische uitdagingen binnen de 
nanogeneeskunde.
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Wetenschappen aan de Radboud Universiteit in Nijmegen. Na het eerste jaar 
afgemaakt te hebben, switchte ze van studie en startte ze in 2007 met de 
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faculteit Biomedische Technologie. Binnen het masterprogramma behaalde zij 
het certificaat “Biological Safety in Molecular and Cell Biological Techniques” 
aan de faculteit Biomedische Technologie, en het certificaat “Technology 
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Kankerbestrijding. Na het behalen van haar masterdiploma, startte ze in 2014 
aan het promotieonderzoek binnen de Radboud Nanomedicine Alliance. Dit 
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De belangrijkste resultaten van het promotieonderzoek zijn beschreven in 
dit proefschrift.
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Bij het tot stand komen van dit proefschrift zijn veel mensen betrokken geweest. 
Velen hebben directe wetenschappelijke bijdragen geleverd, maar ook de niet-
wetenschappelijke bijdragen zijn van onschatbare waarde geweest, en ik wil 
hier heel graag iedereen voor bedanken.
Op de eerste plaats wil ik mijn beide promotoren bedanken voor de kans die 
ze mij gegeven hebben om aan dit uitdagende en interdisciplinaire project 
binnen de Radboud Nanomedicine Alliance te mogen deelnemen.
Beste Jan, bedankt voor je uitstekende begeleiding. Hoewel je het als professor, 
medisch specialist en CEO van Khondrion buitengewoon druk hebt, kon ik altijd 
bij je binnenlopen voor een luisterend oor en advies; veel dank hiervoor. Jouw 
ervaringsverhalen vanuit de kliniek zorgden voor extra motivatie om tijdens 
mijn onderzoek het maatschappelijke belang niet uit het oog te verliezen. Dat ik 
gebruik mocht maken van de expertise en apparatuur binnen Khondrion is van 
groot belang geweest voor mijn onderzoek. Bedankt voor alle mogelijkheden 
en betrokkenheid die je mij gegeven hebt.
Beste Jan, bedankt voor de gelegenheid dat ik na mijn studie vervolg kon 
geven aan een celbiologisch PhD-project, maar toch via jouw lab binding met 
biomedische technologie kon blijven houden. Bedankt voor de mogelijkheid 
dat ik niet alleen ELP-nanoparticles in al zijn soorten en maten kon onderzoeken, 
maar ook voor de fijne en succesvolle samenwerking rondom de polymersomes.
Mijn dank gaat eveneens uit naar het afdelingshoofd van de afdeling Biochemie 
en naar mijn beide co-promotoren beiden werkzaam op deze afdeling. Zij boden 
het grootste deel van de infrastructuur die ik mocht gebruiken en fungeerden 
als mijn dagelijkse wetenschappelijke sparring partners. 
 
Beste Roland, bedankt dat ik zo snel in jouw lab werd opgenomen en dat ik 
van de daar aanwezige kennis en kunde gebruik heb mogen maken. Bedankt 
voor al je input, advies en begeleiding. Met name de targeting meeting op 
donderdagochtend gaf vaak inzichten waar ik weer een volle week op vooruit 
kon. Veel dank hiervoor!
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Beste Werner, bedankt voor al jouw analytische bijdragen, en de mogelijkheden 
die je mij hebt gegeven om meer ervaring op te doen wat betreft mitochondriële 
metingen. Je gestructureerde manier van werken is prettig, en je directe en 
snelle communicatie heb ik erg gewaardeerd. Veel dank voor alle projecten 
waarin je mij hebt betrokken en waar ik veel van geleerd heb.
Als laatste in dit rijtje van begeleiders wil ik graag Peter bedanken. 
Beste Peter, ik herinner me dat toen ik jou voor de eerste keer ontmoette ik 
bij mezelf dacht “dus zo ziet een echte bioloog eruit”. Op dat moment kon ik 
nog niet vermoeden dat ik zóveel van jou zou leren. Met name in het laatste 
jaar hebben we intensief samengewerkt om de lopende projecten tot een goed 
einde te brengen. Ik wil je niet alleen bedanken voor alle celbiologische kennis 
die je met veel geduld hebt overgedragen en met ruimte voor discussie (en 
soms emoties), maar des te meer voor jouw (levens)lessen over wetenschap 
in het algemeen. Door jouw aanpak heb ik van dichtbij kunnen zien waar 
wetenschap in essentie over gaat, los van hiërarchie, status of politiek, en 
deze kennis is cruciaal voor iedere onderzoeker in opleiding. Ook ben je een 
voorbeeld wat betreft je omgang met studenten en je inzet in onderwijs. Ik 
prijs me gelukkig dat jij mijn dagelijks begeleider was, en ik bedank je voor 
onze fijne samenwerking en al jouw lessen, op welk gebied dan ook.
Graag wil ik ook alle leden van mijn manuscriptcommissie bedanken. 
Op de eerste plaats prof. dr. Frans Russel, bedankt voor het voorzitten van 
de commissie, en veel dank voor onze jaarlijkse mentorgesprekken en de 
bijbehorende inzichten die deze opgeleverd hebben. 
Prof. dr. Alessandra Cambi, bedankt voor het kritisch lezen en beoordelen van 
mijn proefschrift. 
Dr. Lorenzo Albertazzi, thank you for being part of my manuscript committee. 
Many thanks for the opportunity to join your lab in Barcelona. I would like to 
thank the Nanoscopy for Nanomedicine research group for the wonderful 
time, in particular Silvia and Natàlia for their technical assistance in learning 
super resolution microscopy.
 
Mevrouw van Damme en Universiteitsfonds Eindhoven, hartelijk dank 
voor het toekennen van de Marina van Damme beurs waarmee ik mijn 
onderzoeksperiode in Barcelona heb kunnen financieren. Ook dank aan 
het Marina van Damme-netwerk voor de jaarlijkse bijeenkomsten die zeer 
inspirerend zijn.
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Dr. Jan Pille, bedankt voor de uitgebreide en fijne samenwerking in de 
onderzoekslijnen wat betreft de ELP nanodeeltjes. Ik denk dat we aan het begin 
niet hadden durven dromen dat er zóveel mogelijk zou zijn, en ik hoop dat 
onze mooie resultaten aan de basis zullen liggen van nog veel meer ELP succes.
I would like to thank dr. David Williams for the good collaboration in the 
polymersome project. Dear Dave, many thanks for working so pleasantly 
together and I wish you all the best for your career at Swansea University. Hierin 
wil ik ook graag dr. Loai Abdelmohsen en Pascal Welzen betrekken; bedankt 
voor jullie input en prettige samenwerking!
Many thanks to the team of Khondrion, for the good collaboration and the 
opportunity to learn about your assays. In het bijzonder wil ik graag Peter van 
Zandvoort en Lisanne Houben bedanken voor de fijne samenwerking en alle 
experimentele bijdragen.
De grootste vreugde in mijn PhD heb ik gehaald uit het samenwerken met en 
begeleiden van studenten. Veel van de in dit proefschrift beschreven resultaten 
zijn het directe resultaat van de inzet van getalenteerde en gemotiveerde 
studenten, en ik wil hen graag allemaal bedanken.
Lisa, door jouw geweldige inzet maakte het ELP-project een bliksemstart en 
konden we al snel allerlei andere projecten eromheen vormgeven. Ik wil je 
bedanken voor de ontzettend fijne samenwerking en ik wens je een succesvol 
en ontspannen vervolg van je eigen promotietraject.
Thomas, bedankt voor jouw inzet rondom de PLGA-nanoparticles. Jouw 
onderzoek is niet terechtgekomen in dit proefschrift, maar was desalniettemin 
van grote waarde omdat het de uitdagingen van een alternatieve strategie liet 
zien. Ik wens je veel succes, maar vooral ook heel veel plezier in de voortzetting 
van je studietijd.
Marleen, dankjewel voor jouw inspanningen met name rondom de cellulaire 
modellen. Jouw handigheid in spheroids doorsnijden is ongeëvenaard, en ik 
denk met veel plezier terug aan onze gezellige babbels over, onder andere, 
Australië. Ik hoop dat het “knutselen met cellen” ook in Eindhoven goed lukt, 
en ik wens je alle goeds toe.
Juul, dankjewel voor al jouw werk met de polymersomes. Door jouw 
experimenten kwamen we er al snel achter dat het door ons ontworpen 
systeem eigenlijk niet naar behoren werkte. 
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Dit is verre van het prettigste onderdeel van onderzoek doen, maar wel een 
cruciaal aspect dat je uitvoerig hebt getest, en hier ben ik je heel dankbaar 
voor. Met jouw talent en geweldige sociale vaardigheden twijfel ik er niet aan 
dat je een mooie carrière tegenmoet zult gaan.
Lisanne, ook jij bent ijverig aan de slag gegaan met de polymersomes en ik was 
onder de indruk van jouw unieke combinatie van de studies geneeskunde én 
moleculaire levenswetenschappen. Dankjewel voor jouw inzet en motivatie, en 
je ambitie zal mooie resultaten voor mens en maatschappij opleveren.
Ook wil ik Niky en Emma bedanken voor het schrijven van hun literatuurthesis 
binnen mijn project.
Tot slot Christiaan, dat zo’n beetje alles wat je aanraakte in goud veranderde 
is de droom van iedere PhD studente aan het einde haar project. Bedankt 
voor al jouw inzet! Naast je experimentele werk heb je meegeschreven aan 
de paper, figuren gemaakt en dit alles vaak onder een flinke tijdsdruk. 
Veel dank voor alles wat je hebt gedaan, en ik vind het heel leuk dat je jouw 
ambitie gaat uitleven in een promotieproject met behulp van super-resolutie 
microscopie.
I would like to thank all (former) colleagues and friends from the department 
of Biochemistry. 
Many thanks to Arie, Corina, Cristiane, Dania, Danique, Dirk, Elianne, 
Estel, Farhan, Ganesh, Herman, Hoa, Jenny, Joames (my dearest neighbor), 
Jori, Judith, Jürgen, Krissie, Lisette, Lionel, Marco, Merel, Omar, Petra, 
Rike, Sander van A., Sander G., Samuel, Valentina and Wouter for helpful 
suggestions, practical tips and tricks, pleasant chats, great working atmosphere 
and fun.
In het bijzonder veel dank aan Sjenet, voor al jouw technische ondersteuning 
en experimentele bijdragen. Ik wens je een vreugdevol pensioen toe!
Ook veel dank voor de samenwerking en gezelligheid met “de (oud-)buren” van 
de afdeling farmacologie-toxicologie. In het bijzonder wil ik graag Janny, 
Jelle, Jitske, Ria, Sanne, Tom N. en Tom S. bedanken voor praktische adviezen 
en fijne gesprekken.
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Ik wil graag mijn vrienden bedanken voor hun interesse, ondersteuning, 
ontspanning en gezelligheid van de afgelopen jaren. Ik heb genoten van ieder 
gesprek, belletje, etentje en borrel met jullie.
In het bijzonder dank aan de bende van Uisge Beatha voor de gezelligheid, 
met name tijdens mijn studietijd. Danny, bedankt dat ik altijd op jou (en je 
kookkunsten) kan rekenen. Geert, je bent en blijft een groot voorbeeld, en 
niet alleen vanwege je indrukwekkende academische succes. Dankjewel dat ik 
je nog steeds af en toe om raad mag vragen. Natasja, dankjewel voor jouw 
vriendschap, gezelligheid en sollicitatietips. Thomas, mijn mede-pre-destillaat, 
bedankt dat je me in Barcelona op bent komen zoeken.
Alexander, wie had gedacht dat toen ik mijn studieboeken bij jou kocht dit 
de basis zou worden van een hechte vriendschap. Bedankt voor jouw briljante 
advies destijds om iedere donderdag naar de borrel te gaan, en voor ál je 
andere adviezen. Wat een geluk dat we beiden van reizen houden, dus elkaar 
nooit lang uit het oog verliezen.
Dorien, bedankt voor jouw vriendschap. Ik vind het bijzonder dat we elkaar 
al van kleins af aan kennen, en nu zoveel jaren later ervaringen uitwisselen. 
Hoewel we elkaar regelmatig spreken maar niet vaak zien, heb ik ons contact 
en gesprekken afgelopen jaren als heel fijn ervaren. 
Kim, dankjewel voor jouw lange vriendschap sinds onze introductiedag op 
Bernardinus. Inmiddels drinken we geen chocomel meer om bij te kletsen, 
maar het liefst een glas wijn of een kopje thee samen met Fiene. Ik hoop dat we 
dit nog vaak mogen doen, en wens jullie alledrie samen heel veel geluk.
Sabine, wat fijn dat ik jou weer tegen het lijf ben gelopen na mijn terugkeer 
in Nijmegen, waar anders dan in het sportcentrum. Bedankt voor jouw 
vriendschap; je doorzettingsvermogen en sportiviteit zijn een voorbeeld en ik 
hoop dat we nog lang (het liefst in Nijmegen!) vriendinnen mogen zijn. Ik wens 
jou en Raymond heel veel geluk toe.
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Anniek, je bent en blijft mijn zonnestraal en ik ben dankbaar dat iedere keer 
als ik je zie je enthousiasme en optimisme aanstekelijk werkt. Ook bedankt voor 
onze heerlijke vakanties samen; alle Vitamin Sea heeft ongetwijfeld bijgedragen 
aan de inhoud van dit proefschrift. Ik hoop dat we nog vaak samen korte of 
lange tripjes mogen ondernemen, en wens jou en Ronald alle goeds toe.
Cindy, wat ben ik blij dat je besloot om aan de groepmeetings van biochemie 
deel te nemen en ik jou hier heb leren kennen. Al snel kwamen we erachter 
dat we zóveel raakvlakken hebben dat we wel zussen zouden kunnen zijn. 
Dankjewel voor je hartverwarmende vriendschap, en dat je mijn paranimf wil 
zijn. Ik hoop dat we nog lang niet uitgepraat zijn en (on)zinnige inzichten met 
elkaar blijven delen, liefst tijdens een lange wandeling samen met Piojo.
Op deze plek wil ik ook graag de familie van Joost bedanken. 
Freek, Maria, Frank & Maaike, Inge & Dennis, en Saar; bedankt voor jullie 
oprechte interesse in mijn onderzoek, en nog veel meer dank voor alle gezellige 
uitjes en samenzijn.
Familie kun je niet kiezen, en des te blijer ben ik dat in de loterij van het leven 
twee grote broers gewonnen heb. 
Ramon & Aimée, Sylvain en Juliette, ik vind het heel gezellig dat jullie nu op 
nummer 45 wonen. Bedankt voor jullie interesse, logeerpartijtjes, spellen en 
feestjes samen! Ik beloof dat ik voor Sylvain en Juliette een boeiender boekje 
dan deze zal kiezen om uit voor te lezen.
Ceryl, bedankt dat je op dit spannende moment als paranimf naast me wil staan. 
Ik ken eigenlijk niemand die hier meer geschikt voor is dan jij, en bovendien staat 
het bijbehorende pekske jou als beste. Dankjewel voor jouw betrokkenheid, en 
ik hoop dat we binnenkort weer een keer samen op wintersport gaan.
Pap en mam, bedankt voor al jullie steun, ieder op jullie eigen manier. De 
afgelopen jaren ben ik af en toe voor langere tijd van huis gegaan en hoe vaker 
ik weg ben, des te meer ik me realiseer dat het weer thuiskomen de waarde 
aan het weggaan geeft. Bedankt voor de thuisbasis die jullie samen gemaakt 
hebben, die ervoor gezorgd heeft dat ik alle mogelijkheden heb kunnen 
benutten die op mijn pad kwamen.
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 Lieve Joost, je bent met afstand mijn belangrijkste ontdekking in Nijmegen en 
mijn laatste woordje van dank gaat dan ook zonder twijfel naar jou. Dankjewel 
voor al je steun in de afgelopen drie jaar; jouw vrolijkheid, intelligentie en 
daadkracht in combinatie met je dazzling smile maken van grote uitdagingen 
een klein hobbeltje waar slechts overheen gehuppeld hoeft te worden. Hoewel 
we in eerste instantie niet echt een idee van elkaar hadden waar we ons zoal op 
dagelijkse basis mee bezig hielden, was je binnen korte tijd enorm betrokken, 
ongeacht hoe druk je het zelf had. Dankjewel voor je duwtjes in mijn rug; met 
name tijdens het soms moeizame schrijfwerk gaven ‘s ochtends je woorden “ik 
zou gewoon lekker aan de slag gaan” de boost die ik nodig had. Ook bedankt 
voor het af en toe samen even op de rem trappen, met als hoogtepunt onze 
geweldige reis van het afgelopen half jaar. Ik hoop dat ons boekje samen nog 
veel en veel dikker mag worden met mooie avonturen.
Bedankt allemaal!
